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General introduction
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Obesity
The increasing prevalence of obesity is a major public health and economic 
burden (1). According to the WHO, obesity and overweight are defined as 
‘abnormal or excessive fat accumulation that may impair health’ (2). The WHO 
estimates that 13% of the adult world population is currently obese, and about 
39% of the adult population overweight (2). Being overweight is defined as 
having a body mass index higher than 25 kg/m2, while obesity is defined as 
having a body mass index exceeding 30 kg/m2 (2). Obesity increases the risk 
for comorbidities like type II diabetes, coronary heart disease, and cancer, and 
it leads to higher overall mortality rates. 
The alarming increase in prevalence of obesity rates creates an urgent need 
for effective prevention and treatment strategies. However, achieving sustained 
weight loss in obese patients has proven to be very challenging, and long term 
life style modifications like dieting and exercise often show disappointing results 
(3). At the moment there are only a few approved pharmacological options 
available, showing only modest results (4, 5), and so far medicinal options 
have proven to be unsuccessful on the longer term due to lack of sustained 
efficacy and (or) severe side-effects. Overall, the most effective treatment for 
obesity today is bariatric (weight loss) surgery, which is a collective term for 
different surgical techniques that either reduce stomach size or bypass parts of 
the intestine (6). These changes result in alterations of gut hormone release, the 
latter playing an important role in the fast effects on glucose homeostasis, and 
gradual loss of body weight. Gut hormones are well-known for their effects on 
food intake behavior (7) and their role in weight loss after bariatric surgery 
is undeniable. Also, one of the recently approved pharmacotherapies for 
type II diabetes and obesity, liraglutide, is a gut hormone (GLP-1) analogue. 
This underlines why gut hormones are considered promising targets for the 
development of new treatment strategies for obesity and its comorbidities (8).
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Gut hormones
The gastrointestinal tract is an important endocrine organ of our body. It secretes 
several pivotal hormones which are released from so-called enteroendocrine 
cells. These cells comprise only 1% of the epithelial lining (9). Many different 
types of enteroendocrine cells have been described and these types were 
originally defined by their supposed specific product. For example, the L-cells 
were defined by their expression and release of glucagon-like peptide-1 
(GLP-1) and peptide YY (PYY), whereas I-cells were characterized by their 
expression and secretion of cholecystokinin (CCK). However, it is now known that 
these subtypes show overlapping secretion profiles with most enteroendocrine 
cells actually expressing a wide array of gut hormones (10). 
Enteroendocrine cells can be subdivided in closed and open cells. The closed 
type, which is not in contact with the lumen of the gastrointestinal tract, responds 
to neural and circulating signals. An example of such type of enteroendocrine 
cell is the histamine secreting enterochromaffin-like cell in the stomach (11). 
The open type of enteroendocrine cell on the other hand has direct contact 
with the luminal content of the gut. This type of cell can be stimulated by 
nutrients to secrete its hormones (12). Once secreted, these hormones can act 
in a paracrine manner by binding to their receptors on neighboring epithelial 
cells or on neurons of for example the vagal afferent fibers. These hormones 
can also enter the circulation and act in an endocrine manner throughout the 
body (13). Many gastrointestinal hormones are secreted upon food intake, and 
have been implicated in food intake regulation and physiological processes 
that underlie the control of metabolic homeostasis. As a result they are also 
involved in body weight management and important for the development of 
obesity. In the next sections the main hormones involved in satiety and satiation 
are discussed. 
Glucagon-like peptide-1
Glucagon-like peptide-1 (GLP-1) is one of the cleavage products of 
proglucagon, which is encoded by the gene GCG. There are different forms of 
GLP-1, the active types are GLP-1(7-36amide) and GLP-1(7-37). These active 
GLP-1 types can be inactivated by the enzyme dipeptidyl peptidase-4 (DPP 
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IV) into the inactive types GLP-1(9-36amide) and GLP-1(9-37) (14). In the 
intestine, GLP-1 is secreted by L-cells which are mainly located in the ileum and 
colon, and to a lower extent in de proximal small intestine (15, 16). Apart from 
the intestine, proglucagon is also expressed in the brain, tongue and pancreas 
(17, 18). There, different post-translational processing results in the formation 
of glucagon (18). Here we focus on GLP-1 produced and secreted by the 
intestine. 
GLP-1 secretion is regulated by many physiological signals from the body, 
including by luminal stimuli in the gut. Upon nutrient ingestion, GLP-1 is secreted 
into the blood in two phases. The early rise in GLP-1, about 15-30 minutes 
post-prandial, is thought to be regulated by neuronal signals, including via 
acetylcholine. The second peak of GLP-1, 90-120 minutes post-prandial, is 
thought to be regulated by the detection of nutrients and their breakdown 
products in the lumen of the gut (19). This process will be discussed in the next 
section ‘nutrient sensing’. Once GLP-1 is secreted, it gets rapidly degraded 
by DPP IV. About 25% of the secreted GLP-1 leaves the gut in its active form 
via the portal vein, of which another 40-50% is subsequently degraded in 
the liver. This results in a short half-life of only 1-2 minutes for active GLP-1 
in the circulation (18). Therefore, it is conceivable that most of its effects are 
paracrine, including via binding to its receptors expressed on the vagal nerve 
endings in the proximity of enteroendocrine cells (20, 21). The GLP-1 receptor 
is not only expressed on enteric nerves in the intestine, but also in many other 
tissues, like the pancreas, cardiovascular system, hypothalamus, brainstem and 
liver (22). Thus, GLP-1 has a large array of effects in the body.
In relation to food intake, GLP-1 inhibits gastric emptying and motility, thereby 
playing an important role in the development of the so-called ‘ileal brake’ 
activation (23). These actions, together with central effects on appetite 
contribute to a reduction of food intake. Next to this, GLP-1 acts as an incretin 
hormone, increasing insulin and decreasing glucagon secretion in a glucose-
dependent manner. Apart from these main effects, GLP-1 also influences 
blood flow, inhibits hepatic glucose production, decreases inflammation, and 
induces proliferation of beta cells in the pancreas (24). Currently, there are an 
increasing number of GLP-1 analogues appearing on the market (exenatide, 
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lixisenatide, dulaglutide, liraglutide etc.). Liraglutide was initially only approved 
for treatment of type II diabetes but its indications for use have recently been 
extended to management of body weight (4, 25).
Peptide YY 
Next to GLP-1, also Peptide YY (PYY) is secreted from enteroendocrine L-cells 
located in the distal intestine (16). Similarly to GLP-1, PYY blood levels show 
an initial rise, starting 15 minutes after food intake and reaching a peak after 
1-2 hours. This suggests that secretion is regulated by neuronal and gut nutrient 
sensing signals, similar to those for GLP-1 (26). PYY is secreted as PYY(1-36) 
and contrary to GLP-1, released PYY is cleaved by DPP IV into its bioactive 
form PYY(3-36), which binds and activates the Y2 receptor. This receptor for 
PYY is mainly expressed in the brain, but also on vagal nerve afferents (27). 
PYY has a half-life of about 9 minutes in the systemic circulation (28). Like GLP-
1, PYY(3-36) also slows down gastrointestinal motility, contributing to the ‘ileal 
brake’. Furthermore, it acts centrally by inhibiting food intake. Remarkably, 
the uncleaved form PYY(1-36) can also activate Y receptors other than Y2, 
contributing to increased food intake (29).
Cholecystokinin
Cholecystokinin (CCK) prepropeptide is the precursor for the many existing 
biologically active molecular forms of CCK, of which the most abundant 
are CCK8, CCK22, CCK33, and CCK58, and can exist in sulfated and non-
sulfated forms (30). The most important enzyme in the synthesis of bioactive 
CCK is prohormone convertase 1/3 (31). CCK is produced by intestinal I-cells, 
which are mainly located in the upper small intestine (16). Furthermore, CCK 
is expressed in the brain and enteric nervous system (29). Intestinal CCK is 
secreted upon food intake and has a plasma half-life of about 2-3 minutes (29, 
32). There are two CCK receptors, the CCK-1 receptor being mainly present 
in the galbladder, pancreas and gastrointestinal tract. The CCK-2 receptor is 
expressed in gastric tissues, and both receptors are expressed in the brain (33). 
The non-sulfated CCK peptide acts as agonist for CCK-2 receptor, whereas 
the sulfated CCK peptides are the main agonists for the CCK-1 receptor. The 
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activation of CCK-1 receptors causes the release of enzymes and bile acids 
stimulating digestion and inhibition of gastric emptying (28, 32). Moreover, 
CCK plays a role in the control of food intake (34).
Ghrelin
Ghrelin is one of the post translational processing products of preproghrelin. 
There are two forms of ghrelin; desacyl-ghrelin and the acylated forms, acyl 
ghrelin, the latter commonly designated as the bioactive molecular form(s). 
Acyl ghrelin is produced by attachment of a fatty acid side-chain (preferably 
C8 or C10) by the action of ghrelin O-acyl-transferase (GOAT). Ghrelin is 
expressed in many tissues, among which the pancreas and brain. Here, we 
focus on gastrointestinal ghrelin, which is secreted by X/A-like cells, mainly 
located in the stomach (35). GOAT is also expressed in many tissues among 
which the stomach and pancreas. Next to the alimentary system, GOAT is also 
present in the plasma (36, 37). Ghrelin is secreted pre-prandially by the empty 
stomach, and its secretion is reduced in a post-prandial state by expansion 
of the stomach, activation of nutrient sensing receptors, and the digestion of 
nutrients in the intestine (38, 39). Acyl ghrelin is a ligand for the growth hormone 
secretagogue receptor (GHSR)1a. Acyl ghrelin has orexigenic effects and it 
stimulates post-prandial gastric emptying. Furthermore, it stimulates growth 
hormone secretion, it influences glucose homeostasis, and stimulates adiposity 
(35). Although desacyl ghrelin is not able to bind to GHSR1a, it is suggested 
that this form of ghrelin also has a function, but these studies are still very 
contradictory (35).
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Nutrient sensing
As described above, the release of many of the gastrointestinal hormones is 
regulated by ingested nutrients and other molecules present in the gastrointestinal 
tract. Various chemosensory mechanisms along the entire gastrointestinal tract 
are continuously monitoring the concentration of nutrients, digestion products 
and microbial metabolites. These chemosensory processes, together with their 
effect on gastrointestinal hormone secretion are often referred to as “nutrient 
sensing”. A large number of G-protein coupled receptors (GPCRs), other 
receptors such as PPARs, and transporters have been identified and linked 
to gut hormone secretion in the recent years. Here, the main receptors and 
transporters known to be involved in the detection of carbohydrates, proteins 
and lipids will be discussed. 
Carbohydrates
In the gastrointestinal tract, ingested carbohydrates are mainly degraded 
to monosaccharides, among which glucose and fructose. Glucose can be 
transported into the cells by its sodium-glucose linked transporter (SGLT-1). Due 
to the cotransport of sodium, small current differences stimulate depolarization 
that results in hormone release from enteroendocrine cells. SGLT-1 mainly 
mediates the secretion of GLP-1 (40, 41). Next to SGLT-1, the sweet taste 
receptor, a heterodimer of T1R2 and T1R3, has been suggested to be 
involved in the sensing of carbohydrates and other sweet tasting compounds, 
including non-caloric sweeteners used in food products. Sweet taste receptors 
are present throughout the gastrointestinal tract, from oral cavity to colon. At 
cellular level they are expressed on GLP-1, GIP and serotonin-positive cells 
(42). Its activation has been shown to induce GLP-1 secretion (43, 44). Apart 
from the effect of monosaccharides via SGLT-1 or the sweet taste receptor, 
monosaccharides like glucose and fructose can also induce hormone secretion 
in a metabolism-dependent way. Metabolism of glucose results in higher ATP 
levels in the enteroendocrine cells, thereby affecting ATP-sensitive potassium 
channels (45, 46).
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Proteins
In the gastrointestinal tract, proteins are degraded to polypeptides and 
amino acids. These can be detected in the gastrointestinal tract by several 
receptors, dependent on their size and composition. Peptones, hydrolyzed 
protein fragments, have been reported to activate GPR93 (GPR92 or LPAR5) 
and induce CCK release (47). Smaller products like di- and tripeptides are 
absorbed by the proton-coupled transporter Pept1. This absorption induces 
changes in membrane potential resulting in GLP-1 secretion (48). Furthermore, 
Pept1 is involved in CCK release (49). Amino acids, the smallest protein 
degradation products, are detected by several GPCRs, including the calcium 
sensing receptor (CaSR), the umami taste receptor (T1R1/T1R3) and GPCRC6a. 
All these amino acid receptors have been shown the play a role in gut hormone 
release (50-53).
Lipids
Ingested triglycerides are degraded to mono- or diglycerides and fatty acids. 
Long chain fatty acids can be detected by GPR120 and GPR40 (FFAR1). Both 
receptors have been implicated in gut hormone release, with GPR120 being 
the most extensively investigated one (54-60). Monoglycerides and fatty acid 
metabolites, like 2-oleoyl glycerol and oleoylethanolamide, are also known to 
activate GPR119 resulting in GLP-1 secretion both in vitro and in vivo (61-64). 
Apart from the ingested fatty acids, short chain fatty acids are also produced 
in the gut by microbiota. These short chain fatty acids activate GPR41 and 
GPR43, thereby inducing the secretion of GLP-1 and PYY (65, 66). 
Other compounds
Next to the macronutrients discussed above, there are also other compounds 
in the gastrointestinal tract that can influence gut hormone secretion. Bitter 
compounds in our food can activate bitter receptors expressed along the 
intestinal tract (67). Bitter receptors belong to the taste receptor 2 family 
(T2R). They are G-protein coupled receptors consisting of approximately 25 
subtypes in human, which exist as homo- or heterodimers. These bitter receptors 
are able to detect a large array of bitter compounds and most of the de-
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orphanized receptors exhibit a large agonist spectrum (68). The activation of 
these receptors can induce GLP-1 and CCK secretion (69-72). Furthermore, 
bitter tastants can stimulate ghrelin secretion (39). Non-dietary compounds 
such as bile acids are also known to induce GLP-1 secretion via the bile acid 
receptor GPBAR1 (TGR5) (73, 74). Lastly, the peptide hormone somatostatin, 
produced amongst others in the stomach can inhibit the secretion of some other 
hormones, including GLP-1, PYY and ghrelin (75-78).
Stevia
As mentioned above, sweet compounds in the food can be detected by the 
sweet taste receptor and subsequently induce hormone release. This thesis will 
focus on a specific sweetener, namely stevia. Stevia is increasingly used in food 
products after its approval in the European Union in 2011 and it is marketed 
as a ‘natural’ sweetener. The active compounds derived from the plant Stevia 
rebaudiana Bertoni are steviol glycosides. The most common steviol glycosides 
are stevioside and rebaudioside A, but there are many more molecular forms 
identified, all consisting of a steviol backbone with different side groups, 
mostly glucose moieties (figure 1.1)(79). These steviol glycosides vary in 
their potencies to induce sweet taste sensations. Stevioside, rebaudioside A 
and rebaudioside D are reported to have the lowest sweet taste threshold 
compared to other common steviol glycosides when tested by a sensory panel. 
Comparable potencies were found in cell-based assays functionally expressing 
the sweet taste receptor. Apart from their sweet taste and capability to activate 
the sweet taste receptor, steviol glycosides have a bitter taste and they can 
activate the human T2R4 and T2R14 bitter receptors (80). 
Upon ingestion of stevia containing products, steviol glycosides remain stable 
throughout the gastrointestinal tract. Only upon contact with the gut microbiota 
the steviol glycosides are broken down to steviol, which can be absorbed (81). 
Based on the stability of steviol glycosides in the stomach and small intestine, 
it can be assumed that intact steviol glycosides activate sweet taste receptors 
throughout the intestinal tract, thereby inducing gut hormone secretion. This 
hypothesis was tested in the current thesis.
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Approaches to study gastrointestinal nutrient sensing
There are many strategies and models to investigate the effects of nutrients on 
gastrointestinal hormone release. Clearly, the ultimate goal for human nutrition 
is to understand the physiology of appetite regulation in man. However, options 
for studies in humans are limited. Therefore, a number of other options are also 
discussed here, among which the experimental approaches used in this thesis.
Studies in humans: intervention studies and measurements in patients 
undergoing bariatric surgery
There are only a few options to study the physiological actions of nutrients in 
the gastrointestinal tract, and their effects on hormone release in humans. An 
advantage of human intervention studies is that they provide the opportunity 
to combine plasma hormone levels with measurements of hunger, satiety and 
feelings of intestinal discomfort using visual analog scales and (or) ad libitum 
Figure 1.1 Chemical structure of Rebaudioside A. 
Adapted from ChemSpider ID: 5294031
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food consumption. However, effects on satiety or satiation are not always 
directly reflecting changes in plasma hormone levels (82).
The most basic intervention design is to study the effects of an ingested meal on 
plasma hormone levels. To investigate the role of specific nutrients on hormone 
secretion in different locations of the intestine, delivery of nutrients by intubation 
of the gastrointestinal tract, or by encapsulation are a better option (83, 84). 
However, intubation is quite invasive which limits its use for larger studies. At 
the same time encapsulation techniques for food products are still in their 
infancy. In order to study the involvement of specific nutrient sensing receptors 
in hormone secretion, the use of agonists and antagonists would provide 
opportunities. However, for human studies only a few compounds are available, 
and their safety is a limitation (85). In humans, it is possible to investigate the 
presence of these nutrient sensing receptors by obtaining mucosal biopsies. 
An excellent opportunity to collect these biopsies is during bariatric surgery. 
This gastrointestinal surgery, intended to lose weight, is mainly applied in 
morbidly obese patients. For this thesis, we were able to use samples from a 
minimally invasive form of bariatric surgery, namely the recently developed 
Articulating Circular Endoscopic (ACE) stapler, which reduces gastric volume 
by gastroplication. The feasibility, safety and efficacy of the ACE stapler 
procedure was assessed and this procedure resulted in a median 35 percent 
of excess weight loss in the first year (86). 
Animal models 
By using animal models in gastrointestinal research it is possible to gain 
fundamental knowledge on the effects of nutrients on gut hormone secretion. 
Animal models also allow fully standardized experimental procedures and 
there are fewer limitations to tissue sampling compared to human studies. 
The vast majority of the animal studies related to gut hormone research are 
performed in mice. In vivo models in mice also provide the possibility to test 
effects in more detail by knocking out or overexpressing certain nutrient sensing 
related genes. However, for other research questions an animal model that 
more closely resembles human gastrointestinal physiology is to be preferred. 
Pigs are omnivorous and show an intermittent eating pattern that to some 
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extent resembles that of humans. They also show a gastrointestinal physiology 
and intestinal transit time comparable to that of humans (87-89). 
One of the limitations of in vivo studies is that one cannot measure local gut 
hormone release, the closest approximation of gastrointestinal secretion being 
to measure the gut hormones in the circulation. A pitfall with this measurement 
is that the released gut hormones in general have a very short half-life. 
Furthermore, many gut hormones also have paracrine functions. Measuring the 
effects in the circulation will most likely not accurately represent its paracrine 
effects . To address these issues, in vitro studies may be able to provide more 
suitable options. 
In vitro models 
There are many in vitro options to study gut hormone release and the mechanisms 
involved, ranging from ex vivo tissue experiments and primary cell cultures, to 
organoids and cell lines. 
There are several ex vivo models, which are mainly used to measure intestinal 
transport. Some of these models segregate the luminal side from the basolateral 
side, like the everted sac and Ussing chamber models (90, 91). Other models 
do not differentiate between the two sides, like the porcine ex vivo segment 
model (92). The latter was used in this thesis. For ex vivo tissue experiments 
using gut material, there is the benefit of having an intact epithelial lining and 
the opportunity to measure direct hormone release by excising parts of the 
intestinal tract. One of the pitfalls of ex vivo studies is the short-term viability 
of the tissue. 
In contrast to ex vivo experiments, primary cells can be maintained for longer 
periods. Primary cells, freshly isolated from the intestine, are theoretically more 
similar to the epithelial cells as they exist in vivo, compared to immortalized 
cell lines. However, the intestinal epithelium only contains low numbers of 
enteroendocrine cells. This, together with the fact that it is difficult to keep 
them alive for a longer period of time makes it a difficult technique to study 
gut hormone secretion from primary enteroendocrine cells (40, 93). Recent 
advances in stem cell biology have led to a more appropriate model, intestinal 
organoids. Intestinal organoids, so-called mini-guts, can be grown from isolated 
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crypts, single Lgr5-CBC cells or pluripotent stem cells (94, 95). These organoids 
closely resemble the in vivo epithelium. It was previously shown that L-cells will 
develop in organoids, and that these are able to secrete GLP-1 in response 
to nutrient stimuli (96, 97). Therefore, intestinal organoids are an interesting 
model to study enteroendocrine cells and gut hormone secretion in their regular 
epithelial environment. However, the most commonly used three dimensional 
model only produces low levels of gut hormones. 
The last model for studying enteroendocrine cell physiology are cell lines. There 
are several hormone-secreting cell lines available. The most commonly used are 
NCI-H716, GLUTag and STC-1. NCI-H716, a human cecal adenocarcinoma 
derived cell line, seems to be the best tool to study human enteroendocrine 
cell behavior. However, this cell line needs to undergo differentiation before 
use and there are doubts about its behavior reflecting human physiology (93). 
GLUTag and STC-1 are extensively used murine-derived cell lines. GLUTag 
cells are isolated from a colon tumor of a transgenic mouse which expressed 
a SV40 large T antigen under the control of the proglucagon promoter. The 
cells have been extensively studied in relation to GLP-1 secretion (98, 99). 
STC-1 cells are derived from a small intestinal neuroendocrine carcinoma from 
a double transgenic mouse (100, 101). These cells are reported to secrete 
CCK, GLP-1, PYY, glucose-dependent insulinotropic polypeptide, pancreatic 
polypeptide, GLP-2 and oxyntomodulin (100).
Outline of thesis
As discussed above, the interactions of dietary components or their breakdown 
products with receptors and transporters in the gastrointestinal tract can induce 
the release of different gut hormones. These hormones influence food intake 
behavior via combinations of different paracrine and endocrine mechanisms, 
making signaling pathways involved in nutrient sensing interesting targets for 
the prevention or treatment of obesity and its comorbidities. However, many 
nutrient sensing mechanisms are still only partly understood and interactions 
between several specific nutrients and their receptors remain to be explored. 
Although gut nutrient sensing is often investigated in relation to appetite 
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control, effects of eating habits or body composition as such on these nutrient 
sensing mechanisms is scarcely investigated. Furthermore, much research in this 
field has been performed in different models and animal species, which often 
hampers proper comparison or translation. 
In this thesis, we aimed to further elucidate gut nutrient sensing mechanisms 
on a cellular level. First, the expression of several gut nutrient sensing related 
genes along the intestinal tract was assessed in three commonly studied species, 
namely mouse, pig and human. Intestinal expression patterns were compared 
between the species, and these results are presented in chapter 2. Next, 
effects of a weight-loss intervention on the gastrointestinal transcriptome were 
investigated in humans. To this end, we analyzed gastric and duodenal biopsies 
of morbidly obese patients who underwent reduction of gastric volume by a 
gastroplication procedure. The findings of this study are described in chapter 3. 
In chapter 4, we sought to investigate the effects of the non-caloric sweetener 
rebaudioside A. This Stevia rebaudiana-derived compound was approved 
on the European market in 2011. As there is still some controversy about the 
effects of sweeteners in general on gut hormone release, we investigated the 
effects of this specific sweetener. Subsequently, in chapter 5, the underlying 
signaling mechanisms of rebaudioside A-induced gut hormone secretion were 
investigated using enteroendocrine STC-1 cells. In chapter 6, a two dimensional 
gut model using intestinal organoids derived from mice intestinal crypts was 
developed to study hormone secretion. These organoids were derived from 
different intestinal locations, allowing us to explore location-specific hormone 
release by rebaudioside A. Furthermore, in this system we were able to look 
at the effects of long term exposure to this compound on the development of 
enteroendocrine cells. The collective findings of these studies are discussed in 
chapter 7.
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Abstract 
Introduction: Intestinal chemosensory receptors and transporters are able 
to detect food-derived molecules and are involved in the modulation of gut 
hormone release. Gut hormones play an important role in the regulation of 
food intake and the control of gastrointestinal functioning. This mechanism 
is often referred to as “nutrient sensing”. Knowledge of the distribution of 
chemosensors along the intestinal tract is important to gain insight in nutrient 
detection and sensing, both pivotal processes for the regulation of food intake. 
However, most knowledge is derived from rodents, whereas studies in man and 
pig are limited, and cross-species comparisons are lacking.
Aim: To characterize and compare intestinal expression patterns of genes 
related to nutrient sensing in mice, pigs and humans.
Methods: Mucosal biopsy samples taken at six locations in human intestine 
(n=40) were analyzed by qPCR. Intestinal scrapings from 14 locations in 
pigs (n=6) and from 10 locations in mice (n=4) were analyzed by qPCR and 
microarray, respectively. The gene expression of glucagon, cholecystokinin, 
peptide YY, glucagon-like peptide-1 receptor, taste receptor T1R3, sodium/
glucose cotransporter, peptide transporter-1, GPR120, taste receptor T1R1, 
GPR119 and GPR93 was investigated. Partial least squares (PLS) modeling 
was used to compare the intestinal expression pattern between the three 
species.
Results and conclusion: The studied genes were found to display specific 
expression patterns along the intestinal tract. PLS analysis showed a high 
similarity between human, pig and mouse in the expression of genes related 
to nutrient sensing in the distal ileum, and between human and pig in the colon. 
The gene expression pattern was most deviating between the species in the 
proximal intestine. Our results give new insights in interspecies similarities and 
provide new leads for translational research and models aiming to modulate 
food intake processes in man.
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Introduction
Various chemosensory mechanisms along the entire gastrointestinal tract are 
continuously monitoring the concentration of nutrients, digestion products and 
microbial metabolites. These chemosensory processes together with their 
effect on gastrointestinal hormone secretion are often referred to as “nutrient 
sensing”. The chemosensory mechanisms involve the action of different receptors 
and transporters generally located on membranes or within the cytoplasm of 
enterocytes, brush cells and enteroendocrine cells (1). The latter cell types 
comprise about 1% of the epithelial cells in the intestine (2). Nutrient sensing 
plays a pivotal role in the local and central regulation of food intake and 
gastrointestinal motility, secretion of mucus and enzymes, transport and uptake 
mechanisms (3). According to the most common view, stimulation of G-protein 
coupled receptors (GPCRs) and/or ion-dependent nutrient transporters located 
at enteroendocrine cells, modulate the release of gut hormones like glucagon-
like peptide-1 (GLP-1), cholecystokinin (CCK) and peptide YY (PYY) (1, 4). For 
example, activation of the umami taste receptor (T1R1 and T1R3) by amino 
acids has been suggested to induce CCK secretion (5), whereas G-protein 
coupled receptor 120 (GPR120) responds to fatty acids, thereby stimulating 
GLP-1 and CCK secretion (6, 7). In addition to receptors, several transporters 
for nutrients are involved in the modulation of gut hormone secretion. The 
sodium-glucose cotransporter member 1 (SGLT-1) has been suggested to 
induce GLP-1 secretion (8, 9). Recently, the peptide transporter (PepT1) was 
also shown to stimulate GLP-1 secretion (10). Secreted gut hormones can act 
via their corresponding receptors on vagal nerve afferents or via the endocrine 
pathway to affect food intake behavior (11). The small intestine plays a 
prominent role in generating this feedback to the brain during and in between 
meals (12).
In spite of the importance of chemosensors in relation to food intake, there 
are only few studies describing the distribution of various chemosensors along 
the human intestinal tract. More knowledge on this (regional) distribution can 
provide better insight in the underlying nutrient-sensing mechanisms potentially 
involved in individual differences in food intake and the likeliness to develop 
metabolic diseases. The issue of cross-species comparison is important since the 
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vast majority of studies in this field has been performed in rodents, such as the 
mouse (10, 13-15). Pigs may serve as a more suitable animal model because 
pigs and humans show more similarity in gut physiology than mice and humans. 
Pigs are omnivorous and show a meal-eating pattern in their eating behavior. 
They have a comparable gastrointestinal physiology and intestinal transit time 
to humans (16-18). However, despite these gross similarities it is not known to 
what extent the two species are similar with respect to gut nutrient sensing.
In the present study we extensively characterized the distribution of a number 
of receptors, transporters and hormones known to be involved in nutrient 
sensing focusing on the small intestinal tract of three species; pig, mouse and 
man. Next to measuring the expression of a selected set of genes involved in 
nutrient sensing we used Partial Least Squares (PLS) modeling to compare the 
three species. Lastly, the effect of fat/carbohydrate content in the diet on the 
expression of the selected genes was investigated.
Methods
Ethics statement
The use of human biopsy material for this study was approved by the Medical 
Ethical Committee of Maastricht University Medical Center+, the Netherlands 
(NCT02051881, NCT01574417). The porcine tissue was collected from control 
animals of a larger study, which was approved by the ASG-Lelystad Animal 
Care and Ethics Committee (Permit number: 2011135.c). Mice material was 
collected in a larger study which had been approved by the Local Committee 
for Care and Use of Laboratory Animals at Wageningen University (Permit 
number: 2010084.c).
Tissue sampling
Human intestine: Biopsies were obtained from 40 healthy subjects (male and 
female between 21 and 82 years), who were referred for gastrointestinal 
endoscopy or participating as healthy controls in another study. Each subject 
gave written informed consent before participation. Exclusion criteria were as 
follows; the observation of any macroscopic or histologic abnormalities, history of 
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severe cardiovascular, gastrointestinal/hepatic-, hematological/immunologic-, 
or metabolic/nutritional disease, major abdominal surgery interfering with 
gastrointestinal functioning or/and excessive alcohol consumption. All biopsies 
were taken with a standard forceps and the subjects were fasted prior to the 
endoscopic procedure. Due to the invasiveness of the procedure, it was only 
feasible to obtain biopsies from one or two locations in most subjects, except for 
the colon where mucosal tissue samples from three or four compartments were 
obtained. Duodenal tissue samples were taken from subjects who underwent an 
upper gastrointestinal endoscopy. These biopsies were taken at approximately 
10cm distal to the pyloric sphincter. Ileal and colonic biopsies were taken from 
subjects who underwent standard flexible colonoscopy. Ileal biopsies were 
taken at approximately 5cm proximal to the ileoceacal valve. Colonic biopsies 
were taken from the ascending, transverse and descending colon and from the 
sigmoid colon, respectively. In nine subjects we were able to collect mucosal 
tissue samples at 40-45cm distal to the pylorus, representing the proximal 
jejunum. All biopsies were snap frozen in liquid nitrogen and stored at -80˚C 
until analysis. 
Porcine intestine: To obtain tissue, six 10 week old male pigs (Large White x 
Landrace) were fasted overnight and killed by exsanguination under deep 
anesthesia. Immediately after this procedure, both the small and large intestine 
were excised and its total length was measured. From the small intestine, pieces 
of approximately 40cm2 were cut out at 10 locations, namely at 3, 6, 20, 40, 50, 
60, 70, 80, 90 and 98% of its total length (proximal to distal). These intestinal 
pieces were rinsed with water and scrapings were obtained. Scrapings were 
also taken from the cecum and at three locations in the large intestine, namely 
at 12.5, 37.5 and 75% of its total length. Apart from scrapings additional 
mucosal biopsies were taken from similar intestinal locations as mentioned 
above. Both the biopsies and scrapings were snap frozen in liquid nitrogen and 
stored at -80˚C.
Mouse intestine: Male C57BL/6J mice (age 4 weeks) were housed 2 per cage in 
the light and temperature-controlled animal facility (12/12 (light/dark), 20°C) 
of Wageningen University. The mice had free access to water and received 
standard laboratory chow (RMH-B, Arie Blok BV, Woerden, the Netherlands) 
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for 3 weeks, followed by a run-in period for 2 weeks during which 4 mice 
received chow diet and 8 mice received a 10E% low-fat diet. Subsequently, 4 
mice remained on the chow diet, 4 mice remained on the low-fat diet and 4 mice 
received a 45E% high-fat diet for the experimental period of 2 weeks. The 
composition of the low-fat and high-fat diets has been previously described by 
de Wit et al. (19). After the mice were fed, the small intestine of the sacrificed 
mice was excised. The small intestine was cut open longitudinally, divided in ten 
equal parts and scrapings were obtained. The colon was not sampled. These 
scrapings were snap frozen in liquid nitrogen and stored at -80°C until RNA 
isolation.
Both the biopsy and scraping sampling methods included similar mucosal and 
submucosal layers of the intestine. However, with biopsies a smaller surface of 
the intestine is taken in comparison to the scrapings. Therefore scrapings were 
expected to give a more representative determination of the epithelial gene 
expression than biopsies. Scrapings were taken from mice and pigs. However, 
to exclude the possibility that interspecies differences are caused by different 
sampling methods, gene expression profiles were compared for biopsies and 
scrapings in pigs. For five genes analyzed no differences were found, only 
CCK and PepT1 showing about 50% lower expression in biopsies compared to 
scrapings (results not shown).
RNA isolation
RNA of the human and porcine samples was isolated by using TRIzol reagent 
(Life technologies, Bleiswijk, Netherlands) and further purified using the RNeasy 
mini kit (Qiagen) with on column DNase treatment (Qiagen, Venlo, Netherlands). 
The RNA isolation of the mouse scrapings was performed using the Promega 
SV total RNA isolation System (Promega Corporation, Madison, USA). RNA 
yield was measured with the Nanodrop ND-1000 Spectrophotometer and the 
quality of the human, mice and some porcine RNA samples was verified with 
an Agilent 2100 Bio analyzer (Agilent Technologies, Amstelveen, Netherlands). 
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Quantitative PCR
Subsequently, 1µg RNA was reversely transcribed using random primers with 
a Reverse Transcription System kit (Promega Corporation, Madison, USA) 
according to the manufacturer’s instructions. For the negative controls, the use 
of the enzyme reverse transcriptase (-RT control) was omitted. 
The qPCR reactions were performed on the CFX384 Real-Time PCR Detection 
System (Bio-Rad Laboratories, Inc., Hercules, USA) using SensiMix SYBR No-ROX 
kit (Bioline, London, UK). Melt curve analysis and the amplification efficiency 
were used to verify the specificity of the amplification. Primers were designed 
using Beacon Designer 7.91 software, or primers were used from literature 
(Table S1 and S2). When using primers for Taqman analysis, the TaqMan 
Universal Master Mix II with UNG was used according to the manufacturer’s 
protocol. 36B4 (RPLP0) was used as reference gene to normalize the mRNA 
abundance of each gene (20). 
Glucagon (GCG, as precursor for GLP-1), CCK, PYY, GLP-1 receptor (GLP1R), 
PepT1 (SLC15A1), SGLT-1 (SLC5A1), T1R3 (Tas1R3), GPR120 (FFAR4), T1R1 
(Tas1R1), T1R2 (Tas1R2), GPR93 (LPAR5) and GPR119 were measured in all 
human and pig samples. However, T1R2 could not be detected by qPCR in 
pig and human intestine (for both species 5 primers were tested), probably 
due to the low level of gene expression as also reported by others (21, 22). 
Furthermore, despite the use of various primers T1R1 was still below detection 
level in the human samples and GPR119 was not detectable in the porcine 
samples. Lastly, GPR93 could not be quantified in pigs as the gene was not 
annotated. However, T1R1 was detected in mouse and pig, whereas GPR119 
and GPR93 were demonstrated in mouse and man (figure S2.5).
Microarray hybridization and analysis
One hundred nanogram of RNA was used for Whole Transcript cDNA synthesis 
(Affymetrix, inc., Santa Clara, USA). Hybridization, washing and scanning of 
Affymetrix GeneChip Mouse Gene 1.1 ST arrays and Affymetrix GeneChip 
Porcine Gene 1.1 ST Arrays was carried out according to standard Affymetrix 
protocols. All arrays of the small intestine were hybridized in one experiment. 
Arrays were normalized using the Robust Multi-array Average method (23, 
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24). Probe sets were assigned to unique gene identifiers, in this case Entrez IDs. 
The probes on the Mouse Gene 1.1 ST arrays represent 21,213 Entrez IDs. The 
probes on the porcine gene arrays represent 17,118 Entrez IDs (25). Array 
data were analyzed using an in-house, on-line system (26). All microarray data 
have been submitted to the Gene Expression Omnibus (GSE59054).
Both microarray and qPCR techniques have been extensively studied in the 
past decades and evidence for a strong correlation of the measured gene 
expression between qPCR and Microarray analysis has been assessed and 
proven in several papers (27-29). Our own data were in accordance with these 
studies as comparisons of qPCR data with microarray data of 12 intestinal 
locations in pigs established that gene expresion patterns were highly similar 
when using both techniques (data not shown). 
Statistical analysis
Partial least squares (PLS) is a linear multidimensional fitting method. The 
method is used to relate sets of complex measurements X to a given external 
parameter Y. In this case the complex measurements are the measurement of 
gene expression and the external parameter is the location in the intestine for 
one of the species. The general formula for the method is Y = aX + b. Given 
an Y-vector and a X-matrix, PLS will calculate: a (loadings) and b (offset) which 
can then be used to predict the Y for any other set of data. The algorithm has 
many inbuilt features for scaling, filtering and cross validation (optimization 
of the number of factors used) of the data and is therefore very suited to 
be used with data where the relation between X and Y does not have to be 
directly linear. PLS was used to compare the intestinal expression patterns of 
eight genes between the species. Microarray data was used in log2 scale and 
subsequently all microarray and qPCR data were autoscaled to correct for 
the influence of the absolute intensities of the measurement. To prevent over 
fitting the PLS model was cross validated using a leave-one-out algorithm (30). 
As the porcine data consisted out of a comprehensive map of the intestinal 
expression patterns for the selected genes, this dataset was selected to model 
the relation between gene expression levels and intestinal location. For this 
model the data of eight genes was used, as these were measured in all three 
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species. Subsequently, the human and murine data were fitted into the porcine 
PLS model to compare the gene expression patterns for the different locations 
between the three species. PLS requires enough samples to cover the full range 
of the Y-values (locations in the intestine) to be fitted and enough samples to be 
able to cross validate the model. The sets used in this manuscript contain more 
than enough samples (pig 84 samples, human 63 samples, mouse 36 samples) 
to fulfill both these demands. For PLS analysis MATLAB (Version: 8.0.0.783, 
R2012b) and Winlin (version 1.8, TNO, Zeist, The Netherlands, (31)) were 
used. 
Results 
Comparison of the gene expression along the intestine between the three 
species 
The relative gene expression pattern of each of the nutrient sensing related 
genes was measured at numerous intestinal locations in pig, man and mice. 
To compare the gene expression data of the three species, a PLS model was 
built for all three species. PLS analysis of the data gives a loading vector as 
listed in table 2.1 and 2.2. In general, high positive loading vectors reflect high 
distal expression, while high negative loading vectors reflect high proximal 
expression. From the porcine loading vectors of table 2.1 it can be seen that 
for example GPR120, PYY and glucagon give a positive contribution to the 
prediction of the location in the intestine i.e. in this model the samples at the 
distal intestine have relative higher expression of GPR120, PYY and glucagon 
than at the proximal intestine. The PLS model built on the human data, gave 
comparable results, with loading vectors of GPR120, PYY and glucagon being 
positive. To compare these two species with mouse, PLS models were built solely 
based on the small intestine. The loading vectors of these three species also 
show positive values for GPR120, PYY and glucagon and thus suggest a more 
distal role for GPR120, PYY and glucagon. Furthermore, the loading for CCK 
was negative in all three species, indicating that in all three species the relative 
expression of CCK is high in the proximal intestine, both in the small intestinal 
PLS models as well as in the complete PLS models. 
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Table 2.1: Loading vectors of the pig and human PLS model. Loading vectors obtained 
from PLS modeling of the complete intestinal data set of pig and human. 
Table 2.2: Loading vectors of the pig, human and mouse PLS model of the small 
intestine. Loading vectors obtained from PLS modeling of the small intestinal data set of 
pig, human and mouse. 
Table	1:	Loading	vectors	of	the	pig	and	human	PLS	model.	Loading	vectors	obtained	from	PLS	modeling	of	the	complete	intes7nal	data	set	of	pig	and	humanTable	2:	Loading	vectors	of	the	pig,	hum n	and	mouse	PLS	 odel	of	the	small	intes>ne. 
Pig Human
5	factors 1	factor
GPR120 50,9005 6,1034
Glucagon 16,0706 1,8761
PYY 11,5365 10,035
GLP-1R 6,1094 -2,9701
SGLT-1 7,534 -3,4999
T1R3 -0,2179 -15,0651
PepT1 -27,4127 -6,8932
CCK -70,5 -5,534
Pig Human Mouse
6	factors 1	factor 3	factors
GPR120 89,5911 20,8624 7,1406
Glucagon 14,6987 3,129 9,0567
T1R3 9,3151 -1,1986 1,0031
PYY 4,6843 9,2374 3,7939
SGLT-1 1,2987 -1,3959 -13,1401
GLP-1R 0,1353 -1,1315 -9,6277
PepT1 -17,4913 -1,6997 6,533
CCK -59,3902 -3,2496 -6,9791
Table	1:	Loading	vectors	of	the	pig	and	human	PLS	model.	Loading	vectors	obtained	from	PLS	modeling	of	the	complete	intes7nal	data	set	of	pig	and	humanTable	2:	Loading	vectors	of	the	pig,	hum n	and	mouse	PLS	 odel	of	the	small	intes>ne. 
Pig Human
5	factors 1	factor
GPR120 50,9005 6,1034
Glucagon 16,0706 1,8761
PYY 11,5365 10,035
GLP-1R 6,1094 -2,9701
SGLT-1 7,534 -3,4999
T1R3 -0,2179 -15,0651
PepT1 -27,4127 -6,8932
CCK -70,5 -5,534
Pig Human Mouse
6	factors 1	factor 3	factors
GPR120 89,5911 20,8624 7,1406
Glucagon 14,6987 3,129 9,0567
T1R3 9,3151 -1,1986 1,0031
PYY 4,6843 9,2374 3,7939
SGLT-1 1,2987 -1,3959 -13,1401
GLP-1R 0,1353 -1,1315 -9,6277
PepT1 -17,4913 -1,6997 6,533
CCK -59,3902 -3,2496 -6,9791
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To further compare the gene expression data of the three species, the human 
en murine data were projected into the porcine model (5 factors, R2=0.6541) 
(figure 2.1). For humans, the combined gene expression of all samples from 
distal ileum to colon were found to fit well to the porcine based model. The 
duodenal and jejunal samples, however, were more deviating from the modeled 
porcine samples when compared to the distal ileum and colon samples. Similar 
to the human proximal intestinal samples, the murine samples of the proximal 
small intestine are different from the modeled porcine samples. However, for 
the distal small intestine the difference between mice and pigs becomes less. 
Figure 2.1: Partial least square analysis. Results of partial least squares (PLS) model in 
which porcine gene expression data (Ο) were used for regression analysis with locations 
in the intestine and the human (□) and murine data (Δ) were projected in the model. The 
PLS prediction model used 5 factors and has a R2=0.6541. The x-axis shows the location in 
the intestine, in which 0-100 resembles the small intestine from proximal to distal, 100-200 
resembles the large intestine.
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Gene expression pattern along the intestine
When studying the expression patterns for the nutrient sensing genes in more 
detail, some general expression patterns or specific patterns could be clearly 
observed for several of the genes (figure 2.2). As shown in the heatmaps the 
gut hormones, glucagon (precursor for GLP-1), CCK and PYY and the receptor 
for GLP-1, all showed specific expression patterns along the intestine, which 
appeared similar for the three species. 
Remarkably, the expression patterns of the nutrient transporters for di- and 
tri-peptides, PepT1, and for glucose, SGLT-1 were almost identical within each 
species. However, the expression patterns of both genes differed between the 
three species. In mice, GPR120 expression increased towards the distal small 
intestine, whereas in human and pigs the expression increased slightly along 
the small intestine. In human and pigs, the expression of this gene was more 
prominent in the colon.
Although the T1R family showed low to undetectable expression in the intestine, 
T1R3 was detected in all three species but showed a scattered expression 
pattern along the intestine. 
Details for the expression patterns of each gene can be found in the 
supplemental data (figure S2.1-S2.5).
Effect of diet on gene expression pattern in mice
To explore the effect of diet on expression of the studied genes, we also 
analyzed material from mice given different diets; chow, high fat-low 
carbohydrate or low fat-high carbohydrate diet. To analyze the effect of the 
three diets on the differences in gene expression of the eight genes along the 
small intestine, a PLS model was developed based on the data of the chow 
diet (using 3 factors, R2=0.9681). Subsequently, the results of the high-fat and 
low-fat diet were fitted in this model (figure 2.3 and figure S2.6). The model 
showed that location in the intestine had a greater effect on gene expression 
level than a dietary intervention. With respect to the selected eight genes, the 
low-fat diet did not show a high deviation from the chow diet. Expression after 
a high-fat diet, however, deviated slightly from expression after a chow diet, 
especially in the distal part of the small intestine. 
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Figure 2.2: H
eatm
ap of pig, hum
an and m
urine gene expression results. H
orizontally the individual sam
ples of different parts of the intestine are 
aligned from
 proxim
al to distal and vertically the eight genes are show
n. G
reen and red indicate low
 and high gene expression com
pared to average, 
respectively. G
rey indicates sam
ples that could not be analyzed/detected. 
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Discussion
Chemosensory receptors and transporters able to detect nutrients and other 
molecules present in the intestinal tract are pivotal for the regulation of food 
intake and other physiological responses to food ingestion. Moreover, nutrient 
sensing in the gut might also play a key role in maintaining metabolic homeostasis, 
for example of glucose. Impairment or changes of these nutrient sensing 
mechanisms may contribute to metabolic diseases, such as type II diabetes 
and obesity (1, 32, 33). It is conceivable that a time- and site dependent 
interaction of food and digestion products with different chemosensory and 
other, including stretch and osmotic, sensors is key to these processes. However, 
detailed studies characterizing patterns of chemosensory receptors and 
transporters along the intestinal tract under normal physiological conditions are 
scarce. Moreover, information on interspecies differences is limited. Instead, the 
majority of studies focused on investigating a single gene in one or two species 
(6, 34-36). 
Our data show a strong similarity between the expression of genes related 
to nutrient sensing in the distal ileum of the three species studied, which is 
mainly explained by the large contribution of glucagon and PYY to the model. 
Figure 2.3: PLS prediction of locations along the intestine based on the gene expression 
in a sample. The PLS prediction model used 3 factors and has an R2= 0.9681. The samples 
of mice fed a chow diet (Δ) were the basis of the model and the data of mice fed a low-
fat (A, indicated with □) and high-fat diet (B, indicated with □) was fitted in the model.
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Furthermore, the expression patterns in the colon of man and pig were highly 
comparable. Similarities in these locations of the intestine might be attributed 
to the similar high expression values of the GLP-1, PYY and GPR120 genes. 
Even though pigs have a higher relative volume and surface area of the large 
intestine than humans, we did not observe differences between the large 
intestine of pigs and humans as far as these genes are concerned (37). As 
became clear from the loading vectors of all PLS models, GPR120, glucagon 
and PYY were predominantly expressed in the distal part of the intestine. 
GPR120 is expressed in L-cells of the intestine, which are enteroendocrine cells 
containing both PYY and GLP-1 (38). To our knowledge the effect of GPR120 
activation on PYY secretion has not been investigated yet, while a relation 
between GPR120 and secretion of GLP-1 and CCK has been described (6, 7, 
39). Hirasawa et al. showed that in both human and mouse intestine GPR120 
was abundantly expressed especially in the colon (6). This fatty acid receptor 
has been linked to obesity. In morbidly obese patients GPR120 expression in 
gastric tissue was higher compared to normal-weight individuals (40). Moreover, 
a GPR120 mutation, found to be associated with obesity in man, influenced 
the ability to secrete GLP-1 in response to α-linolenic acid in enteroendocrine 
NCI-H716 cells (41). 
When considering all genes combined, the most pronounced differences 
between the species studied here were found in the proximal small intestine. In 
the duodenum, the expression of the transporter genes SGLT-1 and PepT1 was 
deviating between the species (figure 2.2 and S2.3). For PepT1, a higher gene 
expression in the human duodenum compared to ileum has been observed 
previously (42). However, this is in contrast to findings of others who did not 
find significant differences between its expression in the duodenum and ileum 
(34). In the porcine and murine intestine, the gene expression of PepT1 was 
highest in the jejunum, which is in agreement with findings of others (43, 44). 
SGLT-1 gene expression along the intestine has been investigated in rodents, 
showing highest expression in the jejunum, whereas our results showed highest 
expression in duodenum and proximal jejunum (38, 45). To our knowledge, 
SGLT-1 expression along the intestinal axis has not been reported previously 
for humans or pigs.
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The basis that may underlie the different gene expression patterns in the 
proximal part of the intestine in the three species is unknown. However, gene 
expression of both transporters is known to be influenced by nutritional status 
or diet composition. High-protein diets are known to increase PepT1 mRNA 
expression and transporter activity (46, 47). However, PepT1 increases found in 
these studies affected the middle and distal small intestine. Furthermore, a fed 
or fasted state might have influenced the amount of PepT1 mRNA, but studies 
show contradictory results (44, 48, 49). Similarly, high-carbohydrate diets 
have been shown to increase SGLT-1 gene expression levels in the proximal 
and mid intestine but not in the distal small intestine (50, 51). This increased 
expression is regulated by the sweet taste receptor (52, 53). Therefore, it can 
be suggested that differences in dietary composition may contribute to the 
duodenal differences in expression patterns of these transporters in the three 
species. The high duodenal SGLT-1 expression in humans might be explained 
by a diet higher in carbohydrates compared to that of pigs and mice as the 
participants had no diet constrains. Interestingly, in our mice study the effect of 
a different fat content in the diet (at the expense of corn starch) on the gene 
expression of SGLT-1 was found to be much smaller than reported for effects 
of dietary carbohydrates in the literature. This could be due to the fact that 
in other studies sucrose was the main source of carbohydrates, whereas starch 
was the main dietary carbohydrate in the present study (53).
In spite of the fact that the expression patterns of the transporters, PepT1 
and SGLT-1 along the intestine were found to differ between the species, 
figure 2.2 and S2.3 show a striking and species-independent similarity in gene 
expression pattern between the two nutrient transporters. This might be due 
to a similar function in the intestine in the uptake of either peptides or glucose 
after the digestion of proteins and carbohydrates. These macronutrients are 
mainly digested by the action of pancreatic and brush border enzymes, which 
primarily takes place in the duodenum and proximal jejunum (54). 
Due to the invasiveness of the procedure, the vast majority of duodenal, 
jejunal and ileal biopsies were obtained from different human subjects. Gene 
expression in the human duodenal samples showed a high inter-individual 
variation compared to the other regions of the intestine. This may at least in part 
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be explained by different dietary habits between individuals. Additionally, 
genotypical differences might play a role as well. 
Microarray and qPCR are two techniques for measuring gene expression 
and there is evidence for a strong correlation between qPCR and Microarray 
analysis (27-29). However as the units of the output of both techniques are 
not directly comparable, the data needs further appropriate processing to 
make a reliable comparison of the data possible. PLS is a tool that can meet 
this demand. PLS is commonly used in the analysis of instrumental chemical 
measurements. Its use with biological data is increasingly being recognized 
(55, 56). 
Our results show a high proximal expression of the GLP-1 receptor (figure 2.2 
and S2.2). This observation was remarkable as GLP-1 is mainly secreted in 
the distal parts of the intestine. However, it was recently shown that the GLP-1 
receptor is expressed in both the small and large intestine (57). In agreement 
with our data, that study showed that the vagal innervation of GLP-1 is reduced 
along the intestinal tract (57). 
In contrast to T1R3, gene expression of its heterodimer T1R2 was not detected 
in both human and porcine intestine. A very low gene expression of T1R2 is 
consistent with findings from other studies (21, 22, 58). An explanation for 
the much lower gene expression of T1R2 compared to the expression of T1R3 
could be the potential dimerization of T1R3 with other GPRs (59). This idea is 
supported by the fact that tissue explants of the jejunum and ileum from T1R3 
knockout mice had no GLP-1 secretion compared to explants from wild type 
animals, whereas ileum explants of T1R2 knockout mice still secreted GLP-1. 
The authors of that study suggested that T1R3 can partially compensate for 
the loss of T1R2 (60). T1R3 was expressed in the intestine of all three species 
suggesting a functional role in the intestine, possibly sensing of amino acids 
and/or sweet compounds. 
In order to study the effect of fat content (at the expense of carbohydrate 
content) on expression of nutrient sensing related genes, we performed a two 
week diet intervention study in mice. The PLS model of these data showed 
slight differences in gene expression of the high-fat/low-carbohydrate diet 
compared to the chow diet in the distal region of the small intestine. Although 
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it has been shown that a high-fat diet can induce changes in gene expression in 
several other pathways, like lipid metabolism and cell cycle, the nutrient sensing 
related genes studied here were hardly influenced by the fat/carbohydrate 
content in the diet (19, 61). 
In conclusion, this study shows that the intestinal expression pattern of genes 
related to nutrient sensing show the highest similarity between humans, pigs and 
mice in the distal ileum and a high similarity between human and pigs in the 
colon. At the same time, more deviating gene expression patterns between the 
species were found for the proximal intestine. For the proximal small intestine 
some prudence in extrapolation of gene expression data from one species to 
the other may be required with respect to nutrient sensing. Lastly, we provided 
detailed information on the specific expression patterns of glucagon, CCK, 
PYY, GLP-1 receptor, PepT1, SGLT-1, T1R3 and GPR120 over the longitudinal 
intestinal axis of human, pigs and mice under normal physiological conditions. To 
our knowledge, this is the first study where gene expression of nutrient sensing 
related mechanisms has been characterized in such detail along the intestinal 
tract, and compared for relevant species, including human. Knowledge of the 
expression patterns of these nutrient sensing related genes in commonly used 
species may contribute to a better understanding of the satiating effects of 
specific diets and products. Furthermore, understanding their site- (and time-) 
specific interactions with molecular ligands may contribute to strategies for 
food intake modulation. 
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Figure S2.1: Gene expression of glucagon and CCK along the intestine of human, 
pig and mouse. Gene expression of glucagon in pig (A), human (B), mice (C) and gene 
expression of CCK in pig (D), human (E), mice (F) as assessed in numerous intestinal 
locations. Human and pig data show relative expression corrected for reference gene 36B4 
determined using qPCR analysis. Mice results show microarray intensity. 
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Figure S2.2: Gene expression of PYY and GLP-1 receptor along the intestine of human, 
pig and mouse. 
Gene expression of PYY in pig (A), human (B), mice (C) and gene expression of GLP-1 
receptor in pig (D), human (E), mice (F) as assessed in numerous intestinal locations. Human 
and pig data show relative expression corrected for reference gene 36B4 determined 
using qPCR analysis. Mice results show microarray intensity. 
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Figure S2.3: Gene expression of PepT1 and SGLT-1 along the intestine of human, pig 
and mouse. Gene expression of PepT1 in pig (A), human (B), mice (C) and gene expression 
of SGLT-1 in pig (D), human (E), mice (F) as assessed in numerous intestinal locations. Human 
and pig data show relative expression corrected for reference gene 36B4 determined using 
qPCR analysis. Mice results show microarray intensity. Both genes were highly expressed in 
all three species.
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Figure S2.4: Gene expression of T1R3 and GPR120 along the intestine of human, pig 
and mouse. Gene expression of T1R3 in pig (A), human (B), mice (C) and gene expression 
of GPR120 in pig (D), human (E), mice (F) as assessed in numerous intestinal locations. Human 
and pig data show relative expression corrected for reference gene 36B4 determined 
using qPCR analysis. Mice results show microarray intensity. 
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Figure S2.5: Gene expression along the intestine of human, pig and mouse. Gene 
expression of T1R1 in pig (A), mice (D) and gene expression of GPR119 in human (B), mice 
(E) and gene expression of GPR93 in human (C), mice (F) as assessed in numerous intestinal 
locations. Human and pig data show relative expression corrected for reference gene 36B4 
determined using qPCR analysis. Mice results show microarray intensity. 
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Figure S2.6: Gene expression along the intestine of mice on chow, high-fat and low-
fat diet. Black bars show chow diet, grey bars show high fat diet and white bars show low 
fat diet. Results show mean microarray intensity of 4 mice per group and the standard 
deviation. 
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Table S2.1: Porcine primers used for qPCR analysis.
Table S2.2: Human primers used for qPCR analysis.
Table	2:	Loading	vectors	of	the	pig,	human	and	mouse	PLS	model	of	the	small	intes>ne. 
Name Forward	primer Reverse	primer
GCG CAAGAGGAACAAGAATAACAT AAGAACTTACATCACTGGTA
CCK TCAGAGGAGGCAGAAGAA TGGACAATGTTACAGACAGATT
PYY AGATATGCTAATACACCGAT CCAAACCCTTCTCAGATG
GLP1R GCATCGTCAAGTACCTCT GGATGATGAGCCAGTAGTTC
Tas1R1 ATCTGTTCTCGAGGCCAAGTCT GCGAGTCCCCACTGTCACTAA
Tas1R3 GCTGGGCGACAGGACAG TTGATTTCCTCCACAGCCAT
SLC5A1 AAAGGAGAGGTCTGGGATGGTAA ATTTCCCTAGTGGCCTGAGATTG
SLC15A1 AATTGTGTCGTTGTCCAT	 AAGTCTGTGAGGTCATTG
LPAR5 TGGGATGTGTCGTTTGTT CCTTGATGCCTTGGTGAT
RPLP0 CTTTAGGCATCACCACTA TGTCTCCAGTCTTAATCAG
Name Forward	primer Reverse	primer
GCG AGCATTTACTTTGTGGCTGGAT CGCTTGTCCTCGTTCATCTGAT
CCK TATCGCAGAGAACGGATG AGGTTCTTAACGATGGACAT
PYY CTGAACCGCTACTACGCCTC CGTCTCTTTTCCCATACCGCT
GLP1R TTGGGGTGAACTTCCTCATC CTTGGCAAGTCTGCATTTGA
Tas1R3 GCTAAATCACCACCAGAC TGCACTGAAGAGTGTTGT
SLC5A1 TCTCTACCGTCTGTGTTG GCTCTCCTGAAGATTCCT
SLC15A1 CTTCTTCATCGTGGTCAA GGTGGACAGGTTATCATC
FFAR4 CAGCAATCACATCTCCTACAT CGTCCTGAATCGGTTCTAAG
GPR119 Hs02825719_s1	(Life	technologies)
LPAR5 TTCTCGCATAGTGACTTGT TTGGACTTGGATGTTGTTG
RPLP0 CGGGAAGGCTGTGGTGCTG GTGAACACAAAGCCCACATTCC
Table	2:	Loading	vectors	of	the	pig,	human	and	mouse	PLS	model	of	the	small	intes>ne. 
Name Forward	primer Reverse	primer
GCG CAAGAGGAACAAGAATAACAT AAGAACTTACATCACTGGTA
CCK TCAGAGGAGGCAGAAGAA TGGACAATGTTACAGACAGATT
PYY AGATATGCTAATACACCGAT CCAAACCCTTCTCAGATG
GLP1R GCATCGTCAAGTACCTCT GGATGATGAGCCAGTAGTTC
Tas1R1 ATCTGTTCTCGAGGCCAAGTCT GCGAGTCCCCACTGTCACTAA
Tas1R3 GCTGGGCGACAGGACAG TTGATTTCCTCCACAGCCAT
SLC5A1 AAAGGAGAGGTCTGGGATGGTAA ATTTCCCTAGTGGCCTGAGATTG
SLC15A1 AATTGTGTCGTTGTCCAT	 AAGTCTGTGAGGTCATTG
LPAR5 TGGGATGTGTCGTTTGTT CCTTGATGCCTTGGTGAT
RPLP0 CTTTAGGCATCACCACTA TGTCTCCAGTCTTAATCAG
Name Forward	primer Reverse	primer
GCG AGCATTTACTTTGTGGCTGGAT CGCTTGTCCTCGTTCATCTGAT
CCK TATCGCAGAGAACGGATG AGGTTCTTAACGATGGACAT
PYY CTGAACCGCTACTACGCCTC CGTCTCTTTTCCCATACCGCT
GLP1R TTGGGGTGAACTTCCTCATC CTTGGCAAGTCTGCATTTGA
Tas1R3 GCTAAATCACCACCAGAC TGCACTGAAGAGTGTTGT
SLC5A1 TCTCTACCGTCTGTGTTG GCTCTCCTGAAGATTCCT
SLC15A1 CTTCTTCATCGTGGTCAA GGTGGACAGGTTATCATC
FFAR4 CAGCAATCACATCTCCTACAT CGTCCTGAATCGGTTCTAAG
GPR119 Hs02825719_s1	(Life	technologies)
LPAR5 TTCTCGCATAGTGACTTGT TTGGACTTGGATGTTGTTG
RPLP0 CGGGAAGGCTGTGGTGCTG GTGAACACAAAGCCCACATTCC
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Abstract
Background/Objectives: Bariatric surgery is an effective intervention strategy 
in obesity, resulting in sustained weight loss and a reduction of comorbidities. 
Gastroplication, using the articulating circular endoscopic stapler, has recently 
been introduced as a transoral bariatric technique. This procedure reduces 
gastric volume and induced 34.9% (IQR 17.8-46.6) of excess weight loss in the 
first year (1). The aim of the present study was to gain more insight in the long-
term effects and underlying mechanisms of gastroplication by investigating 
differences in the genome-wide gastric and duodenal tissue transcriptome 
before, and one year after intervention.
Subjects/Methods: Ten morbidly obese patients (mean BMI 39.8±0.9kg/m2 
(±s.e.m.)) underwent gastroplication. Previous to the procedure and after one 
year, mucosal biopsies were taken from the fundus, antrum and duodenum. 
At the same time blood samples were taken. Gene expression was measured 
using microarray analysis. Additionally, plasma levels of adiponectin, HbA1c, 
IL-1β, IL-6, IL-7, TNF-α, IFN-γ, MCP-1, IL-8, TGF-1, and CRP were determined.
Results: Downregulation of inflammatory genes and gene sets was observed in 
the fundus and duodenum one year after surgery. Furthermore, gene expression 
of ghrelin and its activating enzyme GOAT were downregulated in the upper 
gastrointestinal tract. Patients showed a reduction in plasma HbA1c levels 
(from 6.17±0.51% to 5.32±0.14%, p=0.004) and an increase of plasma 
adiponectin (from 16.87±3.67µg/ml to 27.67±5.92µg/ml, p=0.002). 
Conclusions: Individuals undergoing gastroplication displayed a striking 
downregulation of inflammatory tone in the stomach and duodenum, which 
coincided with improved HbA1c and adiponectin levels. The reduction of 
inflammatory tone in the upper gastrointestinal tract may be a consequence of 
an improved metabolic health status, or alternatively caused by the procedure 
itself. 
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Introduction
Bariatric surgery is the most effective medical option to achieve sustained weight 
loss in severe obesity. Besides traditional procedures such as laparoscopic 
Roux-en-Y gastric bypass (RYGB), vertical sleeve gastrectomy (VSG) and 
adjustable gastric banding (LAGB), less invasive options are available such 
as the (transorally placed) duodenal-jejunal bypass sleeve (DJBS). In general, 
these procedures lead to a loss of body fat, a reduction of comorbidities, and 
improvement of long-term health risks. Remarkably, the mechanisms behind 
these outcomes are still poorly understood, and it is conceivable that these 
comprise different combinations of biological adaptations (2). This is reflected 
in the markedly different immediate effects on glycaemic control following 
different procedures (3). Recently, endoscopic gastroplication has become 
available as a new minimal invasive technique. The Articulating Circular 
Endoscopic (ACE) stapler is used to reduce the volume of the stomach without 
removing tissue or bypassing other intestinal regions. For this procedure no skin 
incisions are necessary; it is performed via a transoral route. This procedure 
results in a median 34.9 percent (IQR 17.8-46.6) loss of excess weight in 
the first year. Moreover, only mild adverse effects were reported so far (1). 
Although several studies have described metabolic and anti-inflammatory 
effects of bariatric surgery at a molecular level, studies on these processes 
within the gastrointestinal (GI) tract are still limited. This holds particularly true 
for the upper GI tract, as most studies in this field have focussed on the mid 
or lower gastrointestinal tract (4-6). Moreover, these studies concern effects 
of RYGB, a procedure extensively changing GI anatomy and physiology. The 
present study was undertaken to gain more insight in the long-term effects and 
underlying mechanisms of gastroplication in the upper GI tract: the stomach 
(fundus and antrum) and the duodenum, and to relate these to general health 
outcomes, including parameters of inflammation. To this end, transcriptome and 
gene set enrichment analysis was performed with biopsies obtained before 
and one year following gastroplication.
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Materials and methods
ACE stapler study
This study used biopsies and blood samples obtained from ten patients 
who were part of the first human ACE stapler study (1). The Medical Ethical 
Committee of the Maastricht University Medical Center+ in the Netherlands 
(NCT02381340) approved the present study as a sub study aiming to further 
unravel underlying mechanisms. Before inclusion, written informed consent 
was obtained from each participant. The inclusion criteria for the Articulating 
Circular Endoscopic (ACE) Stapler study are described in detail by Paulus et al. 
(1). In brief, participants were 18 to 50 years old with a BMI of 40 to 45 kg/m2 
or 30 to 39.9 kg/m2 in combination with one or more comorbidities expected 
to improve with weight loss. The ACE stapler was introduced into the stomach 
together with a thin endoscope. By applying vacuum to the gastric tissue, a 
large full-thickness (transmural) plication was drawn into the stapler head and 
fixed with a staple ring. Reduction of the stomach volume along the greater 
curvature was completed after creating a maximum of 8 plications in the 
fundus and 2 additional plications in the antrum of the stomach. More details 
on the procedure were published previously (1). Mucosal biopsies were taken 
from the fundus, antrum and duodenum with a standard forceps before starting 
the procedure. Afterwards, patients visited the outpatient clinic regularly and 
were stimulated to adhere to a healthy lifestyle. A follow-up endoscopy was 
planned twelve months after the procedure, at which the biopsy procedure was 
repeated. Biopsies were snap frozen in liquid nitrogen and stored at -80˚C until 
analysis. Table 3.1 shows a brief overview of the characteristics of included 
patients. A more detailed description is given by van Avesaat et al. (7). 
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RNA isolation and microarray processing
RNA of the mucosal biopsies was isolated using TRIzol reagent (Life technologies, 
Bleiswijk, Netherlands) and further purified using the RNeasy micro kit (Qiagen, 
Venlo, Netherlands). RNA yield was measured with the Nanodrop ND-1000 
Spectrophotometer and the quality of the RNA samples was verified with an 
Agilent 2100 Bio analyser (Agilent Technologies, Amstelveen, Netherlands). 
One hundred nanogram of RNA was used for Whole Transcript cDNA synthesis 
(Affymetrix, inc., Santa Clara, USA). Hybridization, washing and scanning of 
Affymetrix GeneChip Human Gene 1.1 ST arrays was carried out according to 
standard Affymetrix protocols. 
Microarray analysis
For the analysis of the microarray results, each location (i.e. fundus, antrum and 
duodenum) was analysed separately. Arrays were normalized using the Robust 
Multi-array Average method (8, 9). Probe sets were assigned to unique gene 
identifiers, in this case Entrez IDs. The probes on the arrays represent 19654 
Entrez IDs (10). Array data were analysed using MADMAX pipeline for statistical 
analysis of microarray data (11). Quality control was performed and all arrays 
met our criteria, except for the fundus and antrum arrays from participant 5, 
which were excluded. All data were filtered, and probe sets with expression 
values above 20 in at least 5 arrays were included for further analysis. These 
data were used for gene set enrichment analysis (GSEA; www.broadinstitute.
org/gsea;(12)) in MADMAX. Gene sets with a false discovery rate (FDR) <0.25 
were considered significantly enriched. The gene set enrichment analysis was 
table	1
Average SEM Average SEM
Age 39 2
Male:Female	ra2o 6	:	4
BMI	(kg/m2) 39,8 0,9 33,4 0,9
Excess	weight	loss	(%) 37,9 4,8
Fasted	ghrelin	level	(pg/ml) 46,5 5,9 63,4 5,2
Baseline One	year
Table 3.1: Overview of characteristics of patients undergoing ACE stapler procedure. 
Measurements were performed at baseline and one year after the procedure (7). Ghrelin 
was measured after a 10-hour overnight fast. 
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visualized using the enrichment plugin in Cytoscape with conservative filtering 
(p<0.001 and FDR q<0.05). For further analysis of individual genes, a cut-off 
of IQR>0.25 was used to filter out genes that showed no variation between 
the samples, Intensity-Based Moderated T-statistics (IBMT) was used to assess 
significant differences with p-value <0.05. 
Plasma measurements
Blood samples were collected in EDTA-coated tubes, centrifuged and stored 
at -80 ̐C until analysis. The measurement of plasma adiponectin and cytokine 
levels were performed using an in-house developed and validated multiplex 
immunoassay (Laboratory of Translational Immunology, University Medical 
Center Utrecht, the Netherlands) based on Luminex technology (xMAP, 
Luminex, Austin, USA). The assay was performed as described previously (13). 
Using heteroblock (Omega Biologicals, Bozeman, USA) aspecific heterophilic 
immunoglobulins were preabsorbed. Acquisition was performed with the 
Biorad FlexMAP3D (Biorad laboratories, Hercules, USA) in combination with 
xPONENT software version 4.2 (Luminex, Austin, USA). Data was analysed 
by 5-parametric curve fitting using Bio-Plex Manager software, version 6.1.1 
(Biorad laboratories, Hercules, USA). HbA1c levels were determined routinely 
at the Department of Clinical Chemistry of the Maastricht University Medical 
Center.
Statistical Analysis
Statistical analyses were performed using Prism 5.0 (GraphPad Software, 
Inc. La Jolla, USA). The effects of treatment on plasma levels of inflammatory 
markers and adiponectin were tested by paired t-tests for normally distributed 
variables and Wilcoxon’s signed ranks tests for non-normally distributed 
variables. A p-value <0.05 was considered statistically significant. Data are 
presented as mean with standard error of the mean (SEM). Statistical analysis 
of transcriptome data was described above.
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Results
Effects of gastroplication on systemic metabolic and inflammatory 
parameters one year after intervention
Plasma levels of glycated haemoglobin, adiponectin and several pro-
inflammatory mediators before and after intervention are shown in table 
2. Significant changes were found for adiponectin and HbA1c. Adiponectin 
showed a 1.64 fold increase (p=0.002) in the patients who underwent ACE 
stapler treatment. Glycated haemoglobin (HbA1c) was significantly decreased 
(p=0.004) by the treatment. Plasma IL-6 showed a tendency to decrease 
following ACE stapler treatment by a factor 1.47. MCP-1 levels also showed a 
decrease (1.3 fold) but this effect did not reach statistical significance. 
Table 3.2: The effect of ACE stapler treatment on fasted plasma levels of inflammatory 
and metabolic markers. Plasma levels were measured before the treatment (baseline) and 
one year after. 
Effects on tissue gene expression mainly relate to inflammatory pathways
Gene expression changes one year after intervention compared to baseline 
were analysed for different locations of the upper gastrointestinal tract, 
namely fundus, antrum and duodenum. After intervention 727 genes (259 
upregulated, 468 downregulated) were significantly changed in the fundus, 
1846 (951 upregulated, 895 downregulated) in the antrum and 921 genes 
(480 upregulated, 441 downregulated) in the duodenum. The top 20 up- and 
downregulated genes in all three locations are shown in figure 3.1. In both 
table	2
Plasma	marker Baseline One	year
Unit Average SEM Average SEM Diﬀerence p-value
Adiponec2n µg/ml 16,87 3,67 27,67 5,92 10,8 0.002*
HbA1c % 6,17 0,51 5,32 0,14 -0,85 0.004*
IL-1β pg/ml 1,42 0,06 1,37 0,08 -0,05 0,244
IL-6	 pg/ml 10,90 1,83 7,41 1,80 -3,49 0,069
IL-7	 pg/ml 11,52 1,24 10,43 2,01 -1,09 0,18
TNF-α pg/ml 2,14 0,10 2,00 0,14 -0,14 0,118
IFN-γ pg/ml 2,54 0,27 2,23 0,25 -0,32 0,099
MCP-1	 pg/ml 60,70 7,33 46,68 7,74 -14,02 0,088
IL-8	 pg/ml 7,03 1,03 6,55 1,44 -0,48 0,455
LAP	/	TGF-1 ng/ml 3,11 0,35 3,24 0,36 0,13 0,393
CRP mg/l 12,62 5,66 8,78 2,75 -3,85 0,248
Treatment	eﬀect
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fundus and duodenum a considerable number of downregulated genes have 
been associated with immunity and inflammatory pathways. In the fundus the 
expression of immune-related genes like IGHV3-33, C7, CCL21, IFI6, IFI27, 
C1QB were downregulated and CCL18, CLC, CXCR4, IGHV1-24, RSG1, 
IGLV3-10, IGHV3-33, IGLV7-46 were downregulated in the duodenum. In the 
antrum there was an upregulation of some neuroendocrine associated genes, 
namely PAX6, CHGB, SCG5.
Gene set enrichment analysis reveals potential processes involved
To gain more insight into the processes changed one year following the 
stomach volume reduction procedure, gene set enrichment analysis (GSEA) was 
performed. This computational method uses molecular signatures to associate 
changes in gene expression with known biological processes. Analysis resulted 
in 236 (2 upregulated, 234 downregulated) enriched gene sets for fundus, 546 
(474 upregulated, 72 downregulated) enriched gene sets for antrum and 253 
(182 upregulated, 71 downregulated) enriched gene sets for duodenum. In 
the antrum more gene sets were upregulated, whereas in the fundus most gene 
sets were downregulated (figure 3.2). Of these downregulated gene sets in 
the fundus, many were related to immune responses, mostly to the complement 
system, presentation and recognition of antigens (self or pathogenic) and T-cell 
receptor signaling. Also in the duodenum, some of the downregulated gene sets 
were related to the innate immunity. In the antrum, cell cycle related gene sets 
were strongly enriched. In the duodenum the enrichment analysis showed also 
a slight upregulation of cell cycle processes. Here, more metabolic pathways 
were apparently upregulated, including those associated with ‘fat digestion 
and absorption’ and ‘metabolism of lipids and lipoproteins’. All gene sets are 
specified in supplemental table S3.1.
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Figure 3.1: Expression of m
ost highly significantly upregulated and dow
nregulated genes in fundus, antrum
 and duodenum
, respectively. 
G
reen is a signal log ratio of -2 and red is a signal log ratio of 2. A
part from
 the m
ean fold change (FC
) of the top regulated genes 
by the treatm
ent; signal log ratios are displayed to show
 inter-individual differences.
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Changes in gastrointestinal hormone expression
Being one of the main gastric hormones, ghrelin is not only involved in 
appetite regulation but also in immunity (14). Two genes related to ghrelin 
were significantly changed in specific locations of the GI tract (figure 3.3). 
In the fundus, there was a downregulation of MBOAT4 (FC=-1.49), the gene 
encoding the ghrelin-activating enzyme GOAT4. Furthermore, there was a 
trend for downregulation of ghrelin expression itself in the fundus (FC= -1.88, 
p= 0.19) and antrum (FC= -3.13, p= 0.11) and a significant downregulation 
in the duodenum (FC= -1.34).
Figure 3.3: Changes in gene expression of ghrelin and MBOAT4. The graphs show RMA 
normalised intensities of microarray data at baseline and one year after gastroplication in 
biopsies of fundus, antrum and duodenum. Fold changes are indicated on top of the bars, 
significant changes are marked with * (p<0.05). All graphs show mean and SEM.
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Discussion
Results of the present study add important physiological background information 
to the clinical outcomes observed in patients after undergoing ACE stapler 
gastroplication. Our plasma analyses revealed beneficial effects on HbA1c 
and adiponectin levels one year after surgery, indicating an improvement 
of glycaemic control and a favourable shift in adipose tissue mass and (or) 
inflammatory status, respectively. This rise in plasma adiponectin and reduction 
of HbA1c is in line with previous studies in which a loss of excess body fat 
was achieved, including those involving other surgical and non-surgical weight 
loss interventions (15-18). We also found tendencies for reduced plasma IL-6 
and MCP-1 levels, one year after intervention. Reduced levels of inflammatory 
markers are generally assumed to result from a reduction of visceral fat 
mass in particular, which plays a major role in the low grade inflammatory 
state associated with obesity (19). The total number of patients in our study 
population is quite small, and it is conceivable that statistical significance might 
have been reached with a larger patient group. Several other studies have 
found significant reductions in inflammatory markers like CRP, MCP-1 and IL-6 
after bariatric surgery, while others did not find such an effect (20-22). To 
our knowledge, this study is the first to analyse long-term whole transcriptome 
changes in the upper gastrointestinal tract after a new transoral bariatric 
procedure. Gastroplication reduces gastric volume without altering intestinal 
anatomy, as is the case with Roux-en-Y gastric bypass (RYGB). In contrast to 
bypass surgery, exposure of the intestinal epithelium to nutrients and their 
metabolites is largely maintained after this endoscopic gastroplication. At 
the same time, small changes related to different GI transit characteristics or 
changes in the microbiome might still occur. 
Analysis of the large amount of data using unbiased transcriptome analysis 
clearly pointed towards a reduction in inflammatory tone in the fundus and 
duodenum tissues as manifested by the downregulation of a wide variety of 
inflammation-related gene sets. The downregulated gene sets in the fundus 
were mostly related to innate immunity, and particularly associated with 
downregulation of the complement system, presentation and recognition of 
antigens (self or pathogenic), IFN-γ signalling and T-cell receptor signalling. 
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In the duodenum the main downregulated gene set was associated with the 
complement system. Moreover, the top 20 highly changed genes in these 
locations also suggest notable downregulation of many immune-related 
processes, of which several were related to chemokines, complement system, 
interferon signalling and immunoglobulins. These results coincided with the 
weight loss, improvement of HbA1c levels and decrease of whole-body 
inflammatory tone in these patients.
Based on the present study we cannot establish whether the apparent reduction 
of inflammatory tone in the upper GI tract has a predominantly local cause, 
i.e. due to a changed food-intake pattern or digestion process, or whether it is 
related to a reduction of low-grade systemic inflammation due to the reduction 
of body fat mass. 
Increasing evidence points to a link between intestinal inflammation status in 
general, obesity and (or) diabetes. In obesity, increased innate cell densities, 
among which macrophages, natural killer cells and T-cells, especially the 
proportion of cytotoxic CD8 T-cells, have been observed in the jejunal 
epithelium. These epithelial T-cells were found to be associated with local 
and systemic comorbidities. Furthermore, isolated T-cells from obese patients 
decreased insulin sensitivity of epithelial cells in vitro (23). Another study 
reported that diet-induced weight loss resulted in a downregulation of 
inflammatory pathways and inflammatory cytokines IL-8, TNF-α, MCP-1 and 
IL-1β, in recto-sigmoid mucosal tissue (24). Moreover, increased intestinal 
inflammatory gene expression of TNF-α, IL-6, ICAM and PTGS-2 was found in 
insulin-resistant obese patients compared to non-insulin resistant obese patients, 
suggesting that intestinal inflammation is involved in diabetes during obesity 
(25, 26). A prominent feature of the immune system in the gastrointestinal tract 
is to provide adequate protection without stimulating excessive inflammation, 
thereby maintaining a fine balance (27, 28). A pro-inflammatory immune 
status of the gastrointestinal tract in obese patients might be protective against 
increased luminal challenges associated within obesity but deteriorating for 
insulin resistance (23). Furthermore, this pro-inflammatory status might be 
linked to the increased prevalence of inflammatory bowel disease and cancer 
in obese patients (29-31). In summary, we can only speculate whether the 
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reduced inflammatory microenvironment in gastric and duodenal tissue found 
after gastroplication can be considered as a positive or negative outcome. 
In the antral tissue, gene sets related to cell cycle processes and extracellular 
matrix were increased. This might be explained by dilation of the stomach, 
a common observation after gastric volume reduction (32-35). While gastric 
volume was not quantified, we perceived the stomach as larger at one-year 
follow-up than immediately after gastroplication.
An interesting observation was that the gene expression of ghrelin and the enzyme 
GOAT, responsible for ghrelin acylation, decreased after gastroplication. At 
the same time, plasma fasted ghrelin was increased. Ghrelin is one of the 
most prominent hormones secreted from the upper gastrointestinal tract and 
does not only play a role in appetite regulation but also in inflammation (14). 
Consistent with our results, in RYGB patients significant lower levels of jejunal 
ghrelin gene expression have been reported after 10 months (6). Furthermore, 
GOAT mRNA expression and GOAT-positive cell numbers were lower in a non-
obese group compared to morbidly obese patients, although no changes in 
jejunal ghrelin expression were detected (36). Moreover, more ghrelin positive 
cells were found in the stomach of morbidly obese and overweight patients 
compared to healthy normal weight controls (37, 38), which might indicate 
that with weight loss the number of ghrelin-releasing cells will decrease. The 
discrepancy with ghrelin expression in the gastrointestinal tract and plasma 
ghrelin values might be explained by a reduced secretory activity of (a higher 
number of) ghrelin producing cells in obesity, as suggested by Widmayer et 
al (37). The implications of these changes in ghrelin are not fully understood 
and need further investigation to crystallize the underlying mechanism and to 
explore the potential of these changes in obesity treatment.
There are some strengths and limitations to this study. The within person 
measurement of changes in gastrointestinal gene expression is unique as most 
studies in this field are observational. By applying a prospective design we 
were able to perform paired analysis and look specifically for changes induced 
by the gastroplication treatment instead of comparing obese subjects with lean 
controls. Whole transcriptome analysis enabled us to investigate changes in an 
unbiased manner. One of the limitations of this study is that it was not powered 
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to find differences in inflammatory markers. Therefore the inclusion of more 
patients could have strengthened the study. Furthermore, a control group on 
a lifestyle intervention program could help differentiate between weight loss 
effects and strictly procedural effects. 
This study presents the long-term effects of a new transoral gastroplication 
treatment in morbidly obese patients. We show that this recently developed 
ACE stapler procedure was not only effective in reducing body weight as 
presented before (1), but also improved glycated haemoglobin levels and 
increased plasma adiponectin. Furthermore, whole transcriptome analysis 
suggested a marked downregulation of inflammatory gene sets in both the 
fundus and duodenum, coinciding with changes in plasma cytokines. Moreover, 
gene expression of ghrelin and its activating enzyme GOAT were reduced 
after gastroplication. The apparent reduction of inflammatory tone in the 
upper GI tract may be a consequence of an improved metabolic health status 
as associated with weight loss, or alternatively caused by the procedure itself. 
In conclusion, this new transoral gastroplication treatment which induced 
significant weight loss and improved plasma levels of adiponectin and glycated 
haemoglobin, coincides with a reduced inflammatory tone in the upper GI tract. 
The clinical relevance of our findings remains to be established, as there is still 
limited knowledge on the role of inflammatory pathways in the upper GI tract 
in obesity 
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Table	 S1: 	 Ful l 	 GSEA	 l ist 	 of 	 fundus, 	 antrum	 and	 duodenum.	 Gene	 sets 	 within	 several 	 processes	 using	
conservative	f i lter ing	(p<0.001	and	FDR	q<0.05) 	with	their 	normalised	enrichment	scores	(NES).	
Fundus	 		 		
Process	 Gene	set	 NES	
INTERFERON.SIGNALING	 -1.82327	
KEGG_ALLOGRAFT.REJECTION	 -2.51834	
KEGG_VIRAL.MYOCARDITIS	 -2.4598	
WP2739.AMYLOIDS	 -2.07757	
KEGG_TUBERCULOSIS	 -2.35037	
KEGG_TYPE.I.DIABETES.MELLITUS	 -2.6364	
KEGG_TOXOPLASMOSIS	 -1.86798	
INTERFERON.GAMMA.SIGNALING	 -2.2216	
KEGG_SYSTEMIC.LUPUS.ERYTHEMATOSUS	 -2.86087	
KEGG_ASTHMA	 -2.34147	
CYTOKINE.SIGNALING.IN.IMMUNE.SYSTEM	 -1.76089	
KEGG_AUTOIMMUNE.THYROID.DISEASE	 -2.49038	
KEGG_STAPHYLOCOCCUS.AUREUS.INFECTION	 -2.82522	
WP1835.INTERFERON.ALPHA.BETA.SIGNALING	 -1.83516	
KEGG_CHAGAS.DISEASE.AMERICAN.TRYPANOSOMIASIS.	 -2.24942	
KEGG_INTESTINAL.IMMUNE.NETWORK.FOR.IGA.PRODUCTION	 -2.33433	
KEGG_CELL.ADHESION.MOLECULES.CAMS.	 -2.59037	
WP1836.INTERFERON.GAMMA.SIGNALING	 -2.19636	
KEGG_GRAFT.VERSUS.HOST.DISEASE	 -2.67827	
KEGG_ANTIGEN.PROCESSING.AND.PRESENTATION	 -2.57427	
WP2328.ALLOGRAFT.REJECTION	 -2.33522	
KEGG_LEISHMANIASIS	 -2.43961	
KEGG_INFLUENZA.A	 -1.70275	
Antigen	
presentation	and	
processing	
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
KEGG_RHEUMATOID.ARTHRITIS	 -1.97922	
WP558.COMPLEMENT.AND.COAGULATION.CASCADES	 -2.64551	
WP2806.HUMAN.COMPLEMENT.SYSTEM	 -2.14534	
WP2775.TOLL.LIKE.RECEPTORS.CASCADES	 -2.24403	
WP1829.IMMUNOREGULATORY.INTERACTIONS.BETWEEN.A.LYMPHOID.AN
D.A.NON.LYMPHOID.CELL	
-2.75048	
WP1798.COMPLEMENT.CASCADE	 -2.59545	
WP1794.CELL.SURFACE.INTERACTIONS.AT.THE.VASCULAR.WALL	 -2.22474	
SCAVENGING.OF.HEME.FROM.PLASMA	 -1.98708	
RESPONSE.TO.ELEVATED.PLATELET.CYTOSOLIC.CA2.	 -2.11246	
PLATELET.DEGRANULATION	 -2.13783	
PLATELET.ACTIVATION.SIGNALING.AND.AGGREGATION	 -1.87206	
NITRIC.OXIDE.STIMULATES.GUANYLATE.CYCLASE	 -2.28073	
KEGG_COMPLEMENT.AND.COAGULATION.CASCADES	 -2.67419	
INNATE.IMMUNE.SYSTEM	 -1.92568	
INITIAL.TRIGGERING.OF.COMPLEMENT	 -2.53372	
IMMUNOREGULATORY.INTERACTIONS.BETWEEN.A.LYMPHOID.AND.A.NON
.LYMPHOID.CELL	
-2.73543	
HEMOSTASIS	 -2.03207	
FORMATION.OF.FIBRIN.CLOT.CLOTTING.CASCADE.	 -1.94238	
FCGR.ACTIVATION	 -2.31351	
FCERI.MEDIATED.CA.2.MOBILIZATION	 -2.07759	
CREATION.OF.C4.AND.C2.ACTIVATORS	 -2.33675	
COMPLEMENT.CASCADE	 -2.64418	
CGMP.EFFECTS	 -2.14792	
Complement	
system	
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
CELL.SURFACE.INTERACTIONS.AT.THE.VASCULAR.WALL	 -2.05582	
Supplemental data
Table S3.1: Full GSEA list of fundus, antrum and duodenum. Gene sets within several 
processes using conservative filtering (p<0.001 and FDR q<0.05) with their normalised 
enrichment scores (NES).
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PD.1.SIGNALING	 -2.40159	
TCR.SIGNALING	 -2.3198	
DOWNSTREAM.TCR.SIGNALING	 -2.18912	
COSTIMULATION.BY.THE.CD28.FAMILY	 -2.0165	
WP1927.TCR.SIGNALING	 -2.21863	
PHOSPHORYLATION.OF.CD3.AND.TCR.ZETA.CHAINS	 -2.30236	
GENERATION.OF.SECOND.MESSENGER.MOLECULES	 -2.67015	
T-cell	receptor	
signaling	
		
		
		
		
		
		
		
WP1799.COSTIMULATION.BY.THE.CD28.FAMILY	 -2.11037	
KEGG_CHEMICAL.CARCINOGENESIS	 -2.10708	
GLUTATHIONE.CONJUGATION	 -1.77924	
KEGG_METABOLISM.OF.XENOBIOTICS.BY.CYTOCHROME.P450	 -2.23614	
KEGG_DRUG.METABOLISM.CYTOCHROME.P450	 -2.02946	
Metabolism	of	
xenobiotics	
		
		
		
		
KEGG_DILATED.CARDIOMYOPATHY	 -1.97885	
WP2118.ARRHYTHMOGENIC.RIGHT.VENTRICULAR.CARDIOMYOPATHY	 -1.96139	
KEGG_ARRHYTHMOGENIC.RIGHT.VENTRICULAR.CARDIOMYOPATHY.ARVC.	 -1.99686	
Cardiomyopathy	
		
		 KEGG_HYPERTROPHIC.CARDIOMYOPATHY.HCM.	 -1.95811	
MUSCLE.CONTRACTION	 -2.04807	
WP1864.MUSCLE.CONTRACTION	 -2.02105	
Muscle	contraction	
		
		 SMOOTH.MUSCLE.CONTRACTION	 -2.15383	
PEPTIDE.LIGAND.BINDING.RECEPTORS	 -1.73849	
WP24.PEPTIDE.GPCRS	 -1.82179	
Receptors	
		
		 CHEMOKINE.RECEPTORS.BIND.CHEMOKINES	 -2.16619	
WP619.TYPE.II.INTERFERON.SIGNALING.IFNG.	 -2.14764	
BIOC_NKTPATHWAY	 -2.18916	
MHC.CLASS.II.ANTIGEN.PRESENTATION	 -1.70662	
AMYLOIDS	 -1.81128	
KEGG_HEMATOPOIETIC.CELL.LINEAGE	 -1.92881	
KEGG_LYSOSOME	 -1.73537	
WP560.TGF.BETA.SIGNALING.PATHWAY	 -1.75296	
KEGG_MALARIA	 -1.94819	
KEGG_LONG.TERM.DEPRESSION	 -1.73225	
MOLECULES.ASSOCIATED.WITH.ELASTIC.FIBRES	 -2.00971	
KEGG_PERTUSSIS	 -2.42017	
WP1833.INTEGRIN.CELL.SURFACE.INTERACTIONS	 -1.98508	
ARACHIDONIC.ACID.METABOLISM	 -1.95268	
KEGG_LEUKOCYTE.TRANSENDOTHELIAL.MIGRATION	 -1.8182	
G.PROTEIN.MEDIATED.EVENTS	 -1.70815	
Other	
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
WP2431.SPINAL.CORD.INJURY	 -2.15311	
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Antrum	 		 		
Process	 Gene	set	 NES	
KEGG_ALLOGRAFT.REJECTION	 -1.85431	
FORMATION.OF.THE.BETA.CATENIN.TCF.TRANSACTIVATING.COMPLEX	 1.970776	
WP1775.CELL.CYCLE.CHECKPOINTS	 2.175551	
RNA.POLYMERASE.I.PROMOTER.OPENING	 2.196208	
CELL.CYCLE	 2.353103	
TRANSCRIPTIONAL.REGULATION.BY.SMALL.RNAS	 1.887323	
MITOTIC.METAPHASE.AND.ANAPHASE	 2.200172	
ACTIVATION.OF.APC.C.AND.APC.C.CDC20.MEDIATED.DEGRADATION.OF.MI
TOTIC.PROTEINS	
1.747528	
NORC.NEGATIVELY.REGULATES.RRNA.EXPRESSION	 1.875334	
WP179.CELL.CYCLE	 2.256023	
ORC1.REMOVAL.FROM.CHROMATIN	 1.964168	
REGULATION.OF.DNA.REPLICATION	 2.05806	
REGULATION.OF.APC.C.ACTIVATORS.BETWEEN.G1.S.AND.EARLY.ANAPHASE	 1.695511	
CDC20.PHOSPHO.APC.C.MEDIATED.DEGRADATION.OF.CYCLIN.A	 1.642509	
CYCLIN.A.CDK2.ASSOCIATED.EVENTS.AT.S.PHASE.ENTRY	 1.863858	
ACTIVATION.OF.ATR.IN.RESPONSE.TO.REPLICATION.STRESS	 2.31258	
WP1874.NUCLEOSOME.ASSEMBLY	 2.30575	
WP1858.MITOTIC.G1.G1.S.PHASES	 2.262116	
CYCLIN.E.ASSOCIATED.EVENTS.DURING.G1.S.TRANSITION	 1.828069	
WP2369.HISTONE.MODIFICATIONS	 2.202452	
WP2739.AMYLOIDS	 2.570812	
TCF.DEPENDENT.SIGNALING.IN.RESPONSE.TO.WNT	 1.680383	
REMOVAL.OF.LICENSING.FACTORS.FROM.ORIGINS	 1.97605	
WP1928.TELOMERE.MAINTENANCE	 2.337343	
KEGG_DNA.REPLICATION	 2.309638	
CONDENSATION.OF.PROPHASE.CHROMOSOMES	 2.472027	
PRC2.METHYLATES.HISTONES.AND.DNA	 2.179259	
MITOTIC.ANAPHASE	 2.227793	
SEPARATION.OF.SISTER.CHROMATIDS	 2.265669	
WP45.G1.TO.S.CELL.CYCLE.CONTROL	 2.216835	
MEIOTIC.RECOMBINATION	 1.907697	
WP2757.MITOTIC.METAPHASE.AND.ANAPHASE	 2.385166	
MITOTIC.G1.G1.S.PHASES	 2.388205	
SIGNALING.BY.WNT	 1.675156	
WP2698.MEIOTIC.RECOMBINATION	 1.839597	
WP1898.REGULATION.OF.DNA.REPLICATION	 1.942631	
NUCLEOSOME.ASSEMBLY	 2.48161	
G0.AND.EARLY.G1	 2.180428	
WP2652.MITOTIC.PROMETAPHASE	 2.602052	
SYNTHESIS.OF.DNA	 2.247251	
MISSPLICED.LRP5.MUTANTS.HAVE.ENHANCED.BETA.CATENIN.DEPENDENT.
SIGNALING	
1.682867	
WP2446.RB.IN.CANCER	 2.758937	
MEIOSIS	 1.730538	
DNA.METHYLATION	 2.263346	
MITOTIC.PROMETAPHASE	 2.418687	
M.PHASE	 2.290548	
NEGATIVE.EPIGENETIC.REGULATION.OF.RRNA.EXPRESSION	 1.848622	
MITOTIC.G2.G2.M.PHASES	 1.640014	
Cell	cycle	
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
ACTIVATION.OF.THE.PRE.REPLICATIVE.COMPLEX	 2.57844	
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S.PHASE	 2.294708	
RNA.POLYMERASE.I.PROMOTER.CLEARANCE	 1.710418	
DNA.REPLICATION	 2.317099	
KEGG_SYSTEMIC.LUPUS.ERYTHEMATOSUS	 2.425107	
XAV939.INHIBITS.TANKYRASE.STABILIZING.AXIN	 1.679086	
TELOMERE.MAINTENANCE	 2.313958	
CELL.CYCLE.CHECKPOINTS	 2.155747	
MITOTIC.M.M.G1.PHASES	 2.536521	
G1.S.SPECIFIC.TRANSCRIPTION	 2.569735	
G2.M.CHECKPOINTS	 2.369734	
WP1925.SYNTHESIS.OF.DNA	 2.370287	
CELLULAR.SENESCENCE	 1.838437	
WP2785.M.G1.TRANSITION	 2.181483	
KEGG_CELL.CYCLE	 2.147555	
WP2361.GASTRIC.CANCER.NETWORK.1	 2.383789	
PACKAGING.OF.TELOMERE.ENDS	 2.018427	
CELL.CYCLE.MITOTIC	 2.420983	
DEPOSITION.OF.NEW.CENPA.CONTAINING.NUCLEOSOMES.AT.THE.CENTRO
MERE	
2.464646	
WP466.DNA.REPLICATION	 2.526486	
CHROMOSOME.MAINTENANCE	 2.485708	
RNF.MUTANTS.SHOW.ENHANCED.WNT.SIGNALING.AND.PROLIFERATION	 1.690068	
REGULATORY.RNA.PATHWAYS	 1.751141	
POLO.LIKE.KINASE.MEDIATED.EVENTS	 1.939158	
SENESCENCE.ASSOCIATED.SECRETORY.PHENOTYPE.SASP.	 1.861184	
APOPTOSIS	 1.650792	
M.G1.TRANSITION	 2.204365	
ASSEMBLY.OF.THE.PRE.REPLICATIVE.COMPLEX	 2.020908	
E2F.MEDIATED.REGULATION.OF.DNA.REPLICATION	 2.469653	
DNA.STRAND.ELONGATION	 2.291611	
KEGG_ALCOHOLISM	 2.205282	
EPIGENETIC.REGULATION.OF.GENE.EXPRESSION	 1.87112	
EXTENSION.OF.TELOMERES	 2.140079	
G1.S.TRANSITION	 2.515779	
WP2772.S.PHASE	 2.367719	
RESOLUTION.OF.SISTER.CHROMATID.COHESION	 2.435047	
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
DNA.REPLICATION.PRE.INITIATION	 2.262319	
WP2710.NONSENSE.MEDIATED.DECAY	 1.956784	
WP1889.PROCESSING.OF.CAPPED.INTRON.CONTAINING.PRE.MRNA	 1.987702	
WP411.MRNA.PROCESSING	 2.125963	
MRNA.SPLICING	 1.973784	
WP1811.EUKARYOTIC.TRANSLATION.ELONGATION	 2.037809	
KEGG_SPLICEOSOME	 1.874981	
WP1812.EUKARYOTIC.TRANSLATION.INITIATION	 1.890107	
WP2737.SRP.DEPENDENT.COTRANSLATIONAL.PROTEIN.TARGETING.TO.ME
MBRANE	
1.809973	
WP477.CYTOPLASMIC.RIBOSOMAL.PROTEINS	 2.03664	
WP2683.INFLUENZA.LIFE.CYCLE	 2.231637	
PROCESSING.OF.CAPPED.INTRON.CONTAINING.PRE.MRNA	 1.966031	
MRNA.SPLICING.MAJOR.PATHWAY	 1.968078	
Transcription	and	
translation	
		
		
		
		
		
		
		
		
		
		
		
		
WP1813.EUKARYOTIC.TRANSLATION.TERMINATION	 1.982535	
EXTRACELLULAR.MATRIX.ORGANIZATION	 2.066144	
WP2725.COLLAGEN.BIOSYNTHESIS.AND.MODIFYING.ENZYMES	 1.933647	
KEGG_FOCAL.ADHESION	 1.739328	
Extracellular	matrix	
		
		
		 KEGG_ECM.RECEPTOR.INTERACTION	 2.178188	
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DEGRADATION.OF.THE.EXTRACELLULAR.MATRIX	 1.925916	
WP306.FOCAL.ADHESION	 1.776627	
COLLAGEN.BIOSYNTHESIS.AND.MODIFYING.ENZYMES	 2.084609	
WP185.INTEGRIN.MEDIATED.CELL.ADHESION	 1.66432	
INTEGRIN.CELL.SURFACE.INTERACTIONS	 1.809606	
COLLAGEN.FORMATION	 2.233561	
ELASTIC.FIBRE.FORMATION	 1.798224	
WP2798.ASSEMBLY.OF.COLLAGEN.FIBRILS.AND.OTHER.MULTIMERIC.STRUC
TURES	
2.186452	
		
		
		
		
		
		
		
		
		
ASSEMBLY.OF.COLLAGEN.FIBRILS.AND.OTHER.MULTIMERIC.STRUCTURES	 2.156891	
REGULATION.OF.PYRUVATE.DEHYDROGENASE.PDH.COMPLEX	 -1.96206	
WP1902.RESPIRATORY.ELECTRON.TRANSPORT.ATP.SYNTHESIS.BY.CHEMIOS
MOTIC.COUPLING.AND.HEAT.PRODUCTION.BY.UNCOUPLING.PROTEINS.	
-2.17445	
WP111.ELECTRON.TRANSPORT.CHAIN	 -2.04609	
KEGG_COLLECTING.DUCT.ACID.SECRETION	 -1.96777	
KEGG_OXIDATIVE.PHOSPHORYLATION	 -2.24102	
THE.CITRIC.ACID.TCA.CYCLE.AND.RESPIRATORY.ELECTRON.TRANSPORT	 -2.43706	
PYRUVATE.METABOLISM.AND.CITRIC.ACID.TCA.CYCLE	 -2.15426	
RESPIRATORY.ELECTRON.TRANSPORT	 -2.26064	
WP623.OXIDATIVE.PHOSPHORYLATION	 -2.21162	
WP2766.THE.CITRIC.ACID.TCA.CYCLE.AND.RESPIRATORY.ELECTRON.TRANS
PORT.	
-2.00618	
Cellular	
metabolism	
		
		
		
		
		
		
		
		
		
		
RESPIRATORY.ELECTRON.TRANSPORT.ATP.SYNTHESIS.BY.CHEMIOSMOTIC.C
OUPLING.AND.HEAT.PRODUCTION.BY.UNCOUPLING.PROTEINS.	
-2.279	
CELL.CELL.JUNCTION.ORGANIZATION	 1.957272	
CELL.JUNCTION.ORGANIZATION	 2.081496	
WP1793.CELL.JUNCTION.ORGANIZATION	 1.780006	
CELL.CELL.COMMUNICATION	 1.77621	
Cell	junctions	
		
		
		
		 TIGHT.JUNCTION.INTERACTIONS	 2.166633	
CHAPERONIN.MEDIATED.PROTEIN.FOLDING	 1.957393	
WP1892.PROTEIN.FOLDING	 2.131613	
FORMATION.OF.TUBULIN.FOLDING.INTERMEDIATES.BY.CCT.TRIC	 2.236554	
PREFOLDIN.MEDIATED.TRANSFER.OF.SUBSTRATE.TO.CCT.TRIC	 2.431509	
Protein	folding	
		
		
		
		 COOPERATION.OF.PREFOLDIN.AND.TRIC.CCT.IN.ACTIN.AND.TUBULIN.FOLDI
NG	
2.363184	
KEGG_ARRHYTHMOGENIC.RIGHT.VENTRICULAR.CARDIOMYOPATHY.ARVC.	 2.307521	
KEGG_HYPERTROPHIC.CARDIOMYOPATHY.HCM.	 1.86531	
KEGG_DILATED.CARDIOMYOPATHY	 2.017088	
Cardiomyopathy	
		
		
		 WP2118.ARRHYTHMOGENIC.RIGHT.VENTRICULAR.CARDIOMYOPATHY	 2.31039	
KINESINS	 2.299073	
WP1842.KINESINS	 2.420609	
Kinesins	(move	
along	microtubule	
filaments)	
		
		
MHC.CLASS.II.ANTIGEN.PRESENTATION	 1.797628	
WP1864.MUSCLE.CONTRACTION	 2.033824	
MUSCLE.CONTRACTION	 2.058598	
Muscle	contraction	
		
		 SMOOTH.MUSCLE.CONTRACTION	 2.151354	
WP1422.SPHINGOLIPID.METABOLISM	 -2.01252	
WP2377.INTEGRATED.PANCREATIC.CANCER.PATHWAY	 1.697525	
KEGG_SALMONELLA.INFECTION	 1.824445	
KEGG_PROPANOATE.METABOLISM	 -1.91319	
GAP.JUNCTION.TRAFFICKING	 1.829106	
AXON.GUIDANCE	 1.769707	
WP143.FATTY.ACID.BETA.OXIDATION	 -2.18356	
Other	
		
		
		
		
		
		
		 KEGG_VALINE.LEUCINE.AND.ISOLEUCINE.DEGRADATION	 -2.03598	
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BRANCHED.CHAIN.AMINO.ACID.CATABOLISM	 -2.29066	
KEGG_REGULATION.OF.AUTOPHAGY	 -1.98463	
WP1831.INTEGRATION.OF.ENERGY.METABOLISM	 1.920028	
WP2664.GASTRIN.CREB.SIGNALLING.PATHWAY.VIA.PKC.AND.MAPK	 1.687694	
WP368.MITOCHONDRIAL.LC.FATTY.ACID.BETA.OXIDATION	 -1.97753	
WP536.CALCIUM.REGULATION.IN.THE.CARDIAC.CELL	 1.945329	
GLUTATHIONE.CONJUGATION	 -1.8823	
INTEGRATION.OF.ENERGY.METABOLISM	 1.788005	
GENERATION.OF.SECOND.MESSENGER.MOLECULES	 -1.8954	
EPH.EPHRIN.SIGNALING	 1.729218	
		
		
		
		
		
		
		
		
		
		
		 GENERIC.TRANSCRIPTION.PATHWAY	 -2.103	
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Duodenum	 		 		
Process	 Gene	set	 NES	
PHOSPHOLIPID.METABOLISM	 1.83	
KEGG_FAT.DIGESTION.AND.ABSORPTION	 2.42	
FATTY.ACID.TRIACYLGLYCEROL.AND.KETONE.BODY.METABOLISM	 1.77	
REGULATION.OF.CHOLESTEROL.BIOSYNTHESIS.BY.SREBP.SREBF.	 2.14	
WP197.CHOLESTEROL.BIOSYNTHESIS	 2.20	
PEROXISOMAL.LIPID.METABOLISM	 1.99	
ACTIVATION.OF.GENE.EXPRESSION.BY.SREBF.SREBP.	 2.11	
KEGG_PEROXISOME	 1.93	
SPHINGOLIPID.DE.NOVO.BIOSYNTHESIS	 1.81	
KEGG_GLYCEROPHOSPHOLIPID.METABOLISM	 2.18	
WP2740.GLYCEROPHOSPHOLIPID.BIOSYNTHESIS	 1.98	
CHOLESTEROL.BIOSYNTHESIS	 2.07	
METABOLISM.OF.LIPIDS.AND.LIPOPROTEINS	 2.07	
GLYCEROPHOSPHOLIPID.BIOSYNTHESIS	 1.92	
KEGG_SPHINGOLIPID.METABOLISM	 2.00	
Lipid	metabolism	
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
WP1817.FATTY.ACID.TRIACYLGLYCEROL.AND.KETONE.BODY.METABOLISM	 1.81	
WP702.METAPATHWAY.BIOTRANSFORMATION	 2.09	
KEGG_CHEMICAL.CARCINOGENESIS	 2.31	
KEGG_METABOLISM.OF.XENOBIOTICS.BY.CYTOCHROME.P450	 2.19	
WP43.OXIDATION.BY.CYTOCHROME.P450	 2.03	
KEGG_DRUG.METABOLISM.CYTOCHROME.P450	 1.93	
CYTOCHROME.P450.ARRANGED.BY.SUBSTRATE.TYPE	 2.07	
BIOLOGICAL.OXIDATIONS	 2.23	
PHASE.1.FUNCTIONALIZATION.OF.COMPOUNDS	 2.11	
PHASE.II.CONJUGATION	 1.73	
Metabolism	of	
xenobiotics	
		
		
		
		
		
		
		
		
		
KEGG_RETINOL.METABOLISM	 2.09	
WP2667.ACTIVATION.OF.CHAPERONE.GENES.BY.XBP1.S.	 -1.97	
UNFOLDED.PROTEIN.RESPONSE.UPR.	 -2.33	
XBP1.S.ACTIVATES.CHAPERONE.GENES	 -2.00	
Chaperones	
(protein)	
		
		
		
IRE1ALPHA.ACTIVATES.CHAPERONES	 -2.10	
WP1902.RESPIRATORY.ELECTRON.TRANSPORT.ATP.SYNTHESIS.BY.CHEMIOS
MOTIC.COUPLING.AND.HEAT.PRODUCTION.BY.UNCOUPLING.PROTEINS.	
1.97	
RESPIRATORY.ELECTRON.TRANSPORT	 1.91	
WP111.ELECTRON.TRANSPORT.CHAIN	 1.93	
Respiratory	
electron	transport	
chain	
		
		
		
RESPIRATORY.ELECTRON.TRANSPORT.ATP.SYNTHESIS.BY.CHEMIOSMOTIC.C
OUPLING.AND.HEAT.PRODUCTION.BY.UNCOUPLING.PROTEINS.	
1.86	
INITIAL.TRIGGERING.OF.COMPLEMENT	 -1.91	
IMMUNOREGULATORY.INTERACTIONS.BETWEEN.A.LYMPHOID.AND.A.NON
.LYMPHOID.CELL	
-1.93	
Innate	immunity	
		
		
FCGR.ACTIVATION	 -1.95	
WP1928.TELOMERE.MAINTENANCE	 2.18	
WP466.DNA.REPLICATION	 1.93	
KEGG_DNA.REPLICATION	 2.05	
TELOMERE.MAINTENANCE	 1.89	
WP1925.SYNTHESIS.OF.DNA	 1.72	
DNA.METHYLATION	 1.96	
Cell	cycle	
		
		
		
		
		
		 WP2739.AMYLOIDS	 1.98	
PLATELET.DEGRANULATION	 -1.94	Other	
		 KEGG_BILE.SECRETION	 2.10	
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BIOSYNTHESIS.OF.THE.N.GLYCAN.PRECURSOR.DOLICHOL.LIPID.LINKED.OLI
GOSACCHARIDE.LLO.AND.TRANSFER.TO.A.NASCENT.PROTEIN	
-1.99	
PPARA_TARGETS	 2.26	
KEGG_PROTEIN.EXPORT	 -2.04	
KEGG_PROTEIN.PROCESSING.IN.ENDOPLASMIC.RETICULUM	 -2.26	
KEGG_DRUG.METABOLISM.OTHER.ENZYMES	 1.87	
KEGG_PPAR.SIGNALING.PATHWAY	 2.05	
APOPTOTIC.EXECUTION.PHASE	 1.83	
KEGG_GLYCEROLIPID.METABOLISM	 1.93	
WP2806.HUMAN.COMPLEMENT.SYSTEM	 -2.01	
WP716.VITAMIN.A.AND.CAROTENOID.METABOLISM	 2.17	
KEGG_STAPHYLOCOCCUS.AUREUS.INFECTION	 -2.30	
KEGG_INTESTINAL.IMMUNE.NETWORK.FOR.IGA.PRODUCTION	 -1.90	
WP2840.HAIR.FOLLICLE.DEVELOPMENT.CYTODIFFERENTIATION.PART.3.OF.
3.	
-1.96	
KEGG_PROTEIN.DIGESTION.AND.ABSORPTION	 1.92	
KEGG_HOMOLOGOUS.RECOMBINATION	 2.05	
WP2431.SPINAL.CORD.INJURY	 -1.97	
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
		
KEGG_FATTY.ACID.DEGRADATION	 1.99	
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Abstract
Glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) are hormones 
important for satiation and are involved in the process called “ileal brake”. The 
aim of this study was to investigate the GLP-1- and PYY-stimulating efficacy 
of rebaudioside A, casein, and sucrose. This was studied using tissue segments 
collected from various regions of the pig small intestine. GLP-1 release was 
strongest from the distal ileum. There, control release was 0.06 ± 0.01 (GLP-1) 
and 0.07 ± 0.01 (PYY) pmol/cm2 of tissue. Rebaudioside A (2.5, 12.5, and 25 
mM) stimulated GLP-1 release (0.14 ± 0.02, 0.16 ± 0.02, and 0.13 ± 0.02 
pmol/cm2 of tissue, p < 0.001) and PYY release (0.19 ± 0.02, 0.42 ± 0.06, 
and 0.27 ± 0.03 pmol/cm2 of tissue, p < 0.001). Sucrose stimulated GLP-1 
release (0.08 ± 0.01 pmol/cm2 of tissue, p < 0.05) only at 10 mM. Casein 
(0.5%, 1%, and 2.5%, w/v) stimulated GLP-1 release (0.15 ± 0.03, 0.13 ± 
0.02, and 0.14 ± 0.01 pmol/cm2 of tissue, p < 0.001) and PYY release (0.13 
± 0.02, 0.20 ± 0.03, and 0.27 ± 0.03 pmol/cm2 of tissue, p < 0.01). These 
findings may help in developing dietary approaches for weight management.
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Introduction
The presence of nutrients and other molecules in the small intestine stimulates 
the release of satiety hormones, such as Cholecystokinin (CCK), Glucagon-Like 
Peptide-1 (GLP-1), and Peptide YY (PYY)(1,2). The release of these hormones 
results in decreased gastric emptying and activation of the so-called intestinal 
brake. This poorly explored mechanism refers to a physiological feedback 
mechanism that is triggered by nutrients at a specific location in the intestine 
resulting in reduced appetite and food intake (3,4). Lipids have been widely 
researched and are known to activate this ileal brake mechanism resulting in the 
release of satiety hormones and reduced food intake (5-8). However, whether 
other macronutrients such as carbohydrates and proteins could also activate the 
ileal brake mechanism is still unknown (4). Knowledge of the satiety-hormone-
inducing properties of macronutrients is relevant to better understanding the 
intestinal response to ingested food and may contribute to the development of 
products with satiating properties.
The efficacies of non-caloric sweeteners to induce the release of satiety 
hormones are also partly unknown. However, a study by Anton et al. (2010) 
showed that preloads containing the sweetener stevia reduced daily caloric 
intake by 301 kcal and reduced postprandial glucose and insulin levels 
compared to preloads containing sucrose (9). Such a reduced caloric intake 
as well as glucose and insulin responses may be caused by reduced caloric 
content of the preload but may also be caused by other mechanisms such as 
GLP-1 release. The glycoside rebaudioside A is the one of the most abundant 
sweet compound extracted from the leaves of Stevia rebaudiana bertoni. 
Rebaudioside A is reported to be the most potent sweetener among the steviol 
glycosides(10), with a relative sweetness of 200 – 400 times greater than 
that of sucrose (11). Rebaudioside A is increasingly used in food products as a 
natural noncaloric sweetener. It has been approved in the United States since 
2008(12), and in the European Union since 2010 (13). 
It is unknown if ileal delivery of macronutrients other than lipids and sweeteners 
could also stimulate the release of satiety hormones and consequently activate 
the ileal brake. Stimulation of GLP-1 and PYY release from isolated ileal tissue 
has been demonstrated for lipids including unsaturated fatty acids. This was 
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shown using a recently described ex vivo porcine intestinal model (14). For 
other macronutrients such as sucrose and casein such studies have not been 
performed yet, although their efficacy to induce gut hormone release has 
been shown in cell cultures (15-17). The pig was chosen as a model because 
the gastrointestinal tract of the pig shows a high degree of macroscopic and 
microscopic resemblance with that of humans (18-20). The present study 
primarily focused on the GLP-1 and PYY inducing efficacy of casein, sucrose 
and the non-caloric sweetener rebaudioside A at various locations of the small 
intestine. We hypothesize that rebaudioside A, the protein casein, and the 
carbohydrate sucrose are effective stimulators of GLP-1 and PYY release from 
various locations of the small intestine, and thus may be effective activators of 
the ileal brake in vivo.
Materials and methods 
Chemicals
Casein protein (food grade, sodium caseinate purity >82% batch number 
158156) was obtained from Dutch Protein Services BV, Tiel, The Netherlands. 
Rebaudioside A (figure 4.1, food grade, purity >97% batch number 20110301, 
ChemSpider ID: 5294031) was obtained from SteviJa Natuurlijk BV, Drachten, 
The Netherlands. Sucrose (food grade, purity >99.9%) was supplied by Suiker 
Unie, Oud Gastel, The Netherlands. Safflower oil (food grade, composed 
of 3-8% C16:0, 2-5% C18:0, 9-15% C18:1 and 75-85% of C18:2) was 
provided by De Wit Specialty oils, De Waal, The Netherlands. Xantham Gum 
and Guar gum were supplied by GF Supplies, Amsterdam, The Netherlands. 
Chemicals to make the Krebs Ringer bicarbonate (KRB) buffer (D-glucose 1.8 
gram/L, Magnesium Chloride 0.0468 gram/L, Potassium chloride 0.34 gram/L, 
Sodium Chloride 7.0 gram/L, Sodium Phosphate Dibasic 0.1 gram/L, Sodium 
Phosphate Monobasic 0.18 gram/L, HEPES 5,579 gram/L) were obtained from 
Sigma, Zwijndrecht, The Netherlands. The pH of the KRB buffer was adjusted 
to pH 7.4.
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Collection of porcine intestinal tissues 
Intestinal tissues were obtained from ten healthy male pigs (Sus scrofa domesticus). 
The pigs were considered healthy after evaluation by a veterinarian. The 
protocol for this study was approved by the Animal Ethics Committee Utrecht 
(Ethics Committee permit number 2012.I.09.096, Utrecht, The Netherlands). 
Pigs had a mean (± SEM) body weight of 141 ± 2 kg, and mean (± SEM) age 
of 6 ± 0.1 months. They were housed in groups and were fed ad libitum with 
standard pig diet (vitaal P 003103, de Heus, Ede, The Netherlands) and free 
access to water. Within 10 minutes after the pigs were sacrificed, intestines 
were excised and segments of different anatomical regions were stored in ice-
cold oxygenated (95% O2, 5% CO2) KRB buffer. Jejunum (4.5 meter proximal 
to the ileocecal junction) and proximal, mid and distal ileum (0.5 meter of 
intestine sampled from 1.5, 1 and 0.5 meter proximal to the ileocecal junction, 
respectively) were collected for the experiments. Tissues were transported to 
the laboratory and immediately used for ex vivo experiments. Time between 
excision and start of the experiments was approximately 30 minutes. 
Figure 4.1 Chemical structure of Rebaudioside A. 
Adapted from ChemSpider ID: 5294031
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Nutrient exposure of intestinal tissue and viability tests
Incubation with casein (0.5, 1 and 2.5% w/v), rebaudioside A (2.5, 12.5 and 
25 mM), sucrose (2.5, 5 and 10 mM), and safflower oil (3.35% w/v) were 
performed with porcine intestinal tissue as described previously(14) with some 
minor adaptations. In brief, upon arrival at the laboratory, the intestine was 
rinsed with KRB buffer and cut open in a longitudinal direction. The outer 
muscle layers were carefully stripped off with the basolateral side upwards. 
The mucosal tissue was placed on a gauze (pores = 250 µm, Sefar Nitex 03-
250/50, Sefar Heiden Switzerland) with the apical side upward, and circles 
of tissue with a diameter of 11.8 mm (about 1.0 cm²) were punched out using 
a biopsy punch. The intestinal segments were randomized, per region, in a 
beaker glass and transferred to a 24-wells plate, filled with 500 µl ice cold 
KRB buffer/well, and kept on ice until start of the experiment. Thereafter, 
tissues were brought to room temperature within 30 min, followed by an pre-
incubation step at 37°C for 1 hour in a humidified incubator (5% v/v CO2). To 
study the release of GLP-1 and PYY, incubations were initiated by replacing 
the KRB buffer solution with 500 µl pre-warmed (37°C) KRB without D-glucose 
containing the test compounds. KRB buffer without D-glucose was used as a 
control since D-glucose might induce gastrointestinal hormone release. Then the 
tissue was put in a humidified incubator for 1 hour at 37°C at 5% v/v CO2. After 
incubation, solutions were collected, mixed with 100 µM phenylmethanesulfonyl 
floride (PMSF) (Sigma Aldrich, Zwijndrecht, The Netherlands) to inactivate 
dipeptidyl peptidase IV, aliquoted and stored at 4°C for further analysis of 
lactate dehydrogenase (LDH), or stored at -80°C for further analysis of GLP-1 
and PYY.
Tissue viability was checked by measuring leakage of intracellular LDH in 
supernatant. LDH, a stable cytosolic enzyme, was analyzed using a LDH kit 
(Sigma Aldrich, Zwijndrecht, The Netherlands). LDH activity in supernatant 
was expressed as a percentage of the total LDH activity present in control 
tissue collected before incubation. Total tissue levels of LDH were determined 
per region in 1.0 cm² tissue samples, which were homogenized in ice-cold 
KRB buffer with a Potter-Elvehjem-type Teflon pestle tissue grinder (Braun, 
Melsungen, Germany) for 5 minutes at 200 rounds per minute. Samples were 
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only included for further analysis when LDH leakage did not exceed 10% of 
the total LDH tissue content (14,21). No samples had to be excluded applying 
this criterion.
Analysis of satiety hormones GLP-1 and PYY 
GLP-1 active levels were analyzed using commercially available ELISA 
assay kits obtained from Millipore (Billerica, MA, USA) and used according 
to the manufacturer’s instructions using a BioTek Synergy HT fluorescence 
microplate reader (BioTek Instruments Inc., Winooski Vermont, USA). Since the 
GLP-1 hormone gene sequence is highly preserved, this kit could be applied 
for analyzing porcine GLP-1. The range of this assay is approximately 2 – 
100 pM. The inter-assay coefficient of variation is 11%, and the intra-assay 
variation is 6%. When necessary, samples were diluted in assay buffer from 
the kit to be in this range. 
PYY release was measured from distal ileum only, since PYY is known to be 
co-localized with GLP-1 (22). PYY concentrations were measured using a 
PYY ELISA kit for total PYY (Bachem, Penisula Laboratories, San Carlos, CA, 
USA) according to the manufacturer’s instructions using a BioTek Synergy HT 
microplate reader (BioTek Instruments Inc., Winooski Vermont, USA). This kit 
measures porcine PYY, which is identical to human PYY (23). The range of 
this assay is approximately 0.32 – 5 ng/ml (4.6 – 1150 pM). The inter assay 
coefficient of variation for this assay is 6% and the intra assay coefficient of 
variation is 3%. The lower detection limit of this kit was 20 pg/ml (4.6 pM) It 
was not necessary to dilute samples for this assay. 
Statistical analysis 
Statistical analysis was performed using the SAS statistical software package 
(SAS version 9; SAS institute, Cary, NC, USA). Both variables GLP-1 and PYY 
were compared with a mixed analysis of variance model (ANOVA). GLP-1 
and PYY were both log transformed to meet the requirements for ANOVA. The 
ANOVA model included the fixed factors dose solution (control, sucrose 2.5, 
5 and 10 mM, casein 0.5, 1 and 2.5% w/v, rebaudioside A 2.5, 12 and 25 
mM and safflower oil 3.35% (w/v), intestinal location (jejunum, and proximal 
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mid and distal ileum) and the number of incubations per condition (incubations 
were performed in triplicate). The factor pig, which specifies the individual pig, 
was added to the model as random factor. The Tukey post hoc test was used to 
correct for multiple comparisons. Data are presented as the mean ± SEM and 
considered significant at p< 0.05. 
Results
Effects of rebaudioside A and other compounds / mixtures on GLP-1 
release 
Table 4.1 shows the GLP-1 concentrations in the medium following incubation 
with the test compounds or mixtures using tissues taken from different locations. 
In all parts of the small intestine investigated, rebaudioside A caused a 
significant release of GLP-1 already at the lowest concentration tested (2.5 
mM) (p< 0.01), except for the jejunum where the release was significant at a 
concentration of 12.5 mM (p< 0.05). The highest relative increase of GLP-1 
after incubation with rebaudioside A was seen in the distal ileum (p< 0.001). 
The release at 25 mM was not higher than at 12.5 mM. As also shown in 
table 4.1, safflower oil (3.35% w/v) significantly increased GLP-1 release 
from the proximal ileum (p< 0.05) and even more from the distal ileum (p< 
0.001). Safflower oil did not increase GLP-1 release from the mid-ileum and 
only marginally from the jejunum. At the concentrations tested sucrose did not 
stimulate GLP-1 release from jejunal and mid ileal tissue. The only significant 
stimulation was seen in tissues from the distal ileum at a sucrose concentration 
of 10 mM (p< 0.05).
Casein, at 1 and 2.5 % (w/v) increased GLP-1 release (p< 0.001) from 
tissues collected from the jejunum, whereas 0.5% (w/v) casein did not. Both 
0.5 and 2.5% (w/v) casein stimulated GLP-1 release from the proximal ileum 
(p< 0.001). A concentration of 1% (w/v) casein stimulated GLP-1 release 
from proximal ileum (p< 0.010), but exposure to 0.5% and 2.5% (w/v) casein 
caused a higher GLP-1 release. None of the casein concentrations, 0.5, 1 and 
2.5% (w/v), stimulated GLP-1 release from the mid ileum. All three casein 
100
concentrations stimulated GLP-1 release from the distal ileum (p< 0.001). 
Similar to rebaudioside A, the most pronounced stimulation of GLP-1 by casein 
was observed in the distal ileum. 
Regional differences in GLP-1 release
Exposing intestinal tissue to the control did not result in regional differences 
in control GLP-1 release. However, after exposure to the nutrients, regional 
differences were observed. For GLP-1 both an overall incubation and location 
effect (p< 0.001), and an interaction effect between incubation and location 
was found (p< 0.05). Overall GLP-1 release from all ileal locations (distal, mid 
and proximal ileum), was higher than GLP-1 release from the jejunal locations 
(p< 0.001). Furthermore, GLP-1 release from the distal ileum was higher than 
GLP-1 release from the mid ileum (p< 0.001). Neither hormone release from 
mid and proximal ileum differed, nor did release from proximal and distal 
ileum (p< 0.08). 
Effects of compounds and mixtures on PYY release
The compounds and mixtures stimulating GLP-1 release were also tested for 
their PYY releasing capacity from the distal ileum (table 4.2). Safflower oil 
was found to stimulate PYY release, whereas sucrose at the concentrations 
tested did not. Casein stimulated PYY release from the distal ileum at all three 
concentrations tested. Release after exposure to a concentration of 1% (w/v) 
was higher than with 0.5% (w/v) casein (p< 0.05). Rebaudioside A stimulated 
PYY release from distal ileum (p< 0.001). The effect at 12.5 mM rebaudioside 
A was higher than that at 2.5 mM (p< 0.05). 
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Table 4.1: GLP-1 concentrations released from jejunal, proximal, mid and distal ileum 
intestinal tissue segments after exposure to various compounds. 
a p< 0.05, b p< 0.01, c p< 0.001; p-values are based on comparison to control (ANOVA 
+ Tukey correction). The incubations were performed in triplicate (n=6 for jejunum, n=10 
for proximal, mid and distal ileum)
Table 4.2 PYY concentrations released distal ileum intestinal tissue segments after 
exposure to various compounds.
a p< 0.05, b p< 0.01, c p< 0.001; p-values are based on comparison to control (ANOVA 
+ Tukey correction). The incubations were performed in triplicate (n=10). 
table	1
Solu%on Concentra%on GLP-1	release	(pmol/cm²	%ssue)
Jejunum Proximal	ileum Mid	ileum Distal	ileum
Control 0.04±	0.01 0.07	±	0.02 0.07	±	0.01 0.06	±	0.01
Saﬄower	oil	(%) 0,0335 0.07±	0.02 0.11±0.03	a 0.09±0.02 0.13	±0.02	c
Sucrose	(mM) 2,5 0.05±0.01 0.10±0.02 0.07±0.01 0.06±0.01
5 0.05±0.01 0.17±0.05 0.08±0.01 0.07±0.01
10 0.06±0.01 0.07±0.01 0.08±0.01 0.08±0.01	a
Casein	(%) 0,5 0.06±0.01 0.12±0.02	c 0.09±0.01 0.15±0.03	c
1 0.09±0.01	c 0.09±0.02	b 0.08±0.01 0.13±0.02	c
2,5 0.08±0.02	c 0.13±0.03	c 0.08±0.01 0.14±0.01	c
Rebaudioside	A	(mM) 2,5 0.07±0.01 0.14±0.02	c 0.13±0.02	b 0.14±0.02	c
12,5 0.07±0.01	b 0.11±0.02	c 0.18±0.04	c 0.16±0.02	c
25 0.07±0.01	b 0.14±0.02	c 0.13±0.02	b 0.13±0.02	c
table	2
Solu%on Concentra%on PYY	(pmol/cm²	%ssue)
Distal	ileum	
Control 0.07±0.01
Saﬄower	oil	(%) 3,35 0.17±0.01	c
Sucrose	(mM) 2,5 0.14±0.03
5 0.12±0.02
10 0.08±0.01
Casein	(%) 0,5 0.13±0.02	b
1 0.20±0.03	c
2,5 0.27±0.03	c
Rebaudioside	A	(mM) 2,5 0.19±0.02	c
12,5 0.42±0.06	c
25 0.27±0.03	c
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Discussion 
Our study confirmed our hypothesis that rebaudioside A and casein induce 
GLP-1 and PYY release from porcine intestinal tissue segments. Remarkably, 
rebaudioside A was found to stimulate GLP-1 release from all ileal and jejunal 
regions investigated, whereas sucrose (10 mM) only caused GLP-1 release from 
the distal ileum. Rebaudioside was effective in stimulating hormone release 
from more locations of the small intestine than casein. Therefore, taking into 
account that the model and the tested concentrations make a direct comparison 
difficult, our results suggest that rebaudioside A and the protein casein are 
candidate substances that may activate the ileal brake in vivo via the release 
of GLP-1 and PYY.  
Some sweeteners including sucralose were found not to affect satiety hormone 
release in vivo (24,25). For Stevia Anton et al. (2010) demonstrated satiating 
inducing properties which may be due to increased satiety hormone release. 
However, since satiety hormones were not measured in that study, this 
association cannot be made from these findings. To our knowledge no reports 
have shown the satiety hormone-inducing capacity of the non-caloric sweetener 
rebaudioside A as was done in our study. 
Nutrients, such as casein and sucrose, could stimulate satiety hormone release 
following interaction with G-protein coupled receptors and some solute carrier 
transporters located on enteroendocrine cells in the intestinal epithelium (26). A 
potential mechanism by which rebaudioside A could stimulate GLP-1 and PYY 
release is via the sweet taste receptor. Recently, it was found that rebaudioside 
A has affinity for the sweet taste receptor TAS1R2/TASR3 (10). This receptor 
is involved in glucose dependent release of GLP-1 and PYY in vivo (27). 
Furthermore, TAS1R2/TASR3 is present on brush cells and enteroendocrine 
cells (28). However, other mechanisms than via the taste receptors by which 
rebaudioside A and casein could induce satiety hormone release cannot be 
excluded and should be further studied. 
Already more than 100 compounds have been identified in Stevia rebaudiana. 
However, the steviol glycosides stevioside and rebaudioside A have been 
found to be the most abundant. Steviol glycosides are metabolized into steviol 
upon their arrival in the colon and are absorbed thereafter (29). Incubation 
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of the murine enteroendocrine STC-1 cells with Stevia preparations resulted 
in higher GLP-1 and CCK release compared to incubation with sucrose (17), 
which is in line with our findings. The same study also demonstrated GLP-1 
and CCK release after incubation with sucralose. However, only relatively high 
concentrations of 150 and 300 mM sucralose and of 600 mM sucrose were 
able to stimulate GLP-1 and CCK release from STC-1 cells. In our study 2.5 mM 
rebaudioside A resulted in higher GLP-1 release compared to 2.5 mM sucrose 
(0.14±0.02 vs. 0.06±0.01 p< .001, distal ileum). Concentrations of sucrose 
and rebaudioside A in this study were in the same range (0-25 mM). Further 
in vitro studies should explore dose-effect relationships of these compounds. 
Safflower oil was used as a positive control in our study. Safflower oil 
(3.35%) was found to activate the ileal brake in vivo and to increase satiety 
and gastrointestinal hormone concentrations (5,7). As expected safflower oil 
effectively stimulated GLP-1 release from the ileum mainly from the distal part 
whereas no such stimulation occurred from the mid ileum. This difference may 
relate to the enteroendocrine cell distribution. Enteroendocrine L-cells are most 
abundant in the distal part of the small intestine (30) corresponding to the 
intestinal tissue content of GLP-1 (14). The protein casein increases satiety in 
vivo (31) and in vitro it stimulates GLP-1 release from enteroendocrine murine 
STC-1 and human NCI-H716 cells (15,16,32). In our study casein induced GLP-
1 and PYY release which confirms these previous findings and suggests that 
casein is a candidate to induce the ileal brake in vivo. 
Apart from the differences in efficacy of various nutrients to stimulate GLP-1 
and PYY some other questions remain. An important question is to what extent 
the effects on satiety hormone release found in our model can be reproduced 
in in vivo models and specifically in humans. Another relevant question is 
whether the capacity to induce satiety hormone release will lead into satiation 
in vivo. In one study of Veldhorst et al.(2009) it was shown that breakfast 
with higher casein content (25% vs. 10%) increased VAS scores in fullness and 
satiety whereas subsequent energy intake was not reduced and GLP-1 plasma 
concentrations did not differ per condition (33). Food intake is regulated by 
a whole cascade of responses which have to be taken into account if studying 
satiation in vivo. Therefore, knowledge of the satiety hormone releasing 
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capacity of macronutrients and non-caloric sweeteners could be useful to 
understand this so called ‘satiety cascade’ (34).
The current in vivo data are based on lipid infusions mainly. Those data could 
be extended into infusion studies using rebaudioside A and casein since the 
results from this study suggest that the satiety hormone releasing effect of 
sweeteners and proteins might be at least as effective as fat. These human 
interventions will then further substantiate the relevance of this ex vivo intestinal 
model. 
One could question whether the concentrations of the selected compounds are 
relevant in view of those reached in the gut after dietary intake. Nutrient 
concentrations in the small intestine depend on the rate of gastric emptying 
of a meal, the rate of absorption, and (or) digestion of the nutrients the meal 
contained (35-37). Data on actual concentrations of the selected products 
are very scarce. There is only one animal study showing that luminal glucose 
concentrations after a meal are varying between 0.2 and 48 mM depending 
on postprandial time and the small intestinal region (38). Although the data are 
limited one could estimate intestinal concentrations on the following assumptions; 
1 cup of coffee or tea (200 ml) with 0.3 gram of rebaudioside A (based on ADI 
of 0.4 mg/kg BW/day), or 1 cube of sugar (1 gram), in a total volume of 300 
ml (100 ml gastric juice is added in the stomach)(17). These assumptions would 
yield an estimate of approximate concentrations of 10 mM sucrose and 1 mM 
rebaudioside A for the small intestine. The estimate for casein is based on the 
assumption that 1 glass of milk is consumed (total volume including gastric juice 
300 ml) with a casein concentration of 80% of total milk protein content which 
is approximately 35 g/L. This means that a concentration of approximately 
3% may initially be reached in the small intestine. Although these values are 
estimates only they suggest that the concentrations used in this study may be 
relevant from a dietary perspective.
The hormone secreting capacity of nutrients and other compounds is often 
studied in vitro using enteroendocrine cell lines including murine STC-1 (15,39-
41), GLUTag cells (42) and the human NCI-H716 cell line (43). The advantage 
of the current ex vivo model compared to cell lines is that this model consist 
of all different cell types present in the gut. Another model to study the GLP-
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1 and PYY inducing capacity of nutrients is the Ussing chamber technology 
using animal or human biopsies (44). It is however, challenging to obtain human 
biopsies especially from the ileum which makes the ex vivo intestinal porcine 
segment system a valuable alternative. However, there are still some technical 
limitations such as tissue viability and intra-subject variation. In this study tissue 
viability was evaluated by LDH leakage as before (14) and LDH leakage did 
not exceed 10%. Also, hormone release in the control condition was low. Both 
conditions indicate a good tissue viability. However, we cannot exclude that 
hormone release may be due to aspecific processes like cell lysis. Also, a high 
number of replicates was needed because of a high intra-subject variation. 
This variation may be caused by the relatively low number of enteroendocrine 
cells (reported to account for only 1% of the epithelial cell population in the 
small intestine) and these cells may be unevenly distributed (2,28). 
In conclusion, the present study showed that rebaudioside A and casein, 
but not sucrose, induced satiety hormone release at various locations of the 
small intestine using an ex vivo model. These findings may contribute to the 
development of dietary approaches improving weight management and 
glucose control. However, in vivo studies are necessary to confirm the potential 
satiety inducing properties of rebaudioside A and casein in vivo.
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Abstract
In food products, the molecular mechanisms of action of steviol glycosides is 
only partly understood. Given their intestinal stability, it is likely that interaction 
takes place with nutrient sensing receptors present on the apical membrane 
of enteroendocrine cells. However, these interactions and their possible post-
receptor effects have not been reported in much detail. Here, we have used 
enteroendocrine STC-1 cells and two dimensional organoids prepared from 
mouse ileal crypt cells to investigate the effects of steviol glycosides on GLP-
1 and CCK release. The role of the sweet taste receptor and the involvement 
of cAMP- and calcium signaling in the effects of rebaudioside A were 
investigated using specific inhibitors and live cell imaging. It was established 
that rebaudioside A stimulated GLP-1 and CCK release from STC-1 cells and 
organoids. In STC-1 cells, Rebaudioside A-induced GLP-1 release was reversed 
by MDL-12330A, an adenylate cyclase inhibitor, while gurmarin, a murine-
specific inhibitor of the sweet taste receptor, did not affect GLP-1 release. Our 
findings led us to conclude that the induction of GLP-1 release by rebaudioside 
A occurs independently of the sweet taste receptor (Tas1R2/Tas1R3) and that 
the underlying pathway involves cAMP signaling.
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Introduction
Since the approval of steviol glycosides by EFSA and FDA, stevia products 
are increasingly used as non-caloric sweeteners in food products (1). Steviol 
glycosides are components of the plant Stevia rebaudiana Bertoni, of which 
the leaves are traditionally used in South America (2). Extracts of the plant 
contain numerous steviol glycosides, among which the most abundant and best 
characterized constituents are stevioside and rebaudioside A (3). The different 
steviol glycosides vary in their potencies to induce sweet taste sensations. 
Stevioside, rebaudioside A and rebaudioside D are reported to have the 
lowest sweet taste threshold compared to other common steviol glycosides, 
when tested by a sensory panel. Comparable relative potencies were found in 
cell-based assays functionally expressing the sweet taste receptor (4). 
Despite their increasing use in food products, the effects of steviol glycosides on 
food intake and glucose homeostasis are still far from clear with several studies 
reporting contradictory outcomes. Stevia preloads in humans were reported to 
reduce daily food intake (5). In addition, intragastric infusion of rebaudioside A 
in combination with umami and bitter tastants reduced subsequent food intake 
(6). Furthermore, stevia and stevioside reduced post-prandial blood glucose 
in healthy-, obese- and type II diabetic subjects (5, 7). However, these results 
diverge from other studies where no effect on fasted glucose or energy intake 
was observed (8-10). Also animal studies show contradictory results. Fujita et 
al. found no effects of stevia on glucose levels in a glucose tolerance test or 
on plasma GLP-1 and GIP incretin secretion in rats (11), while others did find 
effects of stevioside and rebaudioside A on glucose and/or insulin in healthy 
and diabetic rodents (12, 13). 
Underlying mechanisms mediating effects of steviol glycosides on food intake 
and metabolic parameters are still poorly understood. After their ingestion 
steviol glycosides remain intact in the small intestine. Only upon contact with 
bacteria in the colon these compounds are degraded and their degradation 
product, steviol, is subsequently absorbed (2). Therefore, stevia compounds 
may interact with chemosensory receptors expressed by the small intestinal 
epithelium (14). Most of these receptors are located on enteroendocrine cells. 
These cells comprise about 1% of the epithelial cells and are well-known for 
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the secretion of satiety hormones like GLP-1, PYY and CCK (15). Recently, 
we showed that rebaudioside A can induce both GLP-1 and PYY release in a 
porcine ex vivo intestinal model (16). 
Here, we aimed to further elucidate the underlying mechanism of GLP-1 
release induced by steviol glycosides, using both STC-1 enteroendocrine cells 
and intestinal organoid cultures. We focused on the role of the sweet taste 
receptor in GLP-1 release and explored intracellular signaling pathways.
Materials and methods
Cell culture 
The STC-1 cell line (ATCC, LGC Standards, Teddington, UK) is a pluripotent 
enteroendocrine cell line derived from a double-transgenic mouse. STC-1 cells 
were cultured in Dulbecco’s modified Eagle’s medium (DMEM), containing 10% 
fetal calf serum (FCS) (Lonza, Verviers SPRL, Belgium). The cells were passaged 
when reaching 80% confluence; passage numbers between 25-50 were used.
Secretion studies
STC-1 cells were grown in 24-well plates. When reaching 80% confluence, 
the medium was removed and the cells were rinsed with HBSS (containing 
1.26 mM Ca2+, 10 mM HEPES with pH 7.4) (Life technologies, Carlsbad, 
USA). Subsequently, the cells were incubated in HBSS or HBSS supplemented 
with rebaudioside A, stevioside or sucralose (Sigma-Aldrich, St. Louis, USA), 
at 37°C. After 2 hours of incubation, the buffer was removed, mixed with 
phenylmethanesulfonyl fluoride (Sigma-Aldrich, St. Louis, USA) to a final 
concentration of 100 µM. Subsequently, this mixture was centrifuged to remove 
cell debris and stored for analysis. The involvement of cAMP in gut hormone 
secretion was investigated by addition of 10 µM MDL-12330A (Sigma-
Aldrich, St. Louis, USA) at the start of the 2 hour incubation period. The role of 
the sweet taste receptor was studied using gurmarin (kindly provided by Loic 
Briand, INRA Dijon Centre, France). This purified recombinant gurmarin was 
shown to have a half-maximal inhibitory concentration of 0.030 µg/ml for the 
sweet taste receptor (Tas1R2/Tas1R3) (17). For experiments using gurmarin, 
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STC-1 cells were pre-incubated with various concentrations of gurmarin and 
subsequently incubated with rebaudioside A in combination with gurmarin or 
with HBSS, for 2 hours.
Cytotoxicity
Effects of the test compounds on the viability of the STC-1 cells were assessed 
using an LDH Cytotoxicity Detection Kit and an XTT Cell Proliferation Kit II (Roche 
Applied Science, Almere, The Netherlands) according to the manufacturer’s 
instructions. Briefly, cells were first incubated with the test compounds for two 
hours. Thereafter, the activity of lactate dehydrogenase, an enzyme released 
from damaged cells into the supernatant, was measured. Simultaneously, the 
cells’ ability to metabolize tetrazolium salt (XTT) to formazan was assessed as 
a measure for cell viability. As a control, Triton X-100 was added to the cells, 
resulting in total cell lysis.
Intestinal organoid secretion study
The use of mouse intestine had been approved by the Local Committee for 
Care and Use of Laboratory Animals at Wageningen University (Permit number: 
2014036.b). Intestinal tissue was collected from six-month old C57Bl/6J 
mice. The isolation and culturing of intestinal organoids will be described in 
chapter 6 of this thesis. Briefly, intestinal crypts were isolated from the ileum 
and cultured in MatrigelR basal membrane matrix, growth factor reduced 
(Corning Incorporated, Corning, USA). For the organoids DMEM/F12 medium 
(containing GlutaMAX supplement, 1mM sodium pyruvate, MEM Non-Essential 
Amino Acids, 100U/ml Penicillin-Streptomycin, R-spondin 1 (homebrew), WNT 
(homebrew), 0.5 µg/ml DMH1, 10% FCS) was used. For the GLP-1 secretion 
study, organoids were cultured in 24 wells plates as described in chapter 
6. After four days, the 2D organoids were pre-incubated for one hour with 
glucose-free DMEM. Subsequently, the organoids were incubated with glucose-
free DMEM supplemented with the test compounds at 37°C and 5% CO2. After 
one hour, supernatants were collected and mixed with phenylmethanesulfonyl 
fluoride (Sigma-Aldrich, St. Louis, USA) to a final concentration of 100 µM for 
subsequent hormone measurements.
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Gut hormone measurements
GLP-1 (active) levels were determined using ELISA (EGLP-35K, Merck Millipore, 
Darmstadt, Germany), according to the manufacturer’s instructions. Standard 
curves were constructed using Prism 5 (GraphPad Software, La Jolla, USA). 
Concentrations of CCK-8 (CCK 26-33) were analyzed with an optimized and 
validated commercial RIA kit (EURIA-CCK, RB302, Euro-diagnostica, Malmö, 
Sweden). Radioactivity of [125I]-CCK-8 was measured by liquid scintillation 
counting using a gamma counter (EC&G, Breda, The Netherlands). 
Intracellular calcium ion measurements
Intracellular [Ca2+] ([Ca2+]i) fluctuations were measured using a Fura-2 calcium 
indicator or using STC-1 cells stably expressing the Cameleon YC3.6 calcium 
reporter protein (18). STC-1 cells were plated onto clear bottom black 96 
wells plates (BD Biosciences, Erembodegem, Belgium). After one day, the cells 
were washed with HBSS and loaded with the acetoxymethyl(AM)-ester of Fura-
2 (5µM, Life technologies, Carlsbad, USA) for 30 minutes at 37°C. After a 
subsequent wash with HBSS the plate was transferred to the incubation chamber 
of the BD pathwayTM 855 (BD Biosciences, Erembodegem, Belgium), which was 
kept a 37°C and 5% CO2. Measurements were performed with excitation at 
340 and 380 nm for ratiometric analysis and images were acquired using 20x 
magnification. Cells were automatically identified as regions of interest and 
changes in 340/380 fluorescence emission ratio for these regions of interest 
were analyzed using BD Attovision software (BD Biosciences, Erembodegem, 
Belgium). Stimuli were applied in a fully automated manner, adding 20 µl of 
10 times concentrated solution.
STC-1 cells stably expressing the Cameleon YC3.6 calcium reporter protein 
were seeded on a disposable 15×45 mm2 borosilicate cover slides, coated with 
100 µg/ml poly-L-Lysine (P6282, Sigma-Aldrich, St. Louis, USA) at a density 
of 3×105 cells/ml in DMEM supplemented with 5.5 mM glucose and grown in 
a CO2 incubator at 37°C for 24h. Subsequently, the slides were mounted in a 
flow cell (Micronit Microfluidics B.V., Enschede, The Netherlands) (18). The cells 
were imaged with a Leica M205 FA Fluorescence Stereo Microscope, equipped 
with CFP and FRET emission filters and images were analyzed using ImageJ 
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software. Slides were given a constant flow of 100 µl/min and samples were 
injected into the flow cell by a 50 µL sample loop.
RNA isolation and microarray hybridization and analysis
RNA was isolated by using TRIzol reagent (Life technologies, Bleiswijk, 
Netherlands) and further purified using the RNeasy mini kit (Qiagen Venlo, 
Netherlands) with on column DNase treatment (Qiagen, Venlo, Netherlands). 
RNA yield was measured with the Nanodrop ND-1000 spectrophotometer and 
the quality of RNA samples was verified with an Agilent 2100 Bio analyzer 
(Agilent Technologies, Amstelveen, Netherlands). One hundred nanogram of 
RNA was used for whole transcript cDNA synthesis (Affymetrix, inc., Santa 
Clara, USA). Hybridization, washing and scanning of Affymetrix GeneChip 
Mouse Gene 1.1 ST arrays was carried out according to standard Affymetrix 
protocols. Arrays were normalized using the Robust Multi-array Average 
method (19, 20). Probe sets were assigned to unique gene identifiers, in this 
case Entrez IDs. The probes on the Mouse Gene 1.1 ST arrays represent 21,213 
Entrez IDs (21). Array data were analyzed using an in-house, on-line system 
(22). All data were filtered, and probe sets with expression values above 20 
in at least 3 arrays were included in further analysis. In addition, a cut-off 
of IQR>0.1 was used to filter out genes that showed no variation between 
the samples. Intensity-Based Moderated T-statistics (IBMT) were used to assess 
significant differences with p-value < 0.05. 
Statistical analysis
Results were plotted in Prism 5 (GraphPad Software, La Jolla, USA), and 
statistical analyses were conducted using a student’s t-test or ANOVA with 
Dunnet’s post hoc test to compare treatment against control or Tukey post hoc 
test to compare multiple treatments. Significant differences are indicated as * 
p<0.05; ** p<0.01; and *** p<0.001.
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Results
Rebaudioside A and stevioside induce GLP-1 and CCK secretion from STC-
1 cells
To investigate whether the low-caloric sweeteners sucralose, rebaudioside A 
and stevioside can induce gut hormone release from enteroendocrine cells, 
STC-1 cells were stimulated for 2 hours with these compounds. Sucralose did not 
induce any significant GLP-1 secretion upon stimulation within a concentration 
range of 0.001 mM to 10 mM (figure 5.1A). Stimulation with rebaudioside A 
as well as stevioside elicited a significant GLP-1 release from enteroendocrine 
STC-1 cells. Concentrations of 0.5 and 1 mM rebaudioside A induced a 1.9 and 
2.3-fold increase in GLP-1 release, respectively. Stevioside (5mM) significantly 
induced a 3.38-fold increase in GLP-1 release (figure 5.1B). However, only 
rebaudioside A was able to induce CCK secretion in the STC-1 cells (figure 
5.1). Interestingly, a significant increase for rebaudioside A-induced CCK 
release was already observed at a 5-fold lower concentration compared to 
rebaudioside-induced GLP-1 release, namely at 0.1 mM. Also, CCK release 
decreased when cells were stimulated with rebaudioside A at a concentration 
of 1mM while GLP-1 secretion still showed an increase at 1 mM. Stevioside 
did not induce any significant increase in CCK release. The compounds at their 
tested concentrations did not induce any cytotoxicity to the cells as determined 
by an LDH assay (figure S5.1). 
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Rebaudioside A induces GLP-1 release in ileal organoids
The effect of steviol glycosides on GLP-1 release was also investigated in 
ileal murine organoids. Using a two-dimensional organoid model, we showed 
that rebaudioside A induced a 3.0-fold and a 7.0-fold GLP-1 release at a 
concentration of 5 and 10mM, respectively. 
< Figure 5.1: Gut hormone secretion by STC-1 cells in response to sweeteners. A) GLP-1 
release after 2 hours of incubation with HBSS supplemented with different concentrations 
of sucralose. Values indicate relative GLP-1 secretion compared to basal GLP-1 secretion 
following incubation with HBSS alone. B) GLP-1 release after 2 hours of incubation with 
HBSS supplemented with different concentrations of rebaudioside A and stevioside, relative 
to the basal GLP-1 secretion following incubation with HBSS alone. C) CCK release after 2 
hours of incubation with HBSS supplemented with different concentrations of rebaudioside 
A and stevioside, relative to the basal GLP-1 secretion following incubation with HBSS 
alone. Values are means ± SEM, n=7 for sucralose, n=4 for Rebaudioside A and n=3 for 
stevioside. * p<0.05, ** p<0.01, *** p<0.001 
Figure 5.2: Relative GLP-1 secretion by ileal organoids in response to rebaudioside 
A. GLP-1 release after one hour of incubation with DMEM supplemented with different 
concentrations of Rebaudioside A, relative to the basal GLP-1 secretion following incubation 
with DMEM alone. Values are means ± SEM, 7 individual stimulations were performed, * 
p<0.05, *** p<0.001 
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GLP-1 release induced by rebaudioside A involves cAMP signaling and 
not intracellular calcium signaling
To investigate intracellular mechanisms that underlie rebaudioside A-induced 
gut hormone release, the role of possible second messengers was investigated. 
Cytosolic [Ca2+]fluctuations in STC-1 cells were measured using the [Ca2+]-
sensitive Fura-2 dye. Ionomycin as a control elicited an increase in [Ca2+]i levels. 
However, upon stimulation with rebaudioside A (2.5 mM) no rise in [Ca2+]i 
levels was observed. Subsequently, we investigated the role of cAMP in the 
rebaudioside A-induced GLP-1 release using MDL-12330A, an inhibitor of 
adenylate cyclase. Adding MDL-12300A to incubations with rebaudioside 
A resulted in a 77% reduction of GLP-1 release compared to rebaudioside 
A treatment alone, suggesting a cAMP-dependent signaling pathway in 
rebaudioside A-induced GLP-1 release in STC-1 cells.
Figure 5.3: Role of intracellular signaling in GLP-1 response to Rebaudioside A. 
A) Intracellular [Ca2+]changes in response to buffer, ionomycin and rebaudioside A were 
measured with Fura-2. Values represent the average 340/380nm ratio of about 40-60 
regions of interest normalized to the time of injection. Values are expressed as means 
± SEM, n=3. B) GLP-1 release after a 2 hour incubation with HBSS supplemented with 
Rebaudioside A and/or adenylate cyclase blocker MDL12330A. Values are means ± SEM, 
n=3. * p<0.05, ** p<0.01, *** p<0.001 (Tukey multiple comparison).
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The sweet taste receptor is not involved in Rebaudioside A- induced GLP-1 
release
The murine sweet taste receptor antagonist gurmarin was used to investigate the 
role of the sweet taste receptor (Tas1r2/Tas1r3) in the rebaudioside A-induced 
GLP-1 release in STC-1 cells. Firstly, effects of gurmarin on sucrose-induced 
[Ca2+]i levels were assessed in STC-1 cells stably expressing the Cameleon 
YC3.6 calcium reporter protein. Figure 5.4A shows that STC-1 cells respond to 
sucrose with a primary immediate [Ca2+]i response and a delayed secondary 
response, around 20-50 seconds later. After the gurmarin injections only the 
secondary response is seen in response to sucrose, indicating that gurmarin 
blocks the primary [Ca2+]i response to sucrose. Subsequently, a concentration 
series ranging from 0.03 to 3 mM gurmarin was used in combination with 1 
mM rebaudioside A in order to investigate the involvement of the sweet taste 
receptor in rebaudioside A-induced GLP-1 secretion. However, at none of 
the concentrations tested gurmarin could reverse the rebaudioside A-induced 
GLP-1 release (figure 5.4B), suggesting that rebaudioside A does not mediate 
its effects via the sweet taste receptor. Furthermore, gene expression levels 
of mTas1r2, mTas1r3 and Gnat3 (α-gustducin) were assessed by microarray 
analysis in STC-1 cells. It was found that mTas1r3 was expressed, while 
mTas1r2 and particularly Gnat3 were expressed around or below threshold 
levels (figure 5.4C).
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< Figure 5.4: Role of sweet taste receptor in Rebaudioside A-induced GLP-1 response. 
A) Effect of gurmarin on sucrose-induced cytoplasmic calcium ion levels in STC-1 cells 
stably expressing the Cameleon YC3.6 calcium reporter protein. Shown are superimposed 
sucrose responses of STC-1 cells before and after application of the sweet receptor blocker 
gurmarin. Cells expressing Cameleon YC3.6 were exposed to 100 mM sucrose (S1-S9) for 
42 seconds every 3 minutes before and after a series of gurmarin injections (2 times 0.3 
µM gurmarin, followed by 3 times 0.3 µM gurmarin plus 100 mM sucrose, followed by 3 
µM gurmarin all in a period of 18 minutes, figure S5.2). The ionomycin (ion) injection (10 
µM) at the end demonstrates cells were not at their [Ca2+] maximum yet. Injections at t=0 
reached cells ca 16.25 seconds later (normalization point =1, greyed time zone). Shown 
are the global averages of all imaged cells (1315 ROIs). A moving average (15 seconds, 5 
values) was used to suppress effects of high frequency calcium oscillations (~3-6 sec, ~0.1 
amplitude) and cell synchronization. B) GLP-1 release after 30 minutes pre-incubation with 
HBSS supplemented with gurmarin and subsequent addition of rebaudioside A (1mM) for 
2 hours. Values represent relative GLP-1 release compared to the basal GLP-1 secretion 
following incubation with HBSS alone. Values are means ± SEM, n=3, * p<0.05 (Tukey 
multiple comparison). C) Gene expression levels (Robust Multi-array Average normalized 
intensity) assessed by microarray analysis of the sweet taste receptor (Tas1R2/Tas1R3) 
and α-Gustducin (Gnat3) after incubation with HBSS or rebaudioside A (1mM) for 2 hours. 
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Discussion
Currently, steviol glycosides are increasingly used in food products. However, 
knowledge on molecular mechanisms underlying steviol glycoside-associated 
effects is still limited. Recently, we reported that the steviol glycoside 
rebaudioside A can elicit GLP-1 and PYY secretion in porcine ex vivo intestinal 
segments (16). Here, we show that steviol glycosides, in particular rebaudioside 
A, are able to enhance the release of GLP-1 and CCK in murine enteroendocrine 
STC-1 cells. The GLP-1 response evoked by rebaudioside A was also present 
in two dimensional ileum-derived organoids. Furthermore, with this study we 
aimed to gain more insight in the sensing mechanisms responsible for the effects 
of rebaudioside A on intestinal GLP-1 release. Data indicate that rebaudioside 
A-induced GLP-1 release occurs independently of the sweet taste receptor 
(Tas1r2/Tas1r3) and suggest that the underlying pathways involve signaling by 
the second messenger cAMP.
Steviol glycosides were shown to be potent ligands for the human sweet taste 
receptor (4), and in mice the sweet taste receptor (Tas1R3) was found to be 
essential for the detection of stevia taste (23). It can be estimated that the 
effective concentrations of steviol glycosides in the two murine in vitro models 
used in our study are in the same order of magnitude as those reached by intake 
of 0.3 gram of rebaudioside A in a cup of coffee (16). The EFSA has established 
an acceptable daily intake level of 4 mg/kg BW/day. The concentrations used 
in our study seem therefore to lie within the range of normal consumption. 
Interestingly, rebaudioside A also evoked a significant CCK release in STC-
1 cells, and the effective concentration was slightly lower for CCK than for 
GLP-1. Furthermore, we did not find a significant effect of stevioside on CCK 
release, whereas in the same experiments a clear effect on GLP-1 was shown. 
CCK has been found to affect the release of digestive enzymes and bile acids, 
it plays a role in the control of food intake, and inhibits gastric emptying (24, 
25). Contrary to GLP-1, CCK is known to be most prominently expressed in the 
proximal small intestine which was also confirmed in our earlier studies (14).
In view of the still disputed roles played by the sweet taste receptor in intestinal 
nutrient sensing, we aimed to unravel the involvement of this receptor in steviol 
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glycoside-induced hormone secretion. The sweet taste receptor is known to be 
expressed in many extra-oral tissues like the pancreas and the gastrointestinal 
tract. In the intestinal tract the receptor was found to be co-expressed with 
GLP-1 and GIP positive cells (26, 27). Several cell-based studies provide 
evidence for a role of the sweet taste receptor in mediating gut hormone 
release. For example, Jang et al. showed that GLP-1 secretion in response 
to sucralose in colon-derived NCI-H716 cells was reduced by the sweet taste 
receptor inhibitor lactisole and these authors also found that this process was 
dependent on signaling via α-gustducin (26). Also, in GLUTag cells sucralose-
stimulated GLP-1- and GIP release were inhibited by gurmarin (28). However, 
others found no evidence for the involvement of the sweet taste receptor in 
GLP-1 release, and showed that glucose-induced GLP-1 release was mediated 
via SGLT-1-dependent transport and inhibition of ATP dependent potassium 
channels. Additionally, in small intestinal primary cells or perfused tissue no 
effect of sucralose on GLP-1 release was observed (29-32).
The data presented here suggest that the sweet taste receptor is not involved 
in rebaudioside A-induced GLP-1 release. Gurmarin, a specific sweet 
taste receptor inhibitor in mice (17) was able to inhibit the primary rise in 
intracellular [Ca2+] evoked by sucrose but did not reverse GLP-1 release 
induced by rebaudioside. Moreover, gene expression of both Tas1r2, one 
of the sweet taste receptor heterodimers, and α-gustducin, the sweet taste 
receptor G-protein were very low in the STC-1 cells used. In the present study 
also no effects of sucralose on GLP-1 release were observed, which is in line 
with the above mentioned reports performed in small intestinal primary cells 
or perfused tissue (29-32). Altogether, this points to the conclusion that other 
pathways are mediating rebaudioside A-induced GLP-1 responses in STC-1 
cells. 
We provide evidence that the GLP-1 release induced by rebaudioside A is 
dependent on cAMP signaling. The compound MDL-12330A in STC-1 cells 
reduces cAMP production and has been shown to block cAMP-dependent GLP-
1 release (33-35). Also in our hands it reduced GLP-1 secretion elicited by 
rebaudioside A. Cyclic AMP has been shown to trigger GLP-1 release (36), 
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suggesting that rebaudioside A by changing cellular cAMP levels might also 
induce GLP-1 release. We did not observe any changes in intracellular [Ca2+]
levels after addition of rebaudioside A to the cells using the [Ca2+]sensitive 
Fura-2 dye (figure 5.3b), nor in the STC-1 cells stably expressing the Cameleon 
YC3.6 calcium reporter protein (not shown). The absence of a rise in [Ca2+]i in 
combination with an increase in cAMP in intestinal cells was reported previously 
(37). A potential explanation for the absence of increased [Ca2+] levels might 
be the oscillatory behavior of the cells. Cyclic AMP induces the opening of 
ion channels, subsequently leading to increased [Ca2+]i. However, this cAMP 
dependent increase in [Ca2+]i is regulated by a local increase in [Ca
2+]i through 
a feedback mechanism (38, 39). This process might lead to high frequency 
calcium oscillations which may cause signals to remain undetected when 
measuring large ensembles of cells. We have observed continuous oscillatory 
behavior in single STC-1 cells (data not shown).
Apart from their sweetness, steviol glycosides are also known for their bitter 
taste. Steviol glycosides bind and activate two distinct human bitter taste 
receptors, hTas2R4 and hTas2r14 (4). Many bitter receptors are expressed 
along the gastrointestinal tract (40) and their activation has been related to GLP-
1 and CCK secretion (41-44). Our preliminary data obtained in collaboration 
with the laboratory of Meyerhof (DIfE, Potsdam, Germany) indeed showed 
that rebaudioside A can activate the mouse homologue of hTas2R4, namely 
mTas2R108. Furthermore, agonists of this receptor could induce GLP-1 release 
in STC-1 cells, and mTas2R108 was found to be expressed in STC-1 cells 
(data not shown). These preliminary data indicate that the Tas2R108 receptor 
might be involved in rebaudioside A-induced gut hormone release. However, 
additional studies are needed to definitely prove the involvement of Tas2R108 
or other receptors in steviol glycoside-mediated incretin release. 
In conclusion, rebaudioside A significantly enhanced the release of GLP-1 and 
CCK in vitro. The stimulation of GLP-1 secretion seems to involve signaling 
by the second messenger cAMP via a sensing mechanism independent of the 
sweet taste receptor. The bitter receptor Tas2R108 might be a likely candidate 
receptor involved in steviol glycosides-related gut hormone release. However, 
future studies are needed to elucidate depict the responsible receptor(s) and 
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underlying mechanism(s) mediating rebaudioside A-induced gut hormone 
release. Given the fact that GLP-1 has satiety and incretin effects, these 
findings are of interest for the development of novel strategies in the treatment 
of obesity and type II diabetes.
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Supplemental data
 
Figure S5.1: LDH leakage by STC-1 cells. Relative LDH leakage is calculated with the OD 
value of HBSS treated (negative control) cells and triton treated cells (positive control). 
Values are means ± SEM, n=2 for Rebaudioside A and n=3 for stevioside, n=4 for sucralose. 
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Figure S5.2: Intracellular [Ca2+] changes of the series of injections of sucrose (S), 
gurmarin (G) and the combinations of both. Effect of gurmarin on sucrose-induced calcium 
responses in STC-1 cells stably expressing the Cameleon YC3.6 calcium reporter protein. 
Shown are the global averages of all imaged cells (1315 ROIs). A moving average (16.25 
seconds, 5 values) was used to suppress effects of high frequency calcium oscillations (~3-6 
sec, ~0.1 amplitude) and cell synchronization.
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Abstract 
The gut hormone GLP-1 contributes to satiety and has a pivotal role in insulin 
secretion and glucose homeostasis. Modulation of GLP-1 release has been 
implicated as a potential strategy for the treatment of obesity and type II 
diabetes. Here, we investigated the effects of stevia-derived rebaudioside 
A on the development of enteroendocrine cells and their secretion of GLP-1 
and other gut hormones. To this end, we developed a two dimensional (2D) 
organoid model derived from mouse duodenal, jejunal and ileal tissues. The 
2D organoids contained crypt cells and differentiated villus cells such as 
enterocytes, goblet- and enteroendocrine cells and maintained their location-
specific gene expression patterns. The non-caloric sweetener rebaudioside A 
induced the secretion of GLP-1 and PYY in a location-specific manner and chronic 
stimulation with this sweetener induced the expression of enteroendocrine-
specific markers. These results might give rise to potentially interesting dietary 
application of rebaudioside A for type 2 diabetic patients. 
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Introduction
Cells along the intestinal tract secrete different peptide hormones with 
autocrine, paracrine and endocrine functions. Their release is time- and location 
specific and amongst others modulated by the presence of food and bacterial 
activity. Given their role in food-intake regulation and incretin effects, several 
of these peptides, including cholecystokinin (CCK), glucagon-like peptide-1 
(GLP-1) and peptide YY (PYY), are considered potential targets for weight 
management or (and) type II diabetes (1, 2).
The incretin GLP-1 is released by enteroendocrine cells (EECs), and signals in an 
endocrine manner via the circulation, and in a paracrine manner via receptors 
located on sensory nerve endings. To study its secretion and interactions with 
other hormones and intestinal cells in more detail, organoids provide useful 
models. These self-sustained mini guts, grown from adult Lgr5 positive stem cells, 
show good resemblance with the in vivo architecture and contain all different 
epithelial cell types (3, 4). This includes EECs, which generally comprise about 
1% of the intestinal epithelium (5). Previous studies by Petersen et al. showed 
that the relative number and secretory activity of GLP-1 positive EECs in 
organoids is enhanced by short chain fatty acids and pharmacologic agents 
(6, 7).
So-called non- or low-caloric sweeteners are increasingly used in foods and 
beverages, however their role in gut hormone release remains controversial. 
Recently, stevia-derived glycosides have been approved in the European 
Union and the United States. One of the most commonly used steviol glycosides 
is rebaudioside A, which is known to activate the sweet taste receptor, a 
heterodimer of Tas1R2 and Tas1R3, and two bitter receptors, Tas2R4 and 
Tas2R14 (8). Upon ingestion, rebaudioside A remains intact throughout the 
small intestinal tract (9), enabling interactions with receptors on EECs (10, 11). 
Recently, we have demonstrated that rebaudioside A augments GLP-1 and 
PYY release from isolated porcine intestinal segments (12). 
Here, we aimed to further investigate the effects of rebaudioside A on the 
number of EECs and their secretion of GLP-1 and other gut hormones, using 
intestinal organoids derived from different locations of the mouse small 
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intestine. For that purpose, we developed and used a novel two dimensional 
organoid model which contains crypt cells and the differentiated villus cells 
such as enterocytes, goblet cells and EECs.
Materials and methods
Organoid isolation and culturing 
The use of mouse intestine had been approved by the Local Committee for 
Care and Use of Laboratory Animals at Wageningen University (Permit number: 
2014036.b). Intestinal tissue was collected from six-month old C57BL/6J mice. 
The small intestine, from pylorus to ileocecal junction, was divided into three 
equal parts, further referred to as duodenum, jejunum and ileum. These intestinal 
segments were opened and thoroughly rinsed with PBS containing calcium 
and magnesium. The tissue was digested twice for 15 minutes with 0.35mg/
ml Collagenase XI (Sigma-Aldrich Chemie, Zwijndrecht, The Netherlands) in 
Dulbecco’s Modified Eagle Medium (DMEM)(Lonza, Verviers SPRL, Belgium). The 
digests were centrifuged at 100RCF for 3 minutes and resuspended in DMEM. 
Subsequently, the crypts were plated in growth factor reduced Matrigel basal 
membrane matrix (Corning Incorporated, Corning, USA) with organoid medium 
(DMEM/F12 medium containing GlutaMAX supplement, 1mM sodium pyruvate, 
MEM Non-Essential Amino Acids, 100U/ml Penicillin-Streptomycin, R-spondin 
1 (homebrew), WNT (homebrew), 0.5µg/ml DMH1) to stimulate organoid 
formation. These organoids were passaged once a week in a 1:4 ratio.
For the secretion assays, immunofluorescent stainings and qPCR analysis, these 
3D organoids were plated to obtain 2D structures by growing them onto 
Matrigel pre-coated wells. For this 24 wells plates were first coated with a 
thin layer of two times diluted Matrigel. After polymerization of the Matrigel, 
a suspension of about 40 crypts in organoid medium supplemented with 10% 
FCS was added to the wells. These organoids were grown for four days at 
37°C and 5% CO2.
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Organoid secretion assay
Four days after 2D organoid plating, the wells were washed twice with DMEM 
without glucose, and subsequently incubated for 1 hour with DMEM without 
glucose. Subsequently, the organoids were incubated with DMEM without 
glucose, supplemented with rebaudioside A (Sigma-Aldrich Chemie ,Zwijndrecht, 
The Netherlands) at 37°C and 5% CO2. After one hour, supernatants were 
collected and mixed with phenylmethanesulfonyl fluoride (Sigma-Aldrich 
Chemie ,Zwijndrecht, The Netherlands) to a final concentration of 100 µM.
Gut hormone measurement
Concentrations of active amylin, total gastric inhibitory polypeptide (GIP), 
active ghrelin, active GLP-1, insulin, leptin, pancreatic polypeptide and total 
PYY were simultaneously quantified using the Milliplex MAP mouse gut hormone 
magnetic bead panel (Millipore, MGTMAG-78K) on a Luminex MAGPIX with 
xPonent software. Concentrations of CCK-8 (CCK 26-33) were analyzed with 
an optimized and validated commercial RIA kit (Euro-diagnostica, Malmö, 
Sweden). Due to the volume needed for the analysis, supernatants of three 
experiments were pooled. Radioactivity of [125I]-CCK-8 was measured 
by liquid scintillation counting using a gamma counter (EC&G, Breda, The 
Netherlands).
Immunofluorescent staining
Cultured organoids were fixed with 4% formaldehyde and permeabilized with 
0.5% Triton-X100. These organoids were incubated with anti-chromogranin 
A antibody (Abcam, Cambridge, UK), anti-GLP-1 (7-36) antibody (Phoenix 
Pharmaceuticals, Karlsruhe, Germany), anti-PYY antibody (Abcam, Cambridge, 
UK), anti-serotonin antibody (Merck Millipore, Darmstadt, Germany), anti-
MUC2 antibody (Abcam, Cambridge, UK), Anti-TROY antibody (abcam, 
Cambridge, UK) or FITC labeled anti-CD24 antibody (BD Biosciences, 
Erembodegem, Belgium) for 2 hours at 37°C. Alexa Fluor 488 goat anti-
rabbit (Life Technologies, Bleiswijk, The Netherlands) and Alexa Fluor 488 
donkey anti-rat (Life Technologies, Bleiswijk, The Netherlands) were used 
as secondary antibodies. Actin and nuclei were stained using rhodamine 
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phalloidin (Life Technologies, Bleiswijk, The Netherlands) and 4’,6-diamidino-
2-fenylindool (DAPI) (Life Technologies, Bleiswijk, The Netherlands) or Hoechst 
33342 (Sigma-Aldrich, Zwijndrecht, The Netherlands). Images were acquired 
on a fluorescence Olympus IX71microscope using cellSens software (Olympus 
Corporation, Tokyo, Japan).
Quantitative PCR and Microarray analysis
RNA was isolated and purified with Quick-RNA MiniPrep kits (Zymoresearch, 
Irvine, USA). cDNA was synthesized using an iScript cDNA synthesis kit (Bio-
rad Laboratories, Hercules, USA). The qPCR reactions were performed on 
the CFX384™ Real-Time PCR Detection System (Bio-Rad Laboratories, Inc., 
Hercules, USA) using SensiMix SYBR No-ROX kits (Bioline, London, UK). The 
primer sequences are specified in table 6.1. To compare the location-specific 
expressions in mice and the organoids, an extensive dataset of ten regions of 
the small intestine sampled in vivo was used (13). 
Table 6.1: Primer sequences used for qPCR analysis.tabel	1
Gene Forward	primer Reverse	primer
Chga CAGGGACACTATGGAGAAGAGA GGTGATTGGGTATTGGTGGCT
Gcg AGGGACCTTTACCAGTGATGT AATGGCGACTTCTTCTGGGAA
Pyy ACGGTCGCAATGCTGCTAAT GACATCTCTTTTTCCATACCGCT
Cck AGCGCGATACATCCAGCAG ACGATGGGTATTCGTAGTCCTC
Hprt GAGAGCFTTGGGCTTACCTC ATCGCTAATCACGACGCTGG
Gpr120 AGGCGGCACTGCTGGCTTTC GCGGGACCACGCGGAACAAG
Slc2a2 CATCAGCCAGCCTGTGTATGC CATGCCAATCATCCCGGTTAGG
Slc30a2 AACTGCCAGGCGTGCCAGGG CCGTGGAGTGGTCCAGGCTGTG
Apoa4 CAACAGGCTGAAGGCTACGAT CGATTTTTGCGGAGACCTTGG
Lyz2 ATGGAATGGCTGGCTACTATGG ACCAGTATCGGCTATTGATCTGA
Lgr5 CCTACTCGAAGACTTACCCAGT GCATTGGGGTGAATGATAGCA
Vil1 TACCTCAAGACCCACCCTGGAA AAAGCCCTTGAAGGCAGGGTAG
Muc2 AGGGCTCGGAACTCCAGAAA CCAGGGAATCGGTAGACATCG
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Statistical analysis
All qPCR gene expression data was first normalized to reference gene HPRT, 
subsequently plotted relative to control. The effect of rebaudioside A treatment 
on hormone release and gene expression was tested using Mann-Whitney test, 
significant differences are indicated as * p<0.05; ** p<0.01; *** p<0.001. 
All graphs show means with SEM.
Results
Two dimensional organoids harbor different epithelial cell types
Two-dimensional organoid structures were obtained by plating 3D organoids 
derived from isolated small intestinal crypts of the duodenum, jejunum and 
ileum in wells coated with two times diluted Matrigel. Matrigel appeared to 
function as basal lamina for the epithelial organoids. Upon contact with the 
Matrigel layer and addition of FCS, different epithelial cell types started to 
grow from the crypts. Intact crypts and associated cells were sustained in the 
presence of R-spondin 1 and BMP4 inhibitor noggin. This way, the luminal side 
of the 2D cultured organoids is easily accessible for test compounds such as 
nutrients and sweeteners. 
The 2D differentiated organoids were characterized using immunofluorescent 
staining and gene expression analysis. From each crypt, a large villus domain 
developed (figure 6.1, 2D overview). The villus domain mostly consisted of 
absorptive and secretory cells. Next to these the presence of enterocytes and 
goblet cells was demonstrated using villin and muc2 antibodies (figure 6.1, 
Muc2 and Villin). The expression of Lgr5 and Lyz2 in the 2D organoids was 
compared with that in the 3D model and demonstrated the presence of intact 
crypts (figure S6.1). The 2D grown organoids also contained enteroendocrine 
cells (EECs), which were identified by the use of several EEC markers among 
which chromogranin A (14). Different types of EEC were identified by staining 
for GLP-1, PYY and serotonin positive cells. Figure 2 shows 2D cultured 
organoids which express the typical L-cell hormones GLP-1 and PYY, and 
enterochromaffin cells which contain serotonin. 
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Figure 6.1: 2D cultured organoids from the small intestine. A) Overview showing actin 
and nuclei staining of whole 2D cultured organoids. Identification of enterocytes, goblet 
cells and enteroendocrine cell using villin, muc2 and chromogranin A staining, respectively. 
Magnification used were 60x,60x, 40x and 10x, from right to left. 
 Figure 6.2: Immunostaining of 2D cultured organoids derived from duodenum, 
jejunum and ileum. Identification of GLP-1, PYY and serotonin positive cells using specific 
antibodies. Merged picture showed co-staining of GLP-1 and serotonin. 
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Intestinal location-specific expression of PYY and GLP-1 is conserved in 
vitro and in vivo 
The three small intestinal locations, duodenum, jejunum and ileum, are 
characterized by their specific gene expression profiles. To establish whether 
organoids originating from different locations along the intestine retained their 
location-specific gene expression profiles, these were assessed and compared 
with those in vivo. 
In line with our immunofluorescent staining data, expression of Gcg, encoding 
GLP-1, was very low in the duodenum and increased along the intestinal tract. 
This was in concordance with the Gcg expression in murine intestine (figure 6.3). 
Pyy and Gpr120 were highly expressed in the ileum, which was also found in 
the mouse intestinal samples. Slc2a2, a duodenum specific villus gene which 
encodes for the glucose transporter GLUT2 (15), showed a similar expression 
profile along the small intestinal axis in both mice as our 2D organoids. A 
comparable parallelism was seen for Slc30a2, a zinc transporter, and Apoa4, 
an apolipoprotein, although variation in the organoids was relatively large.
Rebaudioside A augments gut hormone secretion in a location-specific 
release pattern 
To investigate the effects of Rebaudioside A on gut hormone release in organoids 
from different intestinal locations, we determined the secretion of GLP-1, PYY 
and CCK after a 1 hour rebaudioside A exposure in serum- and glucose-free 
medium. We established that region-specific 2D cultured organoids remained 
functional with respect to hormone secretion. We measured high levels of basal 
GLP-1 release in ileum of 350.5±109.0 pg/ml (mean ± SEM), whereas GLP-1 
release was relatively low in duodenum- (132.2±18.2 pg/ml) and jejunum-
derived (173.3±9.6 pg/ml) organoids. The relative induction of GLP-1 release 
by rebaudioside A was also highest in ileum, being a factor 4 higher compared 
to medium (figure 6.4). Ileum-derived organoids released the highest amounts 
of PYY (9.98±1.90 pg/ml). Jejunal basal secretion of PYY was 8.70±1.29 
pg/ml and undetectable in the medium of duodenum-derived organoids. For 
PYY, the relative induction by rebaudioside A was highest in ileum showing a 
3-fold increase. The basal release of CCK was relatively low in the duodenum-
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Figure 6.3: Gene expression of location-specific genes in the murine intestine and 2D 
organoid cultures. Murine intestinal gene expression data were obtained from a deposited 
data set previously generated in our lab (13). Microarray intensity was shown for the 
intestinal expression of 4 mice fed a chow diet. Organoid data show relative expression 
corrected for the reference gene HPRT and were determined using qPCR analysis. RNA was 
isolated from 2D cultured organoids (N=6 wells), it was shown relative to the ileal gene 
expression. Specific locations were depicted on the x-axis of the graphs. All graphs show 
mean and SEM.
148
derived organoids (0.73±0.36 pM) and higher in jejunum- (1.37±0.60 pM) 
and ileum-derived organoids (2.15±1.35 pM). The release of CCK was not 
significantly changed by rebaudioside A exposure, although a trend for 
increased CCK release could be observed. 
Rebaudioside A increases enteroendocrine cell number in ileal-derived 2D 
organoids 
To examine the effect of prolonged rebaudioside A stimulation, ileal organoids 
were incubated for 18h with this compound at 10mM. Next, qPCR analyses 
were performed for Chga, Gcg, Pyy and Cck. Increased mRNA expression 
was observed for all these EEC markers (figure 6.5A). The increase induced 
by rebaudioside A compared to medium for Chga, Gcg, Pyy and Cck was 3.5, 
3.5, 5.2 and 6.2 fold, respectively. Furthermore, the number of chromogranin 
A positively stained cells increased by prolonged rebaudioside A treatment 
(figure 6.5B). 
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Figure 6.4: Rebaudioside A-induced gut hormone (GLP-1, PYY and CCK) release 
in organoids originating from three different locations. Organoids were exposed 
to Rebaudioside A (10mM) or control medium for 1 hour. From top to bottom: GLP-1 
release, PYY release and CCK release. For GLP-1 and PYY 9 individual stimulations were 
performed, N=9. For CCK release 9 individual stimulations were performed and pooled 
per 3 experiments, N=3. Graphs show mean and SEM, statistical differences are tested 
with Mann-Whitney test, * p<0.05; ** p<0.01, *** p<0.001
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Figure 6.5: Increased expression of specific enteroendocrine markers in ileal organoids 
after overnight culture with rebaudioside A (10mM). A) Graphs show relative gene 
expression determined using qPCR analysis . Organoid RNA was isolated from three 
independent experiments, it was normalized to reference gene HPRT and data was shown 
relative to medium incubation. All graphs show mean and SEM, significant differences of 
p<0.001 were indicated with ***. B) Amount of chromogranin A positive cells per well in 
2D plated ileal organoids. Graphs show induction in two individual experiments, the relative 
change compared to medium was indicated at the top of each experiment.
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Discussion
Results of the present study add to our knowledge on the effects of the steviol 
glycoside Rebaudioside A in the intestinal tract, focusing on GLP-1 secretion 
and EEC differentiation. Rebaudioside A and other preparations from the 
Stevia rebaudiana plant are increasingly used in foods and beverages as non-
caloric sweetener. For our study we established a new two-dimensional (2D) 
organoid model from mouse intestinal stem cells, highly suitable to explore 
effects of (dietary-) compounds on gut hormone release. We characterized 
this 2D organoid model by visualizing the presence of the different epithelial 
cell types. Furthermore, we showed that the organoids derived from different 
segments maintained their regional-specific gene expression patterns. When 
exposed to rebaudioside A the secretion of GLP-1 and PYY were stimulated in 
a location-specific manner and chronic stimulation with this sweetener increased 
the number of enteroendocrine cells. 
Our 2D system has been optimized for direct apical stimulation of intestinal 
organoids without disturbance of the organoids by pipetting. In the 3D culturing 
system as it is commonly used thus far, the villus space is shared among multiple 
crypts (3). In contrast, our 2D system showed large villus-like areas, which grew 
from each individual crypt. As isolated villus cells from mice were shown to 
contain higher glucagon expression compared to the crypt cells (6), a larger 
villus area could be beneficial for determining GLP-1 release. Previously, other 
2D intestinal models have been developed for the study of host-pathogen 
interaction. However, these are likely to show more complete differentiation 
of the crypt cells as these organoids were cultured without R-spondin 1 
and Noggin, typical stem cell niche factors, for three consecutive days (16). 
Furthermore, a human 2D intestinal cell model was shown to have only rare 
Paneth cell expression (17). As these two models do not give rise to all epithelial 
lineages typically found in the intestine, they are less representative for 
studying intestinal physiology compared to our 2D model, in which all typical 
intestinal epithelial cell types are present. Another model similar to ours, but 
more laborious is the 2D culture of air-liquid interface differentiated intestinal 
stem cells (18). Altogether, our 2D model contains all intestinal cell types, and 
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because of the presence of stem and progenitor cells differentiation can be 
studied. Moreover, the mucus membrane is present which is an essential barrier 
in the intestine. Additionally, our 2D model provides direct apical stimulation.
For the development of intestinal organoids we have explicitly discriminated 
between different intestinal regions by culturing duodenal, jejunal and ileal 
organoids. Furthermore, we have shown that the location specific expression 
of Gcg, Pyy, Gpr120, Slc2a2, Slc30a2 and ApoA4 in vivo remains present 
in cultured organoids, indicating that these organoids keep their regional 
characteristics. Our results are in agreement with those of Middendorp et al., 
who showed the similarities between intestinal gene expression and organoid 
gene expression on whole transcriptome level (15). Furthermore, stem cells 
from different regions showed region specific signatures on gene expression 
and their air-liquid interface differentiated cells show even difference in 
morphology (18). These results indicated that stem cells are intrinsically 
programmed with location-specific properties. However, this applies not for all 
genes, for example the expression of Cck in our organoids did not overlap with 
in vivo expression. This was in concordance with raw gene expression data of 
Middendorp et al (15). 
Our data showed that the sweetener rebaudioside A augments the release 
of the incretin GLP-1 in all three organoid-derived intestinal locations. Ileum-
derived organoids generated the highest relative release of both GLP-1 and 
PYY by rebaudioside A. Furthermore, these organoids were also capable 
of secreting basal levels of GLP-1, PYY and CCK. These data confirm our 
previous studies in pig intestinal segment explants, which showed GLP-1 and 
PYY release induced by rebaudioside A (12). Nutrient-sensing receptors and 
nutrient transporters on gut hormone secreting enteroendocrine cells (EECs) 
like the sweet taste receptor and the SGLT-1 transporter have been shown to 
induce gut hormone secretion upon stimulation by glucose and other dietary 
compounds. Recently, KO-organoid models showed that SGLT-1 mediates GLP-
1 release upon glucose stimulation (19). Rebaudioside A has also been shown 
to be able to activate the sweet taste receptor Tas1R2/Tas1R3 and human 
bitter receptors Tas2R4 and Tas2R14 in a transfected HEK cell reporter assay 
6153
(8). Activation of these sweet receptors, bitter receptors and transporters in 
the intestine can generate gut hormone release (11, 19-21), making it highly 
plausible that rebaudioside A might mediate its effects via one of these nutrient 
sensors. Satiating effects of nutrients have been shown to be region-specific as 
gut hormone secretion is dependent on the location of exposure. Van Avesaat 
et al. showed that ileal infusion of protein resulted in higher plasma GLP-1 
levels than jejunal or duodenal infusions (22). Interestingly, infusion of a mixture 
of rebaudioside A, quinine and monosodium glutamate in the human duodenum 
resulted in a significant decrease in food intake of the participants (23). These 
findings indicate that the effects induced by rebaudioside A may be relevant 
for food intake regulation. 
Interestingly, long term incubation with rebaudioside A induced the expression 
of enteroendocrine markers. Not only chromogranin A, an EEC marker, but also 
Gcg, encoding GLP-1, Pyy and Cck were increased by overnight stimulation 
with rebaudioside A. Furthermore, the number of chromogranin A positive cells 
was increased by the treatment. Several other dietary compounds or their 
metabolites have been shown to influence the number of EECs. In intestinal 
organoids, as well as in EECs, the supplementation with short chain fatty acids 
resulted in increased expression of glucagon and L-cell progenitor Foxa1/2 (6, 
24, 25). Furthermore, dietary intake of fibres resulted in enhanced expression 
of glucagon in vivo as well (26, 27). In contrast, a reduction in EEC numbers 
was observed with a high fat diet. Here, a decrease in enteroendocrine 
progenitors Math1 (Atoh1), NeuroD1 and Pax6 was shown (28). The question 
remains what underlies our observed enteroendocrine enrichment. Could it be 
modulation of EEC number by rebaudioside A or does persistent stimulation of 
hormone secretion by rebaudioside A stimulate enteroendocrine development 
in its surrounding cells? Stimulating enteroendocrine L-cell differentiation in a 
pharmacological manner in vivo can restore glucose tolerance (7). We conclude 
that long term rebaudioside A exposure results increased enteroendocrine cell 
numbers in our 2D organoid model. 
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We have highlighted the usefulness of the two dimensional organoid model 
for studying gastrointestinal hormone release. However, the model may be less 
suitable for studying CCK release. The location-specific gene expression of 
CCK did not reflect the in vivo expression (data not shown). Moreover, we have 
observed highest release of CCK in the ileum contrary to the duodenum, which 
is the main site of CCK release in vivo. 
In conclusion, we showed here that rebaudioside A induced hormone release 
in a location-specific manner and increased EEC number in a developed 2D 
intestinal organoid model. Our results might give rise to potential dietary 
strategies for type II diabetic patients. However, the latter merits further 
investigations. 
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Figure S6.1: Comparison of gene expression of Vil1, Muc2, Lyz2, Lgr5 in 2D and 3D 
cultured organoids derived from the duodenum, jejunum and ileum.
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General discussion
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The studies presented in this thesis add to our understanding of the role of 
receptors and other molecular structures assumed to be involved in nutrient 
sensing and gut hormone release. The research presented here was part of a 
larger research project investigating the possibilities to apply nutrient sensing 
for the modulation of food intake. A better understanding of the regulation of 
satiety and satiation remains crucial for developing strategies and new products 
that contribute to effective weight management. In most cases, such knowledge 
will be applied to body weight reduction and management. However, there 
are also groups and individuals for whom involuntary weight loss can pose a 
serious health risk. This general discussion will start with the main findings of the 
thesis. Next, some important issues in intestinal nutrient sensing are discussed, 
followed by general conclusions and future directions.
Main outcomes of this thesis
In summary, the main outcomes of this thesis were:
 Gene expression of receptors, transporters and peptides involved in 
nutrient sensing showed a distinctive distribution pattern along the small 
intestine, which is in the distal small intestine highly similar between mouse, 
pig and man.
 One year after bariatric surgery using a recently developed gastroplication 
technique, tissue expression of genes associated with nutrient sensing was 
hardly changed, while a considerable reduction in inflammatory pathways 
was observed.
 The steviol glycoside rebaudioside A was found to induce GLP-1 and PYY 
release ex vivo from porcine intestinal tissue and two dimensional mouse 
organoids. This induction of the release was specific for intestinal location, 
with the ileum being the most potently stimulated by rebaudioside A. 
Moreover, this steviol glycoside increased enteroendocrine cell numbers in 
two dimensional mouse organoids.
 Rebaudioside A induced GLP-1 and CCK release in STC-1 cells, which was 
not mediated by the sweet taste receptor.
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The role of GLP-1 in the regulation of food intake
It is clear that food intake regulation is a very complex process, involving many 
environmental, behavioral, physiological and other factors. This thesis focuses on 
gut hormones, in particular GLP-1, as intermediate markers. There is little doubt 
that GLP-1 is a physiological signal related to satiety, a process that inhibits 
hunger and further eating which arises as a consequence of food ingestion (1). 
This is amongst others underpinned by the observation that exogenous infusion 
inhibits food intake in both man and rodents (2, 3). Furthermore, GLP-1 has 
been related to fullness as the postprandial plasma levels of this hormone 
ran parallel with feelings of fullness measured by visual analogue scores (4). 
However, it should be kept in mind that several factors are involved in food 
intake regulation, which likely explains the fact that GLP-1 alone does not 
represent a proper biomarker for satiety (4). 
As has been described in chapter 1 of this thesis, GLP-1 is not only involved in 
food intake regulation but also has incretin effects. Its potency in maintaining 
glucose homeostasis is underpinned by the fact that GLP-1 analogues are 
currently used for the treatment of type II diabetic patients. Although this 
thesis focused on the role of gut hormones in food intake, strategies influencing 
endogenous GLP-1 release via nutrient sensing receptors might also contribute 
to type II diabetes management (5). 
Methodological considerations: Local GLP-1 release
Effects of nutrients on gastrointestinal hormone release are often studied 
with the ultimate goal to achieve effective weight management. Therefore, 
understanding intestinal hormone release in vivo is important. However, 
measuring GLP-1 in plasma does not give a good representation of local 
intestinal hormone release because of its short half-life. This short half-life 
might explain why effects of intestinal nutrient infusion on food intake were 
found without significant changes in plasma GLP-1 levels (6). After secretion 
from enteroendocrine cells, active GLP-1 will diffuse to the lamina propria and 
enter the blood stream, where it is rapidly degraded by DPP IV, with less than 
15% reaching the circulation (7). With the short half-life of GLP-1 in mind, it 
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is likely that the activation of GLP-1 receptors by GLP-1 released in the gut 
is predominantly local. In fact the presence of GLP-1 receptors on the nerve 
fibers in the mucosa, in some cases relatively close to the GLP-1 releasing 
L-cells, confirms the idea of a local signaling effect (8). These nerves are mainly 
vagal nerves, which signal to the brain stem, but the GLP-1R was also found 
to be present on the enteric nervous system, meyenteric ganglia, and dorsal 
root ganglia (8, 9). Considering the recent discovery that enteroendocrine cells 
have extensions that often reach beneath 10 to 15 epithelial cells, it is even less 
surprising that there are local signaling effects of GLP-1 and perhaps other gut 
hormones and possibly epithelial cell interactions (10). 
To account for these apparently local roles of GLP-1, effects of nutrient 
stimulation on GLP-1 release were mainly studied in ex vivo and in vitro models 
in which local intestinal endocrine release could be determined. The used models 
enabled us to study the effect of nutrients and other compounds on hormone 
release and the underlying mechanisms. The enteroendocrine STC-1 cell line used 
in this thesis was ideal as a quick screening tool and allowed us to investigate 
intracellular signaling. However, with this model no interactions can be studied 
between different types of epithelial cells. Therefore, ex vivo porcine intestinal 
tissue and organoids were used, as in these models the enteroendocrine cells 
are situated in their normal epithelial environment. To determine the release 
of GLP-1 and other gut hormones, a two dimensional organoid model was 
developed. The additional advantage of intestinal organoids over the ex vivo 
model is their viability and flexibility, which enabled us to investigate long-term 
effects of rebaudioside A stimulation as described in chapter 6. 
However, some limitations of the used models warrant consideration. A major 
pitfall is their lack of discrimination between apical and basolateral sides. 
Furthermore, these models do not properly reflect signaling and regulation 
that is normally taking place in an intact organism. For example, insulin can 
stimulate GLP-1 secretion (11) and vascular exposure to intestinal compounds 
was in some cases more efficient than luminal exposure (12, 13). Therefore, 
care should be taken when translating the results of our models to the in vivo 
situation.
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Molecular targets for nutrients that influence hormone 
release in the intestinal tract
There are several gut nutrient sensing receptors and transporters which are 
found to be involved in gut hormone release and food intake regulation. Table 
7.1 shows a short overview of nutrient sensing receptors and transporters 
for (digested) macronutrients and sweet compounds with their effect on gut 
hormone release, food intake regulation and body weight. In chapter 2 we 
have explored the expression pattern of these receptors and transporters in 
the intestinal tract. 
Effects of diet on the expression of these nutrient sensing related targets
In life, the ability to sense and respond to fluctuations in environmental nutrient 
levels is vital. The same holds true for the response to the body’s nutrient or 
energy status. Gastrointestinal nutrient sensing is an important feature related 
to these mechanisms. In view of this, it is of interest to investigate to what 
extent the processes involved in nutrient sensing themselves are affected by 
dietary patterns. In chapter 2, we have tested the effect of a high fat diet 
on the expression of several nutrient sensing related genes in mice. In the 
statistical model, combining the expression pattern of several genes along the 
intestine, we saw only slight changes induced by a high fat diet in the distal 
small intestine of the mice. However, when looking at individual genes there 
were some changes in the expression. However the sizes of these changes were 
minor, especially compared to those reported in the literature. From literature 
it is known that the expression of several receptors and transporters can be 
increased by a diet rich in their ligands. For example, the expression of peptide 
transporter, Pept1, was found to be increased by a high-protein diet (38-41). 
However, inconsistent results were found with some diets and molecular targets. 
For example, GPR120 expression in the corpus of the stomach and proximal 
intestine was increased in mice having received a high fat diet, whereas it was 
decreased in the antrum of the stomach (42, 43). Taken together, there appear 
to be several knowledge gaps regarding the long term effects of diet and 
other lifestyle factors on the mechanisms involved in intestinal nutrient sensing. 
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Table 7.1: Receptors and transporters involved in nutrient sensingt bel	1
Receptor Eﬀect	on	gut	hormone	release Eﬀect	on	food	intake	
regula7on
GPR120	(FFAR4)	for	detec-on	of	long-
chain	fa3y	acids
GLP-1	release	↑	(14,	15),	CCK	
↑	(16),	GIP	↑	(17)
Body	weight	in	mice↔	(15,	18)
GPR119	for	detec-on	of	lipid	
compounds	like	oleoylethanolamide
GLP-1	release	↑	(19,	20) Food	intake	and	body	weight	in	
rats↓	(21),	OEA	suppression	of	
food	intake	also	in	GPR119-/-	
mice	(22)
Pept1	(SLC15A1)	for	transport	of	di/tri	
pep-des
GLP-1	↑	(23) N/A
SGLT-1	(SLC5A1)	for	transport	of	glucose GLP-1	↑	(24-26),	GIP	↑	(26-28) N/A
GPR93	(LPAR5)	for	detec-on	of	
peptones
GLP-1	↔	(23),	CCK	↑	(29) N/A
CaSR	for	detec-on	of	L-amino	acids GLP-1	↑	(23,	30,	31),	CCK	↑	
(31-33),	PYY	↑	(30),	GIP	↑	(30)
N/A
GPRC6A	for	detec-on	of	L-amino	acids GLP-1	↑	(34,	35) N/A
Tas1R1/Tas1R2	for	detec-on	of	umami	
tastants
CCK	↑	(36),	GLP-1	↑	(37) N/A
Tas1R2/Tas1R3	for	detec-on	of	sweet	
tastants
Speciﬁed	in	a	speciﬁc	sec-on	below
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Effects of bariatric surgery on the expression of nutrient sensing related 
targets
To date, the most effective medical treatment for obesity remains bariatric 
surgery. Surgical procedures used for weight loss influence fasted gut hormone 
levels, and following surgery many gut hormones are increased postprandially 
(44). The observed changes in GLP-1 following Roux-en-Y gastric bypass 
(RYGB) were found to be associated with decreased appetite and weight loss, 
although a causal relationship is not clear (45). The gene expression of several 
of nutrient sensing receptors was found to be changed in obesity and after 
weight loss treatment (42, 46-48). Furthermore, the density of enteroendocrine 
cells and the expression levels of gastrointestinal hormones alters after 
changes in body weight (43, 48, 49). This thesis included a study on the effects 
of a minimally invasive bariatric procedure, endoscopic gastroplication. This 
procedure has shown to induce weight loss in morbidly obese patients and to 
alter gut hormone levels, both in fasted and postprandial states (50). Therefore, 
we sought to investigate the effects of this procedure on the expression levels of 
nutrient sensing related genes. However, whole transcriptome analysis showed 
more pronounced effects in relation to inflammatory pathways, as highlighted in 
chapter 3. Relatively few effects on the expression of nutrient sensing receptors 
and transporters were observed one year after the procedure. Interestingly 
however, we found the expression of the calcium sensing receptor, CaSR, to be 
increased in the antrum (FC= 1.78, p=0.01). This receptor for both calcium ions 
as well as L-amino acids was shown to be enriched in ghrelin-positive cells and 
its activation was able to inhibit ghrelin secretion ex vivo (51). In these patients 
the postprandial decrease in ghrelin levels was found to be restored after 
weight loss (50). Surprisingly, no significant changes in GPR120 expression 
were detected after one year of weight loss resulting from  gastroplication. 
This was in contrast to other studies which found increased levels of gastric 
GPR120 expression in morbidly obese subjects compared to normal weight 
subjects (46), and an observed positive correlation between duodenal GPR120 
expression and BMI (48). A plausible explanation for this could lie in the degree 
of weight loss. Even though these patients lost on average 20kg, their BMI 
was still relatively high (33.4kg/m2) one year after intervention. Furthermore, 
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there might be some other changes in the gastrointestinal physiology or on the 
whole body level induced by gastroplication that influences the expression of 
these receptors. Young et al. showed that not only luminal nutrients but also 
plasma glucose levels can influence the expression of the sweet taste receptor 
(52). Lastly, it could be that the nutrient sensing mechanisms are not always 
regulated at the gene expression level of receptors and transporters, but 
by post-translational modifications or via their cellular location, for example 
regulation through brush border membrane mobilization. 
Other nutrient sensing receptors and targets of potential interest
This thesis focused on the receptors and transporters for macronutrients and 
non-caloric sweet compounds. As a consequence, a number of other potentially 
relevant molecular targets received less attention. These include receptors 
for short chain fatty acids and bile acids (53-56). Next to these well-known 
chemosensory receptors, intestinal olfactory receptors may become of more 
interest as targets for the regulation of food intake. These receptors represent 
a large family of GPCRs that is primarily known for its capacity to detect 
odors. However, increasing evidence suggests a role in the intestines as well. 
Several olfactants have been shown to influence serotonin release from 
enterochromaffin cells (57, 58). As the olfactory receptors are a very large 
family of more than 500 genes or pseudogenes, specialized in the detection of 
many chemical compounds (59), it would be interesting to see if the expression 
of these receptors is enriched in enteroendocrine cells compared to other 
epithelial cells and to further investigate their role in gut hormone release. 
The importance of location-specific nutrient sensing
Location-specific hormone release
Considering the effectiveness of especially RYGB in reducing weight, it has 
been suggested that nutrient delivery to the more distal parts of the small 
intestines is of particular importance. In human infusion studies, location-
specific differences in food intake and plasma hormone levels in response to 
nutrients were observed. Ileal exposure to casein resulted in reduced food 
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intake, compared to duodenal or placebo infusion, which had no effect. 
Furthermore, plasma GLP-1 levels were highest after casein stimulation of the 
ileum compared to jejunum and duodenum (60). We were able to confirm 
location-specific effects on gut hormones as presented in chapters 4 and 6. In 
the intestinal organoids derived from different locations, we found the highest 
GLP-1 and PYY release in response to rebaudioside A in the ileum. In chapter 
4 we showed that rebaudioside A was able to stimulate GLP-1 release from 
all regions, whereas sucrose only induced GLP-1 release from the distal ileum, 
confirming region-specific stimulation of GLP-1. These region-specific releases 
of hormones may result from location-specific receptor or transporter expression 
and location-specific hormone expression, which was shown in chapter 2. The 
direct link between the level of expression and the release of hormones would 
be interesting for further investigation. Obviously, when studying these location-
specific effects in species other than man, differences between species should 
be taken into account. 
Cross-species comparison
In chapter 2, we sought to investigate location-specific differences between 
species. The first difficulty we encountered were differences in anatomy and 
nomenclature of the intestinal locations in different species. For example 
the anatomy of the pig large intestine, which has a spiral form, is different 
compared to that in humans (61). There even appears to be some degree 
of inconsistence between definitions of anatomical locations within a certain 
species (van der Meulen, personal communication). Therefore, we chose to 
compare levels of expression between the species based on location relative 
to the full length of the intestine. Our key finding was that there appears to 
be a strong parallelism between the expression patterns of genes related to 
nutrient sensing in the distal ileum of the three species, but larger differences 
in the proximal intestine. The main differences in nutrient sensing related genes 
we observed in the proximal intestine might be related to general differences 
in the digestive system. On top of this, dietary effects are also likely to play a 
role for a given species. 
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Effects of non-caloric sweeteners on food intake regulation and weight 
management
Changing food composition using specific components plays an important role 
in current weight management strategies. Since a few decades low-caloric 
sweeteners of different chemical structure are in use. Their use is to replace 
sugar and thus reduce caloric intake. Their application is not without debate, 
one of the arguments being the suggestion that consumption of low-caloric 
sweeteners might lead to compensation as these compounds are thought not 
to satiate and even to increase hunger (62). However, systematic reviews and 
meta-analyses of studies have shown that, in general the use of low-caloric 
sweeteners is associated with a reduced energy intake and body weight (63). 
In this thesis we have specifically focused on the low-caloric sweetener 
Rebaudioside A from Stevia rebaudiana Bertoni. The leaves of this plant were 
traditionally used in South America (64). Preparations from Stevia rebaudiana 
are receiving considerable interest as it is marketed as a ‘natural’ sweetener. 
When using stevia as a preload, it reduced total daily energy intake 
compared to a sugar-sweetened preload (65). Also, intraduodenal infusion of 
rebaudioside A in combination with other tastants reduced subsequent energy 
intake (6). However, studies on long-term intake of capsulated rebaudioside A 
showed no effects on body weight or food intake compared to control (66, 67). 
A recent systemic review of the randomized clinical trials concluded that based 
on the currently available studies, rebaudioside A may influence blood glucose 
although effects are small and more studies are needed (68). 
Involvement of the sweet taste receptor in GLP-1 release
The role of the sweet taste receptor in GLP-1 secretion is still very controversial. 
Different models have generated different outcomes. Moreover, the use of 
different agonists and antagonists has led to inconsistent conclusions. These 
differences are discussed in the next paragraph. 
In cell studies, results show convincingly that GLP-1 is released in response to 
sweet tasting compounds. Jang et al. showed the induction of GLP-1 release 
by different sweet taste receptor ligands; glucose (165-555mM), sucrose (40-
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145mM) and sucralose (1-5mM) in human colon NCI-H716 cells. The effect of 
sucralose was inhibited by the hTas1R3 inhibitor lactisole. Furthermore, sweet 
taste receptor related G-protein α-gustducin knock-down resulted in a reduction 
of glucose-stimulated GLP-1 release (69). Similar to these results, sucralose, 
saccharin, acesulfame K and glycyrrhizin (50mM) were shown to induce GLP-
1 release in human duodenum-derived Hutu-80 cells, which was inhibited by 
lactisole (70). Moreover, GLP-1 inducible effects of sucralose (50mM) could 
be inhibited by the mTas1R3 inhibitor gurmarin in GLUTag cells (71). Also, in 
isolated primary murine colon cells, glucose (0.1-100mM) and sucralose (20mM) 
induced GLP-1 release while acesulfame K (2mM) did not. In primary murine 
cells of the upper small intestine no effects of sucralose (1-20mM) were found, 
although glucose (1-100mM) did induce GLP-1 release (72). This observation 
was confirmed by extensive studies using isolated perfused rat small intestine, 
where neither sucralose (0.25% w/v) nor acesulfame K (0.78% w/v) were 
found to induce GLP-1 release (24).
In all these in vitro studies there is a discrepancy between the concentrations of 
ligands used, and besides that the relative sweetness of the tested solutions was 
not always taken into account. In general, most of the used concentrations of 
non-caloric sweeteners were high, considering the relative sweetness compared 
to sucrose (73, 74). Another complicating aspect is the fact that some sweet 
compounds might induce GLP-1 release via other mechanisms not involving the 
sweet taste receptor. Glucose for instance has been shown to also mediate its 
effects on GLP-1 independently of the sweet taste receptor and to use other 
mechanisms including those involved in absorption and metabolism of glucose 
(24, 25, 72, 75). 
In vivo studies, measuring GLP-1 in plasma, have not clarified the role of 
the sweet taste receptor in intestinal sensing either. A study in rats showed 
no effects on GLP-1 plasma levels following oral delivery of low-caloric 
sweeteners, whereas glucose (all 1g/kg) elevated plasma GLP-1 in this study 
(76). In line with these animal studies there are several human studies that 
could also not detect a relation between low-caloric sweeteners and GLP-1 
release. Intragastric sucralose (0.4-4mM) infusion caused no significant increase 
in plasma GLP-1 compared to saline, whereas a sucrose load, equisweet to 
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the lowest sucralose solution, did (77). However, low-caloric sweeteners, given 
as a pre-load before glucose ingestion showed contradicting effects on GLP-
1 plasma levels (78-81). Studies in mice showed that glucose can increase 
plasma GLP-1 levels and support the involvement of the sweet taste receptor 
in the observed GLP-1 release as α-gustducin-/- mice showed reduced plasma 
GLP-1 levels after an oral glucose load (69). Also, human studies, using the 
inhibitor lactisole to block the glucose-induced rise in plasma GLP-1 levels by 
intragastric or intraduodenal infusion, suggested the involvement of the sweet 
taste receptor (82, 83). 
Altogether, available in vivo studies where  sweet taste receptor Tas1R3 
blockers and   G-protein α-gustducin knock-out models were used, clearly point 
towards the involvement of the sweet taste receptor in glucose-induced GLP-1 
release. However, although low-caloric sweeteners are potent agonists of the 
sweet taste receptor in both gustation and cell-based assays, a lack of effects 
of these sweeteners on plasma GLP-1 is observed. In our hands, the low-caloric 
sweetener sucralose had no effect on GLP-1 release, whereas the sweetener 
rebaudioside A showed consistent GLP-1 induction in the models used. 
Rebaudioside A induces gut hormone release
As described in chapters 4, 5 and 6 we showed that GLP-1 (and PYY, CCK) 
release was potently stimulated by rebaudioside A in multiple models. 
Rebaudioside A is a steviol glycoside that is known for its sweet taste and it 
was shown to activate the human sweet taste receptor (88). In chapter 5, we 
have shown that blocking the murine Tas1R3 with gurmarin did not attenuate 
GLP-1 release in STC-1 cells. These results have led us to believe that the 
sweet taste receptor is not involved in the release of GLP-1 by rebaudioside 
A. Furthermore, we provided evidence that rebaudioside A-elicited GLP-1 
secretion involves cAMP signaling.
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The role of nutrient sensing in relation to food intake in 
man
Targeting gut nutrient sensing receptors and transporters by specific stimulation 
of the enteroendocrine system might contribute to a solution for the obesity 
pandemic. This view is also supported by results coming from pharmacological 
interventions involving liraglutide, a GLP-1 analogue, which was recently 
approved for the treatment of obesity. Two years of treatment with this GLP-1 
analogue resulted in an average weight loss of about 10 kg (BMI reduction of 
3.4). However, this degree of weight loss was mainly achieved by emotional, 
restrained or indifferent eaters and not by external eaters (84). Liraglutide was 
also reported to have side-effects, which consisted mostly of gastrointestinal-
related complaints like nausea and vomiting (85). An endogenously generated 
stimulation of GLP-1 release by nutrients in the intestine might in theory be 
attractive when it would result in a similar loss of body weight, without producing 
these side-effects. As most of the consumed food is digested and absorbed 
before it reaches the distal intestine, encapsulation of specific secretagogues 
might provide interesting options. Recently, the effect of 6 gram encapsulated 
glutamine was tested in healthy and diabetic volunteers. The intervention 
resulted in increased peak GLP-1 levels, but surprisingly led to a rise instead 
of a decrease in subsequent food intake in healthy volunteers (86). It was 
suggested that other GLP-1 secretagogues or higher doses of the compound 
might provide other results. Two human studies have shown that a combination 
of tastants infused in the duodenum and 6 gram safflower oil or 15 gram 
casein, or 13 gram sucrose infused in ileum resulted both in a reduction of 
food intake. However, in both studies no effects on plasma AUC GLP-1 levels 
were observed (6, 87). Altogether, to influence food intake using gut nutrient 
sensing mechanisms, multiple factors should be taken into account among which 
dose, compound(s), intestinal location of delivery and timing. Finally, a proof 
of principle study is needed, exploring the effects outside the laboratory 
environment and including the effects on long-term weight management.
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General conclusions and future directions
The world-wide rising obesity rates continue to fuel research on the modulation 
of body weight. Achieving sustained weight loss in obese patients by dietary 
or lifestyle intervention has proven to be very challenging. At the same time, 
pharmacological modulation of body weight has not been very successful as 
well, and the few compounds available do not reach a similar extent of weight 
loss as bariatric surgery, which is commonly regarded as the most effective 
treatment for obesity. 
Based on the results presented in this thesis and data from other studies it 
would be too optimistic to conclude that promising strategies to modulate body 
weight based on targeting gastrointestinal nutrient sensing mechanisms are 
on the horizon. What we do know now is that several factors play a role in 
gut hormone release. This includes not only the nature and dose of the active 
compound(s), but also the location and timing of its (their) interactions with 
receptors and other targets along the gastrointestinal tract. As previously 
described, metabolic effects of RYGB appear to go beyond creating a 
situation of malabsorption only. Changes in location and timing of nutrient-
receptor interactions are probably also playing a major role. In that respect 
these effects could be used a guiding principle to develop less invasive 
strategies. We have shown that rebaudioside A may be a potential compound 
to induce gut hormone release in vivo, especially when applied to the distal 
small intestine. Therefore, rebaudioside A could be of interest to influence food 
intake and it is likely to have the most potent effects when delivered in the 
ileum. Based on the studies presented in this thesis, some recommendations for 
future research on rebaudioside A can be formulated.
Considering the fact that the sweet taste receptor does not seem to play a role in 
rebaudioside A-induced hormone release, future studies should include further 
investigations on the mechanism(s) underlying rebaudioside A-induced hormone 
release. Steviol glycosides can also activate the human bitter receptors Tas2R4 
and Tas2R14 (88). Their mouse homologues are Tas2R140 and Tas2R108, and 
these receptors are putative candidates to explain rebaudioside A-induced 
GLP-1 release found in our murine models. Preliminary results generated as 
a result of a recently started collaboration with the laboratory of Prof W. 
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Meyerhof (DIfE, Potsdam, Germany) showed that rebaudioside A is able to 
activate (murine) Tas2R108. Furthermore, our experiments showed that agonists 
of this receptor induced GLP-1 release in STC-1 cells. These preliminary data 
suggest that the Tas2R108 receptor is involved in rebaudioside A-induced gut 
hormone release, which will be investigated in future studies by knocking out 
this receptor.
Another topic that merits further investigation are possible effects of prolonged 
exposure to rebaudioside A, as the compound seems to increase the number 
of enteroendocrine cells. It would be interesting to see if this effect is due 
to persistent GLP-1 release or induced by rebaudioside A stimulation itself. 
Moreover, it should be studied whether the increased number of enteroendocrine 
cells also results in a substantially enhanced GLP-1 release upon stimulation. 
Knowing the effects of rebaudioside A on GLP-1 release, in vivo effects of 
rebaudioside A on food intake should be studied more extensively. As an 
increase in enteroendocrine L-cell number by pharmacologic treatment could 
restore glucose tolerance in mice (89), the effects of rebaudioside A should 
also be tested in relation to glucose homeostasis. Several factors, like timing, 
dosage form, dosing concentration and intestinal location, seem to play a role.
Intestinal organoids provide a perfect model to study the cell interactions 
between different epithelial cell types. The possibility of this model to study 
intercellular signals and crosstalk in the intestinal epithelial tissue gives rise to 
a new interesting field of research in intestinal nutrient sensing. Future studies 
using murine and human organoids might add to the development of novel 
pharmacological or nutritional strategies in order to modulate food intake.
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The alarming increase in obesity rates creates an urgent need for effective 
prevention and treatment strategies. The most effective treatment for obesity 
today is bariatric surgery. Bariatric surgery comprises a number of different 
procedures having in common that they induce weight loss and alter gut 
hormone release. Gut hormones are well known for their effects on food intake 
behavior and their role in weight loss after bariatric surgery is undeniable. In 
addition, the therapeutic use of GLP-1 (Glucagon-Like Peptide-1) analogues 
including liraglutide in type II diabetes and obesity is on the rise. This underlines 
why gut hormones are considered promising targets for the development of 
new treatment strategies against obesity and its comorbidities.
The secretion of gut hormones, among which GLP-1, is influenced by nutrient 
ingestion. The interactions of dietary components or their breakdown products 
with receptors and transporters located on the enteroendocrine cells of the 
intestinal tract can induce their release, a process called intestinal nutrient 
sensing. In this thesis, we aimed to further elucidate intestinal nutrient sensing 
mechanisms on a cellular level. First, the regional expression of several gut 
nutrient sensing related genes along the intestinal tract was assessed in three 
commonly studied species, namely mouse, pig and man. Gene expression 
of receptors, transporters and peptides involved in nutrient sensing shows a 
distinctive distribution pattern along the small intestine, which is in the distal 
small intestine highly similar between the species. Subsequently, we sought 
to investigate if this expression was changed after a weight loss inducing 
bariatric procedure. By whole transcriptome analysis, we showed that upper 
gastrointestinal tissue expression of genes associated with nutrient sensing 
was hardly changed. In contrast, a considerable reduction in inflammatory 
pathways was observed.
Next, we sought to investigate the effects of the non-caloric sweetener 
rebaudioside A. This Stevia rebaudiana-derived compound was approved 
on the European market in 2011. As there is still some controversy about the 
effects of sweeteners in general on GLP-1 release, we investigated the effects 
of this specific sweetener. Because of the short half-life of GLP-1, the effect 
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of nutrient stimulation was mainly studied in ex vivo and in vitro models in 
which local intestinal hormone release could be determined. A two dimensional 
gut model using intestinal organoids derived from murine intestinal crypts was 
developed to study location-specific hormone secretion. Rebaudioside A was 
found to induce GLP-1 and PYY release ex vivo from porcine intestinal tissue 
and in two dimensional organoids. This induction of the release was specific 
for the intestinal location, with the ileum being most potently stimulated by 
rebaudioside A. Moreover, prolonged exposure to rebaudioside A increased 
enteroendocrine cell numbers in two dimensional organoids. When studying 
the underlying mechanism in enteroendocrine STC-1 cells, we concluded that 
rebaudioside A-induced GLP-1 release was independent of the sweet taste 
receptor.
The studies presented in this thesis add to our understanding the role of receptors 
and other molecular structures that are likely to be involved in nutrient sensing 
and the modulation of gut hormone release. What we know now is that several 
factors play a role in gut hormone release. This includes not only the nature 
and dose of the active compound(s), but also the location and timing of its 
(their) interactions with receptors and other targets along the gastrointestinal 
tract. We have shown that rebaudioside A may be a potential compound to 
induce gut hormone release in vivo, especially when applied to the distal small 
intestine. Therefore, rebaudioside A may be a promising compound to influence 
food intake, possibly most potent when delivered in the ileum. 
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Regulation of energy intake: the role of product properties 
(Wageningen, 2012)
Workshop ‘Measuring Gut Hormones’ (Copenhagen, 2012)
Fifth National Nutrition Conference (Ede,  2012)
8th NUGO week (Wageningen, 2011)
General courses
Alison Douglas Summer School (Fraueninsel am Chiemsee, 2013)
Teaching and supervising thesis students (Wageningen, 2012)
Presentation skills (Wageningen, 2012)
Basic Intellectual property for researchers of TI food and nutrition 
(Wageningen, 2012)
VLAG PhD week (Baarlo, 2012)
Techniques for Writing and Presenting Scientific Papers (Wageningen, 2012)
Speed reading (Wageningen, 2011)
Project realisation programme of TI Food and Nutrition ‘from ambition to 
results’ (Wageningen, 2011)
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Optional activities
Project meetings TI Food and Nutrition (2011-2015)
Nutrition and Pharmacology scientific meetings (weekly, 2011–2015)
NMG-Pharma scientific meetings (weekly, 2011–2015)
PhD study tour and organisation committee (Australia, 2013)
Preparation research proposal (2011)
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